fluoxetine has been researched along with Anxiety in 346 studies
Fluoxetine: The first highly specific serotonin uptake inhibitor. It is used as an antidepressant and often has a more acceptable side-effects profile than traditional antidepressants.
fluoxetine : A racemate comprising equimolar amounts of (R)- and (S)-fluoxetine. A selective serotonin reuptake inhibitor (SSRI), it is used (generally as the hydrochloride salt) for the treatment of depression (and the depressive phase of bipolar disorder), bullimia nervosa, and obsessive-compulsive disorder.
N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine : An aromatic ether consisting of 4-trifluoromethylphenol in which the hydrogen of the phenolic hydroxy group is replaced by a 3-(methylamino)-1-phenylpropyl group.
Anxiety: Feelings or emotions of dread, apprehension, and impending disaster but not disabling as with ANXIETY DISORDERS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Severity of anxiety does not appear to influence the antidepressant response to fluoxetine during acute treatment of major depressive disorder (MDD)." | 10.21 | Long-term treatment outcomes of depression with associated anxiety: efficacy of continuation treatment with fluoxetine. ( Fava, M; Joliat, MJ; Michelson, D; Miner, CM; Schmidt, ME; Trapp, NJ; Zhang, S, 2004) |
| "Fluoxetine improved FMMS and reduced anxiety and depression." | 9.41 | The efficacy and safety of fluoxetine versus placebo for stroke recovery: a meta-analysis of randomized controlled trials. ( Qin, G; Wu, J, 2023) |
| "To determine the efficacy of fluoxetine for reducing the frequency and severity of obsessive-compulsive behaviors in autism spectrum disorders." | 9.30 | Effect of Fluoxetine on Obsessive-Compulsive Behaviors in Children and Adolescents With Autism Spectrum Disorders: A Randomized Clinical Trial. ( Dossetor, D; Granich, J; Hazell, P; Kohn, M; Lee, KJ; Marraffa, C; Mouti, A; O'Sullivan, M; Orsini, F; Reddihough, DS; Santosh, P; Silove, N; Whitehouse, AJO; Wray, J, 2019) |
| " Fluoxetine is effective against anxiety and panic disorders, while its use has shown promising results for VVS." | 9.24 | Fluoxetine vs. placebo for the treatment of recurrent vasovagal syncope with anxiety sensitivity. ( Flevari, P; Katsaras, D; Katsimardos, A; Leftheriotis, D; Lekakis, J; Repasos, E, 2017) |
| "These results suggest that although chronic fluoxetine treatment proves positive effects in animal models of depression, it may simultaneously increase anxiety in adolescent animals in a dose-related manner." | 9.22 | Effects of chronic fluoxetine treatment on anxiety- and depressive-like behaviors in adolescent rodents - systematic review and meta-analysis. ( Chocyk, A; Kryst, J; Majcher-Maślanka, I, 2022) |
| "To compare anxiety levels experienced during 4 stressful periods of in vitro fertilization (IVF) and treatment outcomes between women taking fluoxetine and a placebo." | 9.14 | Fluoxetine treatment for anxiety in women undergoing in vitro fertilization. ( Grosman, A; Lobo, DS; Motta, EL; Rocha, AM; Seibel, D; Serafini, P, 2009) |
| "This open clinical trial examined the feasibility, tolerability, and efficacy of treating adolescents who suffer from bulimia nervosa with fluoxetine." | 9.10 | An open trial of fluoxetine for adolescents with bulimia nervosa. ( Davies, M; Devlin, MJ; Kotler, LA; Walsh, BT, 2003) |
| "Low-dose cotherapy of fluoxetine with clonazepam was safe and accelerated response over 21 days of treatment, decreasing anxiety and sleep disturbance as symptoms and partially suppressed them as SSRI side-effects; it also modestly reduced core symptoms of low mood and loss of interest." | 9.09 | Short-term cotherapy with clonazepam and fluoxetine: anxiety, sleep disturbance and core symptoms of depression. ( Glaudin, V; Londborg, PD; Painter, JR; Smith, WT, 2000) |
| "Fluoxetine, a specific serotonin reuptake inhibitor, was compared to amitriptyline in the treatment of 51 outpatients with primary major depressive disorder." | 9.05 | A double-blind controlled clinical trial of fluoxetine and amitriptyline in the treatment of outpatients with major depressive disorder. ( Chouinard, G, 1985) |
| " Regular use of fluoxetine apparently prevented the onset of anxiety, depression, aggressiveness, and suicide ideation, even with the concurrent use of AAS." | 8.02 | Effective treatment and prevention of attempted suicide, anxiety, and aggressiveness with fluoxetine, despite proven use of androgenic anabolic steroids. ( Amaral, JMX; Aquino Neto, FR; Baker, JS; Chagas, SV; Cruz, MS; Mullen, C; Padilha, MC; Vieira Neto, L, 2021) |
| "to evaluate the influence of two maternal high-fat diets with different caloric contents on anxiety-like behavior in young-adult offspring and their sensitivity to acute fluoxetine." | 8.02 | High-caloric or isocaloric maternal high-fat diets differently affect young-adult offspring behavior in anxiety-related tests and offspring sensitivity to acute fluoxetine. ( Benjamim, RAC; Cadena-Burbano, EV; Cavalcanti, CCL; Costa, TL; Da Silva Aragão, R; Lago, AB; Manhães-De-Castro, R; Oliveira, TRDP; Silva, EHM; Silva, JM, 2021) |
| "The objective of this study was to evaluate whether juvenile fluoxetine (FLX) exposure induces long-term changes in baseline responses to anxiety-inducing environments, and if so, whether its re-exposure in adulthood would ameliorate this anxiety-like phenotype." | 8.02 | Adolescent fluoxetine treatment mediates a persistent anxiety-like outcome in female C57BL/6 mice that is ameliorated by fluoxetine re-exposure in adulthood. ( Castillo, SA; Flores-Ramirez, FJ; Garcia-Carachure, I; Iñiguez, SD; Lira, O; Preciado-Piña, J; Robison, AJ; Rodriguez, M; Sierra-Fonseca, JA; Themann, A; Warren, BL, 2021) |
| "Radiation therapy and concomitant temozolomide chemotherapy are commonly used in treatment of brain tumors, but they may also result in behavioral impairments such as anxiety and cognitive deficit." | 7.91 | Fluoxetine reverses brain radiation and temozolomide-induced anxiety and spatial learning and memory defect in mice. ( Chai, D; Gan, H; Wu, S; Zhang, Q; Zhu, B, 2019) |
| "The aim of this study was to determine the effects of maternal fluoxetine treatment on anxiety-like and depressive-like behaviours in adolescent offspring as well as associated glutamatergic markers, using a clinically relevant rodent model of depression." | 7.91 | Perinatal exposure to fluoxetine increases anxiety- and depressive-like behaviours and alters glutamatergic markers in the prefrontal cortex and hippocampus of male adolescent rats: A comparison between Sprague-Dawley rats and the Wistar-Kyoto rat model o ( Fernandez, F; Lum, JS; Millard, SJ; Newell, KA; Weston-Green, K, 2019) |
| "We sought a robust behavioural test that evoked increased anxiety-like behaviour during the late dioestrus phase of the oestrous cycle (similar to the premenstrual period in women) and tested whether this could be prevented by acute low-dose fluoxetine (FLX)." | 7.91 | Short-term, low-dose fluoxetine prevents oestrous cycle-linked increase in anxiety-like behaviour in female rats. ( Brandão, ML; de Carvalho, MC; Lovick, TA; Machado Figueiredo, R, 2019) |
| " Accordingly, we investigated the effects of two field-realistic levels of the SSRI fluoxetine (61 and 352 ng/L) on sociability and anxiety-related behaviors in eastern mosquitofish ( Gambusia holbrooki) for 28 days." | 7.91 | Antidepressants in Surface Waters: Fluoxetine Influences Mosquitofish Anxiety-Related Behavior at Environmentally Relevant Levels. ( Bertram, MG; Brooks, BW; Burket, SR; Deal, NDS; Fursdon, JB; Hannington, SL; Martin, JM; Mole, RA; Saaristo, M; Wong, BBM, 2019) |
| "We identified a "sensitive period" during periadolescence (postnatal days 21-42) in which developmentally timed fluoxetine administration rescued anxiety-like phenotypes in BDNF Val66Met mice in adulthood." | 7.85 | Effect of Early-Life Fluoxetine on Anxiety-Like Behaviors in BDNF Val66Met Mice. ( Bath, KG; Casey, BJ; Dincheva, I; Freilingsdorf, H; Glatt, CE; Hempstead, B; Huang, C; Jing, D; Lee, FS; Li, A; Marinic, T; Yang, J, 2017) |
| " The aim of this study was to investigate whether anxiety or depression-like behavior can be found in rat strains with different susceptibility to audiogenic seizures (AS) and whether chronic fluoxetine treatment affects this co-morbidity." | 7.85 | Genetic background contributes to the co-morbidity of anxiety and depression with audiogenic seizure propensity and responses to fluoxetine treatment. ( Fedotova, IB; Kostina, ZA; Nikolaev, GM; Perepelkina, OV; Poletaeva, II; Sarkisova, KY; Surina, NM, 2017) |
| "The effects of the SSRI fluoxetine on genetically based, depression-related circadian disruptions at the behavioral and molecular level were examined using mice selectively bred for high anxiety-related and co-segregating depression-like behavior (HAB) and normal anxiety/depression behavior mice (NAB)." | 7.83 | Fluoxetine normalizes disrupted light-induced entrainment, fragmented ultradian rhythms and altered hippocampal clock gene expression in an animal model of high trait anxiety- and depression-related behavior. ( Cabatic, M; Pollak, DD; Ronovsky, M; Sartori, SB; Savalli, G; Schaufler, J; Singewald, N, 2016) |
| "Early life stress increases risks of fear and anxiety related disorders in adulthood, which may be alleviated by fluoxetine treatment." | 7.81 | Fluoxetine treatment reverses the intergenerational impact of maternal separation on fear and anxiety behaviors. ( Cao, J; Mao, RR; Xiong, GJ; Xu, L; Yang, Y, 2015) |
| " We found that chronic treatment of a mouse model of anxiety/depression (CORT model) with a selective serotonin reuptake inhibitor (SSRI, fluoxetine, 18mg/kg/day) reversed CORT-induced anxiety/depression-like behavior in mice." | 7.81 | Nrf2-signaling and BDNF: A new target for the antidepressant-like activity of chronic fluoxetine treatment in a mouse model of anxiety/depression. ( Ali, ZE; Damiens, MH; David, DJ; Gardier, AM; Kerdine-Römer, S; Mendez-David, I; Pallardy, M; Tritschler, L, 2015) |
| "Postnatal treatment with the selective serotonin reuptake inhibitor fluoxetine, evokes anxiety and depressive behavior in rodent models in adulthood." | 7.80 | Postnatal fluoxetine-evoked anxiety is prevented by concomitant 5-HT2A/C receptor blockade and mimicked by postnatal 5-HT2A/C receptor stimulation. ( Chachra, P; Sarkar, A; Vaidya, VA, 2014) |
| " Therefore, the present study was aimed at investigating the effect of ondansetron, a selective 5HT3 receptor antagonist in attenuating depression and anxiety-like behavior comorbid with diabetes." | 7.80 | Ondansetron, a 5HT3 receptor antagonist reverses depression and anxiety-like behavior in streptozotocin-induced diabetic mice: possible implication of serotonergic system. ( Gupta, D; Kurhe, Y; Radhakrishnan, M, 2014) |
| " We have developed a mouse model of anxiety/depression based on addition of corticosterone to drinking water." | 7.78 | Functional status of somatodendritic serotonin 1A autoreceptor after long-term treatment with fluoxetine in a mouse model of anxiety/depression based on repeated corticosterone administration. ( David, DJ; Gardier, AM; Guiard, BP; Nguyen, HT; Quesseveur, G; Rainer, Q, 2012) |
| " In the present study, pain sensitivity was assessed in a mouse model of anxiety/depression on the basis of chronic corticosterone (CORT) administration through the drinking water (CORT model)." | 7.78 | Antinociceptive effects of fluoxetine in a mouse model of anxiety/depression. ( Coudoré, F; David, DJ; Gardier, AM; Guiard, BP; Hache, G; Le Dantec, Y; Orvoën, S, 2012) |
| "The GABA amides of the antidepressants nortriptyline and fluoxetine, 1 and 2, were compared to their respective parent compounds in rodent models of pain." | 7.75 | Gamma-aminobutyric acid amides of nortriptyline and fluoxetine display improved pain suppressing activity. ( Aharoni, A; Geffen, Y; Gil-Ad, I; Halbfinger, E; Nisemblat, Y; Nudelman, A; Rephaeli, A; Tarasenko, I; Tarasenko, N; Weizman, A, 2009) |
| " Here we describe a mouse model of an anxiety/depressive-like state induced by chronic corticosterone treatment." | 7.75 | Neurogenesis-dependent and -independent effects of fluoxetine in an animal model of anxiety/depression. ( Antonijevic, IA; Artymyshyn, RP; Craig, DA; David, DJ; Drew, M; Gardier, AM; Gerald, C; Guiard, BP; Guilloux, JP; Hen, R; Leonardo, ED; Marsteller, D; Mendez, I; Rainer, Q; Samuels, BA; Wang, JW, 2009) |
| " We report a case of recurrent priapism that was treated with Fluoxetine and low dose Perphenazine." | 7.74 | Treatment of idiopathic recurrent priapism with fluoxetine and low dose Perphenazine. ( Ahmadi, A; Khazaie, H; Moradi, M; Tahmasian, M, 2008) |
| "The objective of this study was evaluate the anxiety and locomotor activity (LA) in 52 Wistar adult male rats, being 26 treated with fluoxetine (10 mg/Kg - sc) in the neonatal period." | 7.74 | Neonatal administration of fluoxetine did not alter the anxiety indicators, but decreased the locomotor activity in adult rats in the elevated plus-maze. ( Aniceto, HK; Fraga, Sdo N; Guerra-Ribas, Rde M; Manhaes-de-Castro, R; Martins, HA; Ribas, KH; Ribas, VR; Ribeiro-Ribas, V; Vasconcelos, CM; Viana, MT, 2008) |
| "A dysregulated hypothalamic-pituitary-adrenal axis (HPA) has been implicated in major depressive disorder and most commonly used animal models of depression have been shown to elevate circulating levels of plasma corticosterone." | 7.74 | Chronic low dose corticosterone exposure decreased hippocampal cell proliferation, volume and induced anxiety and depression like behaviours in mice. ( Hutson, PH; Murray, F; Smith, DW, 2008) |
| "The effects of acute and chronic fluoxetine treatment in intact and anxiety-depressive male and female inbred mice of the C57BL/6J strain were studied." | 7.74 | [Effects of acute and chronic introduction of fluoxetine on anxiety-depressive condition of male and female mice]. ( Avgustinovich, DF; Kovalenko, IL; Tolstikova, TG, 2007) |
| "Escitalopram, the active enantiomer of the selective serotonin reuptake inhibitor (SSRI) citalopram, has effects in animal models for the detection of antidepressant and anxiolytic effect and in patients with major depressive and anxiety disorders." | 7.73 | Prediction of anti-panic properties of escitalopram in the dorsal periaqueductal grey model of panic anxiety. ( Hogg, S; Jessa, M; Michan, L, 2006) |
| " We initially assessed four inbred mouse strains for their behavioral response to chronic treatment with the selective-serotonin reuptake inhibitor fluoxetine (0, 5, 10 mg/kg/day in drinking water), which is used for the treatment of mood and anxiety disorders." | 7.72 | Effects of chronic fluoxetine in animal models of anxiety and depression. ( Dulawa, SC; Gundersen, B; Hen, R; Holick, KA, 2004) |
| "In keeping with the anxiolytic property of selective serotonin reuptake inhibitors (SSRIs) in humans, we have examined in the spontaneously hypertensive rat (SHR) and the Wistar-Kyoto (WKY) rat, which display low and high anxiety, respectively, some psychoneuroendocrine effects of a repeated treatment with the SSRI fluoxetine (5 or 10 mg/kg daily, for 3 weeks)." | 7.70 | Effects of repeated fluoxetine on anxiety-related behaviours, central serotonergic systems, and the corticotropic axis axis in SHR and WKY rats. ( Aguerre, S; Berton, O; Chaouloff, F; Combourieu, I; Durand, M; Edno, L; Mormède, P, 1999) |
| "The aim of this study was to evaluate the acute and chronic effects of two SSRIs (sertraline and fluoxetine) on anxiety by the elevated plus-maze test." | 7.70 | The effects of sertraline and fluoxetine on anxiety in the elevated plus-maze test in mice. ( Arik, AC; Celik, S; Kurt, M, 2000) |
| "The 5HT uptake inhibitor fluoxetine had no effect on motor activity or directed exploration (head-dipping) in a holeboard test or in an elevated plusmaze test of anxiety." | 7.67 | Behavioral interactions of fluoxetine and other 5-hydroxytryptamine uptake inhibitors with ethanol in tests of anxiety, locomotion and exploration. ( Durcan, MJ; Eckardt, MJ; Linnoila, M; Lister, RG, 1988) |
| "Medication is commonly used to treat youth depression, but whether medication should be added to cognitive behavioural therapy (CBT) as first-line treatment is unclear." | 6.90 | The addition of fluoxetine to cognitive behavioural therapy for youth depression (YoDA-C): a randomised, double-blind, placebo-controlled, multicentre clinical trial. ( Amminger, GP; Berk, M; Catania, L; Chanen, AM; Cotton, SM; Davey, CG; Dean, OM; Harrison, BJ; Hetrick, SE; Kazantzis, N; Kerr, M; Koutsogiannis, J; McGorry, PD; Mullen, E; Parker, AG; Phelan, M; Quinn, AL; Ratheesh, A; Rice, S; Weller, A, 2019) |
| "Moclobemide is a reversible selective inhibitor of monoamine oxidase A." | 6.68 | Moclobemide for anxiety disorders: a focus on moclobemide for panic disorder. ( Behnke, K; Bouwer, C; Tiller, JW, 1997) |
| "In general, effective treatments for trichotillomania have been elusive." | 6.67 | Clinical characteristics of trichotillomania and its response to fluoxetine. ( Jones, JS; Molcho, A; Stanley, B; Stanley, M; Winchel, RM, 1992) |
| "Fluoxetine was compared to doxepin in geriatric out-patients with major depressive illness." | 6.66 | Double-blind comparative trials of fluoxetine and doxepin in geriatric patients with major depressive disorder. ( Cohn, JB; Feighner, JP, 1985) |
| "Severity of anxiety does not appear to influence the antidepressant response to fluoxetine during acute treatment of major depressive disorder (MDD)." | 6.21 | Long-term treatment outcomes of depression with associated anxiety: efficacy of continuation treatment with fluoxetine. ( Fava, M; Joliat, MJ; Michelson, D; Miner, CM; Schmidt, ME; Trapp, NJ; Zhang, S, 2004) |
| "Female adult Wistar rats subjected to PTSD were treated with moderate treadmill exercise or fluoxetine, or a combination of both." | 5.91 | Effect of combination fluoxetine and exercise on prefrontal BDNF, anxiety-like behavior and fear extinction in a female rat model of post-traumatic stress disorder (PTSD): a comparison with male animals. ( Akhoundzadeh, K; Nikkhah, F; Shafia, S, 2023) |
| "Gabapentin is a commonly prescribed antiepileptic agent for seizures, which is also used for pain and addiction management." | 5.91 | Effect of Gabapentin-Fluoxetine Derivative GBP1F in a Murine Model of Depression, Anxiety and Cognition. ( Ali, G; Alkahramaan, YMSA; Arif, M; Gohar, A; Khan, MS; Rashid, U; Rauf, K; Sewell, RDE, 2023) |
| "Major depression is a leading contributor to the global burden of disease." | 5.72 | Lower antidepressant response to fluoxetine is associated with anxiety-like behavior, hippocampal oxidative imbalance, and increase on peripheral IL-17 and IFN-γ levels. ( Becker, G; Bochi, GV; Camargo, LFM; da Silva Carlotto, M; Dos Santos, BM; Fialho, MFP; Oliveira, SM; Pereira, GC; Pillat, MM; Piton, E; Ramanzini, LG; Trevisan, G; Zanchet, EM, 2022) |
| "Fluoxetine resulted in a faster reduction of patients' inflammation without association with depression and anxiety." | 5.69 | Efficacy and safety of adding fluoxetine to the treatment regimen of hospitalized patients with non-critical COVID-19 pneumonia: A double-blind randomized, placebo-controlled clinical trial. ( Ala, S; Alizadeh Arimi, F; Elyasi, F; Ghasemian, R; Mehravaran, H; Moosazadeh, M; Sedighi, F; Zarghami, M, 2023) |
| "Fluoxetine (FLX) is a common selective serotonin reuptake inhibitor, which is used in adolescents with psychiatric disorders." | 5.56 | Effects of adolescent administration of fluoxetine on novel object recognition memory, anxiety-like behaviors, and hippocampal brain-derived neurotrophic factor level. ( Adak, O; Dehghany, R; Saadati, H; Sadegzadeh, F; Sakhaie, N, 2020) |
| " At the end of dosing schedule, neurobehavioral tests were conducted; followed by mechanistic evaluation through biochemical analysis, RTPCR and western blot in serum and hippocampus." | 5.48 | Antidepressant activity of vorinostat is associated with amelioration of oxidative stress and inflammation in a corticosterone-induced chronic stress model in mice. ( Js, IC; Kv, A; Lahkar, M; Madhana, RM; Naidu, VGM; Sinha, S, 2018) |
| "Fluoxetine treatment exerted antidepressant effect in all rat lines irrespective of its effect on AS." | 5.43 | Effect of chronic fluoxetine treatment on audiogenic epilepsy, symptoms of anxiety and depression in rats of four lines. ( Fedotova, IB; Nikolaev, GM; Perepelkina, OV; Poletaeva, II; Sarkissova, KY; Surina, NM, 2016) |
| "The alprazolam was tapered completely and was only used episodically on two occasions." | 5.43 | COMBINATION THERAPY WITH FLUOXETINE AND ALPRAZOLAM TO CONTROL ANXIETY IN A HAND-REARED SNOW LEOPARD (UNCIA UNCIA). ( Holman, HJ, 2016) |
| "Laquinimod is a novel oral immunomodulatory drug for the treatment of multiple sclerosis (MS)." | 5.42 | Effects of the anti-multiple sclerosis immunomodulator laquinimod on anxiety and depression in rodent behavioral models. ( Amit, BH; Gil-Ad, I; Gueta, RU; Hayardeni, L; Taler, M; Tarasenko, I; Weizman, A, 2015) |
| "Fluoxetine improved FMMS and reduced anxiety and depression." | 5.41 | The efficacy and safety of fluoxetine versus placebo for stroke recovery: a meta-analysis of randomized controlled trials. ( Qin, G; Wu, J, 2023) |
| "Fluoxetine-treated dams gave birth to litters 15% smaller than usual and to pups of reduced weight (until postnatal day 7)." | 5.37 | Fluoxetine administration to pregnant rats increases anxiety-related behavior in the offspring. ( Afrasiab-Middelman, A; Dederen, JP; Homberg, JR; Jonkers, M; Kiliaan, AJ; Korte-Bouws, GA; Martens, GJ; Olivier, JD; Peeters, EJ; Roelofs, JJ; Schubert, D; Vallès, A; van Heesch, F, 2011) |
| "We present the results of a comparative analysis of the effects of the chronic administration of the selective serotonin reuptake inhibitors fluoxetine (5." | 5.37 | [Influence of fluoxetine and paroxetine on anxiety-like behavior in young and adult prenatally stressed male rats]. ( Akulova, VK; Fedotova, YO; Ordian, NÉ; Pivina, SG, 2011) |
| "Fluoxetine treatment reversed MDMA-induced anxiety in the emergence test and depressive-like effects in the forced swim test, yet exhibited no effects on the social interaction test." | 5.32 | Chronic fluoxetine treatment partly attenuates the long-term anxiety and depressive symptoms induced by MDMA ('Ecstasy') in rats. ( Clemens, KJ; Cornish, JL; Gurtman, CG; Hunt, GE; Li, KM; McGregor, IS; Thompson, MR, 2004) |
| " In the second experiment, in order to assess the effects of chronic dosing or handling on baseline UEEPM behaviour, subjects received either 21 days vehicle injection (p." | 5.31 | Further evidence for the predictive validity of the unstable elevated exposed plus-maze, a behavioural model of extreme anxiety in rats: differential effects of fluoxetine and chlordiazepoxide. ( Duxon, MS; Jones, N; King, SM, 2002) |
| "To determine the efficacy of fluoxetine for reducing the frequency and severity of obsessive-compulsive behaviors in autism spectrum disorders." | 5.30 | Effect of Fluoxetine on Obsessive-Compulsive Behaviors in Children and Adolescents With Autism Spectrum Disorders: A Randomized Clinical Trial. ( Dossetor, D; Granich, J; Hazell, P; Kohn, M; Lee, KJ; Marraffa, C; Mouti, A; O'Sullivan, M; Orsini, F; Reddihough, DS; Santosh, P; Silove, N; Whitehouse, AJO; Wray, J, 2019) |
| "Fluoxetine is a selective serotonin re-uptake inhibitor and thus being a specific antidepressant has its specific responder." | 5.29 | Fluoxetine in patients with major depressive disorder--a responder analysis. ( Heinrich, K; Klieser, E; Lehmann, E, 1995) |
| " Fluoxetine is effective against anxiety and panic disorders, while its use has shown promising results for VVS." | 5.24 | Fluoxetine vs. placebo for the treatment of recurrent vasovagal syncope with anxiety sensitivity. ( Flevari, P; Katsaras, D; Katsimardos, A; Leftheriotis, D; Lekakis, J; Repasos, E, 2017) |
| "These results suggest that although chronic fluoxetine treatment proves positive effects in animal models of depression, it may simultaneously increase anxiety in adolescent animals in a dose-related manner." | 5.22 | Effects of chronic fluoxetine treatment on anxiety- and depressive-like behaviors in adolescent rodents - systematic review and meta-analysis. ( Chocyk, A; Kryst, J; Majcher-Maślanka, I, 2022) |
| "To compare anxiety levels experienced during 4 stressful periods of in vitro fertilization (IVF) and treatment outcomes between women taking fluoxetine and a placebo." | 5.14 | Fluoxetine treatment for anxiety in women undergoing in vitro fertilization. ( Grosman, A; Lobo, DS; Motta, EL; Rocha, AM; Seibel, D; Serafini, P, 2009) |
| " The aim of this study was to assess the efficacy and safety of acupuncture in combination with fluoxetine as an intervention for major depressive disorder (MDD)." | 5.14 | Combination of acupuncture and fluoxetine for depression: a randomized, double-blind, sham-controlled trial. ( Yang, XB; Zhang, WJ; Zhong, BL, 2009) |
| "Combined therapy with adapted IPT was superior to fluoxetine alone in BPD patients, concerning a few core symptoms of the disorder, anxiety, and quality of life." | 5.14 | Adaptation of interpersonal psychotherapy to borderline personality disorder: a comparison of combined therapy and single pharmacotherapy. ( Bellino, S; Bogetto, F; Rinaldi, C, 2010) |
| "The objective of this study was to assess the relationship between early changes in anxiety/somatization symptoms and treatment outcome among major depressive disorder patients during a 12-week trial of fluoxetine." | 5.14 | Anxious depression and early changes in the HAMD-17 anxiety-somatization factor items and antidepressant treatment outcome. ( Alpert, J; Baer, L; Bitran, S; Chuzi, S; Clain, AJ; Dording, C; Farabaugh, AH; Fava, M; McGrath, PJ; Mischoulon, D; Papakostas, GI; Witte, J, 2010) |
| "This open clinical trial examined the feasibility, tolerability, and efficacy of treating adolescents who suffer from bulimia nervosa with fluoxetine." | 5.10 | An open trial of fluoxetine for adolescents with bulimia nervosa. ( Davies, M; Devlin, MJ; Kotler, LA; Walsh, BT, 2003) |
| " This is the first report aimed at studying the beneficial therapeutic effects of fluoxetine alone on anxiety dimension in first episode drug naive patients suffering from DSM-IV major depression (MDD) and double depression (DD)." | 5.10 | Fluoxetine alone in the treatment of first episode anxious-depression: an open clinical trial. ( Caltagirone, C; Pasini, A; Spalletta, G, 2002) |
| "Common adverse events associated with initiating fluoxetine treatment in depressed patients, including nausea, insomnia, nervousness, and somnolence, resolve in the majority of patients and become significantly less frequent with continued treatment over a 6-month period." | 5.09 | Changes in adverse events reported by patients during 6 months of fluoxetine therapy. ( Amsterdam, JD; Beasley, CM; Michelson, D; Quitkin, FM; Reimherr, FW; Rosenbaum, JF; Sundell, KL; Tamura, RN; Zajecka, J, 1999) |
| "Differences between the side effect profiles of clomipramine (CMI) and the selective serotonin reuptake inhibitors may be important factors in both treatment outcome and patient selection in obsessive-compulsive disorder (OCD)." | 5.09 | Side effects as predictors of drug response in obsessive-compulsive disorder. ( Ackerman, DL; Bystritsky, A; Greenland, S, 1999) |
| "Patients (N = 108) with DSM-IV major depression and high levels of anxiety (a HAM-D-Anxiety/Somatization Factor score > or =7) were randomized to fluoxetine, sertraline, or paroxetine treatment in a double-blind fashion." | 5.09 | Fluoxetine versus sertraline and paroxetine in major depression: tolerability and efficacy in anxious depression. ( Fava, M; Hoog, SL; Kopp, JB; Nilsson, ME; Rosenbaum, JF; Tepner, RG, 2000) |
| "Low-dose cotherapy of fluoxetine with clonazepam was safe and accelerated response over 21 days of treatment, decreasing anxiety and sleep disturbance as symptoms and partially suppressed them as SSRI side-effects; it also modestly reduced core symptoms of low mood and loss of interest." | 5.09 | Short-term cotherapy with clonazepam and fluoxetine: anxiety, sleep disturbance and core symptoms of depression. ( Glaudin, V; Londborg, PD; Painter, JR; Smith, WT, 2000) |
| "Twenty-two female patients with anorexia nervosa, restricted type, 14-35 years old, were treated with a 4-month course of combined cognitive-behavioral therapy, nutritional counselling and antidepressant drugs (nortriptyline for 7, fluoxetine for 15)." | 5.08 | Combined cognitive-behavioral, psychopharmacological and nutritional therapy in eating disorders. 1. Anorexia nervosa--restricted type. ( Brambilla, F; Brunetta, M; Draisci, A; Peirone, A, 1995) |
| "This randomized, double-blind, parallel-group design study of 100 outpatients with major depressive disorder is the first study in the United States to compare the efficacy and tolerability of fluvoxamine (100-150 mg/day) and fluoxetine (20-80 mg/day)." | 5.08 | A comparison of fluvoxamine and fluoxetine in the treatment of major depression. ( Bradford, D; Coccaro, E; Fabre, L; Holland, P; Perse, T; Rapaport, M; Sheline, Y, 1996) |
| "The objective was to present naturalistic 1-year follow-up information of 96 child and adolescent outpatients with major depressive disorder who had been randomized in an 8-week double-blind, placebo-controlled trial of fluoxetine." | 5.08 | Fluoxetine in child and adolescent depression: acute and maintenance treatment. ( Carmody, T; Emslie, GJ; Kowatch, RA; Mayes, TL; Rush, AJ; Weinberg, WA, 1998) |
| " By the response of the patients to alprazolam (anxiolytic) and fluoketin (antidepressant) given by a special scheme, 3 types of comorbidity of obsessional-phobic and affective disturbances were recognized: 1) prevalent depression, 2) combination of dysthymia with marked obsessional-phobic disorders, 3) overcoming of obsessional-phobic and affective disorders." | 5.07 | [The psychopharmacotherapy of anxious-depressive states (the interrelationship of the structure of the comorbidity to the choice of drug therapy)]. ( Andriushchenko, AV; Koliutskaia, EV; Morkovkina, IV; Smulevich, AB; Tkhostov, ASh, 1994) |
| " To assess rates and temporal patterns of activation and sedation as well as dose-effect relationships, adverse event data were evaluated from a fixed-dose study comparing placebo and fluoxetine 5, 20, and 40 mg/day in the treatment of major depressive disorder (N = 363) and two fixed-dose studies pooled together comparing placebo and fluoxetine 20, 40, and 60 mg/day in the treatment of major depressive disorder (N = 746)." | 5.07 | Fluoxetine: activating and sedating effects at multiple fixed doses. ( Beasley, CM; Potvin, JH; Sayler, ME; Weiss, AM, 1992) |
| " For individual adverse events that developed or worsened during therapy, more fluoxetine-treated patients reported rhinitis and tremor (p less than or equal to ." | 5.07 | Fluoxetine versus trazodone: efficacy and activating-sedating effects. ( Beasley, CM; Bosomworth, JC; Dornseif, BE; Pultz, JA; Sayler, ME, 1991) |
| "Fluoxetine, a specific serotonin reuptake inhibitor, was compared to amitriptyline in the treatment of 51 outpatients with primary major depressive disorder." | 5.05 | A double-blind controlled clinical trial of fluoxetine and amitriptyline in the treatment of outpatients with major depressive disorder. ( Chouinard, G, 1985) |
| "The effect of dose frequency on fluoxetine efficacy and safety was evaluated in a double-blind study in patients with major depressive disorder." | 5.05 | Comparison of two dosage regimens of fluoxetine in major depression. ( Amsterdam, JB; Glaudin, V; Rickels, K; Settle, GP; Smith, WT; Weise, C, 1985) |
| "During and following pregnancy, women are at high risk of experiencing depression, for which fluoxetine (FLX; brand names Prozac, Sarafem, Rapiflux) is the most commonly prescribed treatment." | 4.89 | Long-term outcomes of developmental exposure to fluoxetine: a review of the animal literature. ( Dyck, RH; Kiryanova, V; McAllister, BB, 2013) |
| "The selective serotonin reuptake inhibitor (SSRI) Prozac® (fluoxetine) is widely prescribed for the treatment of depression and anxiety-related disorders." | 4.87 | The age-dependent effects of selective serotonin reuptake inhibitors in humans and rodents: A review. ( Arentsen, T; Blom, T; Homberg, JR; Olivier, JD, 2011) |
| " Therefore, in this study, we combined subchronic fluoxetine (Flx) with 7-nitroindazole (NI), a selective nNOS inhibitor, and evaluated their efficacy against anxiety-related behavior in an animal model of PTSD." | 4.31 | Neuronal nitric oxide synthase inhibition accelerated the removal of fluoxetine's anxiogenic activity in an animal model of PTSD. ( Chamanara, M; Dehpour, AR; Fekrvand, S; Foroutani, L; Hemmati, S; Hosseini, Y; Nassireslami, E; Sadeghi, MA; Yousefi Zoshk, M; Yousefi-Manesh, H, 2023) |
| " In particular, we treated female and male rats with fluoxetine (FLX 15 mg/kg dissolved in drinking water) during prenatal or early postnatal life, and we evaluated different pathological-like phenotypes (cognitive deficit, anhedonia, and anxiety) by exposing the rats to a battery of behavioral tests during adolescence and adulthood." | 4.31 | Perinatal serotonergic manipulation shapes anhedonic and cognitive behaviors in a sex- and age-dependent manner: Identification of related biological functions at central and peripheral level. ( Brivio, P; Calabrese, F; Dolci, B; Fumagalli, F; Gallo, MT, 2023) |
| "During pregnancy, women are prone to depression, for which selective serotonin reuptake inhibitors (SSRIs), such as fluoxetine, are usually the first-line treatment." | 4.12 | Prenatal exposure to fluoxetine modulates emotionality and aversive memory in male and female rat offspring. ( Brandão, LEM; Câmara, DA; Cavalcante, JS; de Aquino, ACQ; Engelberth, RCJG; Fiuza, FP; Lima, RH; Linhares, SSG; Meurer, YDSR, 2022) |
| " Regular use of fluoxetine apparently prevented the onset of anxiety, depression, aggressiveness, and suicide ideation, even with the concurrent use of AAS." | 4.02 | Effective treatment and prevention of attempted suicide, anxiety, and aggressiveness with fluoxetine, despite proven use of androgenic anabolic steroids. ( Amaral, JMX; Aquino Neto, FR; Baker, JS; Chagas, SV; Cruz, MS; Mullen, C; Padilha, MC; Vieira Neto, L, 2021) |
| "We conclude that oral G115® significantly potentiates the antidepressant-like effect of fluoxetine in the FST in the absence of potentially confounding effects on locomotion and anxiety." | 4.02 | Standardised ginseng extract G115® potentiates the antidepressant-like properties of fluoxetine in the forced swim test. ( MacDonald, DS; Tasker, RA; Terstege, DJ, 2021) |
| "to evaluate the influence of two maternal high-fat diets with different caloric contents on anxiety-like behavior in young-adult offspring and their sensitivity to acute fluoxetine." | 4.02 | High-caloric or isocaloric maternal high-fat diets differently affect young-adult offspring behavior in anxiety-related tests and offspring sensitivity to acute fluoxetine. ( Benjamim, RAC; Cadena-Burbano, EV; Cavalcanti, CCL; Costa, TL; Da Silva Aragão, R; Lago, AB; Manhães-De-Castro, R; Oliveira, TRDP; Silva, EHM; Silva, JM, 2021) |
| " Furthermore, stressed dams were treated with different doses of fluoxetine (FLX; 5, 10and 25 mg/kg) during pregnancy and the postpartum period." | 4.02 | Perinatal fluoxetine dose-dependently affects prenatal stress-induced neurobehavioural abnormalities, HPA-axis functioning and underlying brain alterations in rat dams and their offspring. ( Amani, M; Homberg, JR; Houwing, DJ; Salari, AA, 2021) |
| "Fluoxetine is often prescribed to treat depression during pregnancy." | 4.02 | Prenatal fluoxetine impairs non-hippocampal but not hippocampal memory in adult male rat offspring. ( Ampuero, E; de Vries, EF; Díaz-Galarce, R; Donoso-Ramos, JP; Doorduin, J; Linsambarth, S; Moraga-Amaro, R; Pacheco, R; Peña, F; Stehberg, J; Ugalde, V; Wyneken, U, 2021) |
| "A 21-year-old female with a history of generalized anxiety disorder and major depression presented with increased depressive symptoms over several months while taking fluoxetine 20 mg daily." | 3.96 | A Case Report of Serotonin Syndrome in a Patient on Selective Serotonin Reuptake Inhibitor (SSRI) Monotherapy. ( Blake, CS; Hudd, TR; Nguyen, TT; Rimola-Dejesus, Y; Zaiken, K, 2020) |
| " In this regard, we chronically treated normal female mice with different dosages (0, 10, and 20 mg/kg) of fluoxetine (FLU) for 2 weeks before mating them with drug-free male mice and then tested the offspring for anxiety/depression-like behaviors with the elevated plus maze and the tail-suspension test after exposing to acute or chronic stress in adult period." | 3.91 | Chronic exposure to fluoxetine of female mice before mating causes impaired stress resilience in female offspring. ( Li, J; Si, J; Suo, L; Yang, C; Zhang, Y, 2019) |
| "Radiation therapy and concomitant temozolomide chemotherapy are commonly used in treatment of brain tumors, but they may also result in behavioral impairments such as anxiety and cognitive deficit." | 3.91 | Fluoxetine reverses brain radiation and temozolomide-induced anxiety and spatial learning and memory defect in mice. ( Chai, D; Gan, H; Wu, S; Zhang, Q; Zhu, B, 2019) |
| " This study investigated antidepressant-like effects and possible underlying mechanisms of Lactobacillus paracasei PS23 (PS23), live or heat-killed, in a mouse model of corticosterone-induced depression using fluoxetine as standard drug." | 3.91 | Antidepressant-like activities of live and heat-killed Lactobacillus paracasei PS23 in chronic corticosterone-treated mice and possible mechanisms. ( Cheng, YF; Hsu, CC; Liao, CL; Tsai, YC; Wang, S; Wei, CL; Wu, CC; Yen, JT, 2019) |
| "The aim of this study was to determine the effects of maternal fluoxetine treatment on anxiety-like and depressive-like behaviours in adolescent offspring as well as associated glutamatergic markers, using a clinically relevant rodent model of depression." | 3.91 | Perinatal exposure to fluoxetine increases anxiety- and depressive-like behaviours and alters glutamatergic markers in the prefrontal cortex and hippocampus of male adolescent rats: A comparison between Sprague-Dawley rats and the Wistar-Kyoto rat model o ( Fernandez, F; Lum, JS; Millard, SJ; Newell, KA; Weston-Green, K, 2019) |
| "We sought a robust behavioural test that evoked increased anxiety-like behaviour during the late dioestrus phase of the oestrous cycle (similar to the premenstrual period in women) and tested whether this could be prevented by acute low-dose fluoxetine (FLX)." | 3.91 | Short-term, low-dose fluoxetine prevents oestrous cycle-linked increase in anxiety-like behaviour in female rats. ( Brandão, ML; de Carvalho, MC; Lovick, TA; Machado Figueiredo, R, 2019) |
| "The antidepression and anti-anxiety drug fluoxetine reduced TPA-induced skin lesions and increased expression of BDNF and TrkB in K5." | 3.88 | Depression- and anxiety-like behaviour is related to BDNF/TrkB signalling in a mouse model of psoriasis. ( Hong, S; JiaWen, W; Jing, L; ShengXiang, X, 2018) |
| "We studied the effect of chronic injections of serotonin reuptake inhibitor fluoxetine to rats during pregnancy on physiological and behavioral characteristics of female offspring during the prepubertal period." | 3.88 | Effect of Fluoxetine in Prenatal Period on Nociceptive System Reactivity and Psychoemotional Behavior in Young Female Rats. ( Butkevich, IP; Mikhailenko, VA, 2018) |
| " The current study investigates possible effects of SSRIs, fluoxetine, and paroxetine on SB in patients with anxiety and depression." | 3.85 | BiteStrip analysis of the effect of fluoxetine and paroxetine on sleep bruxism. ( Aksoy, S; Atıcı, M; Erdogan, MS; Ertaş, ET; Isa Kara, M; Kelebek, S; Ozen, E, 2017) |
| " The aim of this study was to investigate whether anxiety or depression-like behavior can be found in rat strains with different susceptibility to audiogenic seizures (AS) and whether chronic fluoxetine treatment affects this co-morbidity." | 3.85 | Genetic background contributes to the co-morbidity of anxiety and depression with audiogenic seizure propensity and responses to fluoxetine treatment. ( Fedotova, IB; Kostina, ZA; Nikolaev, GM; Perepelkina, OV; Poletaeva, II; Sarkisova, KY; Surina, NM, 2017) |
| "The effects of the SSRI fluoxetine on genetically based, depression-related circadian disruptions at the behavioral and molecular level were examined using mice selectively bred for high anxiety-related and co-segregating depression-like behavior (HAB) and normal anxiety/depression behavior mice (NAB)." | 3.83 | Fluoxetine normalizes disrupted light-induced entrainment, fragmented ultradian rhythms and altered hippocampal clock gene expression in an animal model of high trait anxiety- and depression-related behavior. ( Cabatic, M; Pollak, DD; Ronovsky, M; Sartori, SB; Savalli, G; Schaufler, J; Singewald, N, 2016) |
| " Here we used a rodent model of anxiety/depression-like states, which is based on chronic CORT administration and studied the effects of the antidepressant fluoxetine (FLX) on behavior, olfaction, and adult neurogenesis in the dentate gyrus (DG), olfactory bulb (OB), and the olfactory epithelium (OE)." | 3.83 | Anxiety- and Depression-Like States Lead to Pronounced Olfactory Deficits and Impaired Adult Neurogenesis in Mice. ( de Chaumont, F; Denizet, M; Gabellec, MM; Guilloux, JP; Lazarini, F; Lledo, PM; Olivo-Marin, JC; Siopi, E, 2016) |
| " Here, we examine the effects of experimental lidocaine-induced anosmia on anxiety-like behavior and whole-body cortisol levels in adult zebrafish (Danio rerio)." | 3.83 | The smell of "anxiety": Behavioral modulation by experimental anosmia in zebrafish. ( Abreu, MS; Barcellos, LJ; Giacomini, AC; Kalueff, AV, 2016) |
| " We assessed fluoxetine's effects on motivated behaviors in pubescent female hamsters - anhedonia in the reward investigational preference (RIP) test as well as anxiety in the anxiety-related feeding/exploration conflict (AFEC) test." | 3.83 | Fluoxetine disrupts motivation and GABAergic signaling in adolescent female hamsters. ( DuBois, DW; Fincher, AS; Frye, GD; Henry, MM; Morgan, C; Shannonhouse, JL; Vela, AM; Wellman, PJ, 2016) |
| "Fluoxetine (FLX) is prescribed to treat depression and anxiety in adolescent patients." | 3.81 | Short-term fluoxetine treatment induces neuroendocrine and behavioral anxiogenic-like responses in adolescent male rats. ( García-García, L; Gomez, F; Venero, C; Viveros, MP, 2015) |
| "Early life stress increases risks of fear and anxiety related disorders in adulthood, which may be alleviated by fluoxetine treatment." | 3.81 | Fluoxetine treatment reverses the intergenerational impact of maternal separation on fear and anxiety behaviors. ( Cao, J; Mao, RR; Xiong, GJ; Xu, L; Yang, Y, 2015) |
| " We found that chronic treatment of a mouse model of anxiety/depression (CORT model) with a selective serotonin reuptake inhibitor (SSRI, fluoxetine, 18mg/kg/day) reversed CORT-induced anxiety/depression-like behavior in mice." | 3.81 | Nrf2-signaling and BDNF: A new target for the antidepressant-like activity of chronic fluoxetine treatment in a mouse model of anxiety/depression. ( Ali, ZE; Damiens, MH; David, DJ; Gardier, AM; Kerdine-Römer, S; Mendez-David, I; Pallardy, M; Tritschler, L, 2015) |
| " Finally, we used therapeutic interventions to explore mechanisms that may be involved in producing this increase in jump latency by administering the anti-depressant fluoxetine prior to the long jump assay, and also tested for potential changes in anxiety levels after stroke." | 3.81 | So you think you can jump? A novel long jump assessment to detect deficits in stroked mice. ( Hurn, PD; Kumar, S; Martin, L; Mittal, N; Ofomata, A; Palmateer, J; Pan, J; Pandya, A; Schallert, T, 2015) |
| "Postnatal treatment with the selective serotonin reuptake inhibitor fluoxetine, evokes anxiety and depressive behavior in rodent models in adulthood." | 3.80 | Postnatal fluoxetine-evoked anxiety is prevented by concomitant 5-HT2A/C receptor blockade and mimicked by postnatal 5-HT2A/C receptor stimulation. ( Chachra, P; Sarkar, A; Vaidya, VA, 2014) |
| "After 6 months, in the group receiving fluoxetine, the reduction of the level of anxiety was obtained from 22." | 3.80 | [The effect of fluoxetine and tianeptine on emotional and eating disorders in postmenopausal women]. ( Chojnacki, J; Jałocha, W; Klupińska, G; Tomaszewska-Warda, K; Walecka-Kapica, E, 2014) |
| " Therefore, the present study was aimed at investigating the effect of ondansetron, a selective 5HT3 receptor antagonist in attenuating depression and anxiety-like behavior comorbid with diabetes." | 3.80 | Ondansetron, a 5HT3 receptor antagonist reverses depression and anxiety-like behavior in streptozotocin-induced diabetic mice: possible implication of serotonergic system. ( Gupta, D; Kurhe, Y; Radhakrishnan, M, 2014) |
| " Fluoxetine and its metabolite, norfluoxetine, were quantified in the plasma of individual fish and linked to behavioural anxiety-related endpoints." | 3.80 | Quantitative cross-species extrapolation between humans and fish: the case of the anti-depressant fluoxetine. ( Cumming, RI; de Polo, A; Margiotta-Casaluci, L; Owen, SF; Panter, GH; Rand-Weaver, M; Sumpter, JP; Winter, MJ, 2014) |
| "Our results demonstrate that fluoxetine reduces anxiety-related behaviors in wild-derived zebrafish and alters their neurogenomic state." | 3.79 | Behavioral and neurogenomic transcriptome changes in wild-derived zebrafish with fluoxetine treatment. ( Godwin, J; Oxendine, SE; Wong, RY, 2013) |
| " The aim of the current study was to examine the sensitivity of the CRM paradigm to serotonergic manipulation with fluoxetine, a commonly prescribed selective serotonin reuptake inhibitor for anxiety disorders." | 3.79 | Subacute fluoxetine enhances conditioned responding and conditioning-specific reflex modification of the rabbit nictitating membrane response: implications for drug treatment with selective serotonin reuptake inhibitors. ( Burhans, LB; Schreurs, BG; Smith-Bell, CA, 2013) |
| " To test this hypothesis, we administered the AChE inhibitor physostigmine to mice and demonstrated an increase in anxiety- and depression-like behaviors that was reversed by administration of nicotinic or muscarinic antagonists." | 3.79 | Cholinergic signaling in the hippocampus regulates social stress resilience and anxiety- and depression-like behavior. ( Calarco, CA; Fote, GM; Li, AM; Mineur, YS; Obayemi, A; Picciotto, MR; Wigestrand, MB, 2013) |
| " In the present study, female rats were treated long term with clinically used antidepressants (fluoxetine, nortriptyline or mirtazapine) and subjected to the plus-maze discriminative avoidance task to evaluate learning, memory, extinction and anxiety-related behaviors as well as behavioral despair in the forced swimming test." | 3.78 | Antidepressants differentially modify the extinction of an aversive memory task in female rats. ( Cabral, A; Ferreira, LS; Izídio, GS; Macedo, PT; Melo, TG; Ribeiro, AM; Silva, RH; Sousa, DS, 2012) |
| " In the present study, pain sensitivity was assessed in a mouse model of anxiety/depression on the basis of chronic corticosterone (CORT) administration through the drinking water (CORT model)." | 3.78 | Antinociceptive effects of fluoxetine in a mouse model of anxiety/depression. ( Coudoré, F; David, DJ; Gardier, AM; Guiard, BP; Hache, G; Le Dantec, Y; Orvoën, S, 2012) |
| " Here we investigate changes in cell proliferation and neurogenesis along the septo-temporal axis of the hippocampus induced by the Unpredictable Chronic Mild Stress model of depression (UCMS), chronic fluoxetine treatment and enriched environment." | 3.78 | Differential environmental regulation of neurogenesis along the septo-temporal axis of the hippocampus. ( Belzung, C; Minier, F; Rainer, Q; Surget, A; Tanti, A, 2012) |
| " During adulthood, SFR and IMS mice received chronic treatment (∼3 weeks) with the selective serotonin reuptake inhibitor (SSRI) fluoxetine (18 mg/kg/day), and were assessed for anxiety- and depression-related behavior in the light/dark test and forced swim tests (FST), respectively." | 3.77 | Infant maternal separation impairs adult cognitive performance in BALB/cJ mice. ( Dulawa, SC; Jiao, J; Wang, L, 2011) |
| "The study demonstrated that tianeptine is as effective as fluoxetine in the treatment of PTSD, with even stronger effect on anxiety and equal tolerance." | 3.77 | Tianeptine in the combined treatment of combat related posttraumatic stress disorder. ( Frančišković, T; Janović, S; Letica-Crepulja, M; Nemčić-Moro, I; Rončević-Gržeta, I; Stevanović, A; Suković, Z, 2011) |
| "In the present study was examined the effect of treatment with olanzapine or risperidone, given separately or in combination with fluoxetine, in the elevated plus-maze test (an animal model of anxiety) in male Wistar rats." | 3.77 | Anxiolytic-like effects of olanzapine, risperidone and fluoxetine in the elevated plus-maze test in rats. ( Rogóż, Z; Skuza, G, 2011) |
| " Experiment 2 showed that fluoxetine treatment administered via drinking water attenuated depressive-like behaviour in the FST and TST in individually housed female C57BL/6J mice, but had no effect on anxiety-like behaviour." | 3.76 | The lonely mouse: verification of a separation-induced model of depression in female mice. ( Brown, RE; Martin, AL, 2010) |
| "The scope of this study was to investigate the acute effects of leptin on anxiety-related behaviors in comparison with the SSRI antidepressant fluoxetine." | 3.76 | Acute administration of leptin produces anxiolytic-like effects: a comparison with fluoxetine. ( Bronner, J; Garza, JC; Kim, CS; Liu, J; Lu, XY; Zhang, W, 2010) |
| "The objective of the present study is to investigate the effects of single and simultaneous lesions of the noradrenergic and serotonergic pathways (NA-X, 5-HT-X and XX, respectively) by intracerebroventricular administration of selective neurotoxins N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine-HCl (DSP-4) and 5,7-dihydroxytryptamine (5,7-DHT) on anxiety-like behavior in rats." | 3.76 | Effects of single and simultaneous lesions of serotonergic and noradrenergic pathways on open-space and bright-space anxiety-like behavior in two animal models. ( Kompagne, H; Kuki, Z; Lévay, G; Markó, B; Nagy, KM; Sziray, N, 2010) |
| " We therefore tested for panic and anxiety-related behaviour in rats coadministered with the selective serotonin reuptake inhibitor fluoxetine hydrochloride and the CB1 agonist delta9-tetrahydrocannabinol." | 3.76 | Behavioural effects of co-administration of delta9-tetrahydrocannabinol with fluoxetine in rats. ( Ashton, JC; Goddard, M; Smith, PF, 2010) |
| "The GABA amides of the antidepressants nortriptyline and fluoxetine, 1 and 2, were compared to their respective parent compounds in rodent models of pain." | 3.75 | Gamma-aminobutyric acid amides of nortriptyline and fluoxetine display improved pain suppressing activity. ( Aharoni, A; Geffen, Y; Gil-Ad, I; Halbfinger, E; Nisemblat, Y; Nudelman, A; Rephaeli, A; Tarasenko, I; Tarasenko, N; Weizman, A, 2009) |
| " Here we describe a mouse model of an anxiety/depressive-like state induced by chronic corticosterone treatment." | 3.75 | Neurogenesis-dependent and -independent effects of fluoxetine in an animal model of anxiety/depression. ( Antonijevic, IA; Artymyshyn, RP; Craig, DA; David, DJ; Drew, M; Gardier, AM; Gerald, C; Guiard, BP; Guilloux, JP; Hen, R; Leonardo, ED; Marsteller, D; Mendez, I; Rainer, Q; Samuels, BA; Wang, JW, 2009) |
| " We report a case of recurrent priapism that was treated with Fluoxetine and low dose Perphenazine." | 3.74 | Treatment of idiopathic recurrent priapism with fluoxetine and low dose Perphenazine. ( Ahmadi, A; Khazaie, H; Moradi, M; Tahmasian, M, 2008) |
| "Mice (C57BL/6J) received injections of SB, fluoxetine, or a combination of both drugs either acutely or chronically for a period of 28 days and were subjected to a battery of tests to measure anxiety and behavioral despair." | 3.74 | Antidepressant-like effects of the histone deacetylase inhibitor, sodium butyrate, in the mouse. ( Akbarian, S; Crusio, WE; Lin, CL; Schroeder, FA, 2007) |
| "A dysregulated hypothalamic-pituitary-adrenal axis (HPA) has been implicated in major depressive disorder and most commonly used animal models of depression have been shown to elevate circulating levels of plasma corticosterone." | 3.74 | Chronic low dose corticosterone exposure decreased hippocampal cell proliferation, volume and induced anxiety and depression like behaviours in mice. ( Hutson, PH; Murray, F; Smith, DW, 2008) |
| "The effects of acute and chronic fluoxetine treatment in intact and anxiety-depressive male and female inbred mice of the C57BL/6J strain were studied." | 3.74 | [Effects of acute and chronic introduction of fluoxetine on anxiety-depressive condition of male and female mice]. ( Avgustinovich, DF; Kovalenko, IL; Tolstikova, TG, 2007) |
| "Escitalopram, the active enantiomer of the selective serotonin reuptake inhibitor (SSRI) citalopram, has effects in animal models for the detection of antidepressant and anxiolytic effect and in patients with major depressive and anxiety disorders." | 3.73 | Prediction of anti-panic properties of escitalopram in the dorsal periaqueductal grey model of panic anxiety. ( Hogg, S; Jessa, M; Michan, L, 2006) |
| " When placed in stressful settings, BDNF(Met/Met) mice exhibited increased anxiety-related behaviors that were not normalized by the antidepressant, fluoxetine." | 3.73 | Genetic variant BDNF (Val66Met) polymorphism alters anxiety-related behavior. ( Bath, KG; Chen, ZY; Hempstead, BL; Herrera, DG; Ieraci, A; Jing, D; Khan, T; Lee, FS; McEwen, BS; Siao, CJ; Toth, M; Yang, C, 2006) |
| "The main objective of this report was to identify patient characteristics that led psychiatrists in an academic anxiety disorders clinic to make a decision about intensive treatment of patients with panic disorder with agoraphobia (PDA) with cognitive-behavioral therapy (CBT) alone, CBT plus a high-potency benzodiazepine (CBT+BZ) or CBT combined with BZ and an antidepressant, fluoxetine (CBT+BZ+AD)." | 3.72 | Treatment of panic disorder with agoraphobia in an anxiety disorders clinic: factors influencing psychiatrists' treatment choices. ( Kolar, D; Latas, M; Linden, M; Starcevic, V; Uhlenhuth, EH, 2004) |
| " We initially assessed four inbred mouse strains for their behavioral response to chronic treatment with the selective-serotonin reuptake inhibitor fluoxetine (0, 5, 10 mg/kg/day in drinking water), which is used for the treatment of mood and anxiety disorders." | 3.72 | Effects of chronic fluoxetine in animal models of anxiety and depression. ( Dulawa, SC; Gundersen, B; Hen, R; Holick, KA, 2004) |
| "The purpose of this study was to examine the relationship between the degree of anxiety or somatic symptoms present before treatment with the subsequent diagnosis of treatment-related adverse events (TRAEs) in patients with major depressive disorder (MDD) enrolled in an 8-week open trial of fluoxetine (20 mg)." | 3.72 | Anxiety and somatic symptoms as predictors of treatment-related adverse events in major depressive disorder. ( Alpert, JE; Fava, M; Hughes, ME; Nierenberg, AA; Papakostas, GI; Petersen, T, 2004) |
| "Fluoxetine, a selective serotonin reuptake inhibitor, shows moderate efficacy and potency in the rat forced swimming depression test and the shock-induced ultrasonic vocalization anxiety test, whereas the 5-HT(1A) receptor agonist (+/-)-8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) is highly efficient and potent in both models." | 3.72 | 5-HT1A receptors are differentially involved in the anxiolytic- and antidepressant-like effects of 8-OH-DPAT and fluoxetine in the rat. ( Dalmus, M; De Vry, J; Jentzsch, KR; Melon, C; Schreiber, R, 2004) |
| " They also had mature onset obesity characterized by a dramatic 80-150% increase in body weight, increased linear growth, and elevated serum levels of leptin, insulin, glucose, and cholesterol." | 3.71 | Conditional deletion of brain-derived neurotrophic factor in the postnatal brain leads to obesity and hyperactivity. ( Bates, B; Fan, G; Fekete, C; Jaenisch, R; Kelly, J; Kuehn, R; Lechan, RM; Rios, M, 2001) |
| "In keeping with the anxiolytic property of selective serotonin reuptake inhibitors (SSRIs) in humans, we have examined in the spontaneously hypertensive rat (SHR) and the Wistar-Kyoto (WKY) rat, which display low and high anxiety, respectively, some psychoneuroendocrine effects of a repeated treatment with the SSRI fluoxetine (5 or 10 mg/kg daily, for 3 weeks)." | 3.70 | Effects of repeated fluoxetine on anxiety-related behaviours, central serotonergic systems, and the corticotropic axis axis in SHR and WKY rats. ( Aguerre, S; Berton, O; Chaouloff, F; Combourieu, I; Durand, M; Edno, L; Mormède, P, 1999) |
| " These experiments investigate in mice the interactions of the 5HT reuptake inhibitors fluoxetine, citalopram and fluvoxamine and the NA uptake inhibitor desipramine with ethanol in the holeboard test and the elevated plusmaze test of anxiety." | 3.67 | Interactions of 5HT reuptake inhibitors and ethanol in tests of exploration and anxiety. ( Durcan, MJ; Eckardt, MJ; Linnoila, M; Lister, RG, 1988) |
| "The 5HT uptake inhibitor fluoxetine had no effect on motor activity or directed exploration (head-dipping) in a holeboard test or in an elevated plusmaze test of anxiety." | 3.67 | Behavioral interactions of fluoxetine and other 5-hydroxytryptamine uptake inhibitors with ethanol in tests of anxiety, locomotion and exploration. ( Durcan, MJ; Eckardt, MJ; Linnoila, M; Lister, RG, 1988) |
| "Medication is commonly used to treat youth depression, but whether medication should be added to cognitive behavioural therapy (CBT) as first-line treatment is unclear." | 2.90 | The addition of fluoxetine to cognitive behavioural therapy for youth depression (YoDA-C): a randomised, double-blind, placebo-controlled, multicentre clinical trial. ( Amminger, GP; Berk, M; Catania, L; Chanen, AM; Cotton, SM; Davey, CG; Dean, OM; Harrison, BJ; Hetrick, SE; Kazantzis, N; Kerr, M; Koutsogiannis, J; McGorry, PD; Mullen, E; Parker, AG; Phelan, M; Quinn, AL; Ratheesh, A; Rice, S; Weller, A, 2019) |
| "Patients suffering from major depressive disorder (MDD) have been reported to have substantial long-lasting limitations in multiple domains of health-related quality of life (HRQoL)." | 2.78 | Health-related quality of life and symptom severity in Chinese patients with major depressive disorder. ( Cao, Y; Li, W; Luo, X; Malison, RT; Shen, J; Zhang, Y, 2013) |
| "Patients with major depressive disorder (MDD) and significant anxiety are less responsive to antidepressants than those without anxiety." | 2.76 | A post hoc analysis of the effect of nightly administration of eszopiclone and a selective serotonin reuptake inhibitor in patients with insomnia and anxious depression. ( Fava, M; Huang, H; Iosifescu, DV; Mischoulon, D; Schaefer, K; Wessel, TC; Wilson, A, 2011) |
| "Anxious depression, defined as major depressive disorder (MDD) accompanied by high levels of anxiety, seems to be both common and difficult to treat, with antidepressant monotherapy often yielding modest results." | 2.75 | Fluoxetine-clonazepam cotherapy for anxious depression: an exploratory, post-hoc analysis of a randomized, double blind study. ( Ameral, VE; Baer, L; Brintz, C; Clain, A; Fava, M; Glaudin, V; Londborg, PD; Painter, JR; Papakostas, GI; Smith, WT, 2010) |
| "Cotherapy was effective in reducing insomnia but not anxiety or core symptoms (low mood, suicidality, reduced interest)." | 2.70 | Is extended clonazepam cotherapy of fluoxetine effective for outpatients with major depression? ( Glaudin, V; Londborg, PD; Painter, JR; Smith, WT, 2002) |
| "nortriptyline) was done." | 2.70 | Clinical and treatment response characteristics of late-life depression associated with vascular disease: a pooled analysis of two multicenter trials with sertraline. ( Clary, CM; Doraiswamy, PM; Krishnan, KR, 2001) |
| "Paroxetine appears to produce an earlier improvement in agitation and psychic anxiety symptoms compared with fluoxetine." | 2.69 | A Canadian multicenter, double-blind study of paroxetine and fluoxetine in major depressive disorder. ( Bakish, D; Beauclair, L; Bélanger, MC; Chouinard, G; Manchanda, R; Morris, P; O'Neill, MC; Ravindran, A; Reesal, R; Remick, R; Saxena, B; Vasavan Nair, NP, 1999) |
| "Moclobemide is a reversible selective inhibitor of monoamine oxidase A." | 2.68 | Moclobemide for anxiety disorders: a focus on moclobemide for panic disorder. ( Behnke, K; Bouwer, C; Tiller, JW, 1997) |
| "In general, effective treatments for trichotillomania have been elusive." | 2.67 | Clinical characteristics of trichotillomania and its response to fluoxetine. ( Jones, JS; Molcho, A; Stanley, B; Stanley, M; Winchel, RM, 1992) |
| "Fluoxetine was compared to doxepin in geriatric out-patients with major depressive illness." | 2.66 | Double-blind comparative trials of fluoxetine and doxepin in geriatric patients with major depressive disorder. ( Cohn, JB; Feighner, JP, 1985) |
| "Stroke is the major cause of adult disability." | 2.48 | Selective serotonin reuptake inhibitors (SSRIs) for stroke recovery. ( Claxton, A; Hackett, ML; Hankey, GJ; Hsieh, CF; Kutlubaev, MA; Lee, R; Mead, GE, 2012) |
| "Female adult Wistar rats subjected to PTSD were treated with moderate treadmill exercise or fluoxetine, or a combination of both." | 1.91 | Effect of combination fluoxetine and exercise on prefrontal BDNF, anxiety-like behavior and fear extinction in a female rat model of post-traumatic stress disorder (PTSD): a comparison with male animals. ( Akhoundzadeh, K; Nikkhah, F; Shafia, S, 2023) |
| "Gabapentin is a commonly prescribed antiepileptic agent for seizures, which is also used for pain and addiction management." | 1.91 | Effect of Gabapentin-Fluoxetine Derivative GBP1F in a Murine Model of Depression, Anxiety and Cognition. ( Ali, G; Alkahramaan, YMSA; Arif, M; Gohar, A; Khan, MS; Rashid, U; Rauf, K; Sewell, RDE, 2023) |
| "Depression is a psychiatric disorder that affects about 10% of the world's population and is accompanied by anxiety." | 1.72 | Alpha2-antiplasmin deficiency affects depression and anxiety-like behavior and apoptosis induced by stress in mice. ( Asahi, S; Hori, K; Kanno, Y; Maruyama, C; Matsuo, O; Ozaki, KI; Teramura, H; Tsuchida, K, 2022) |
| "Depression is a mood disorder with a high prevalence rate globally, which is associated with abnormalities in 5-hydroxytryptamine (5-HT) metabolism." | 1.72 | Oral administration of ( Chen, C; Chen, S; Farzi, A; Gao, K; Ke, X; Li, Y; Wang, H; Yu, T; Yu, Y, 2022) |
| "Major depression is a leading contributor to the global burden of disease." | 1.72 | Lower antidepressant response to fluoxetine is associated with anxiety-like behavior, hippocampal oxidative imbalance, and increase on peripheral IL-17 and IFN-γ levels. ( Becker, G; Bochi, GV; Camargo, LFM; da Silva Carlotto, M; Dos Santos, BM; Fialho, MFP; Oliveira, SM; Pereira, GC; Pillat, MM; Piton, E; Ramanzini, LG; Trevisan, G; Zanchet, EM, 2022) |
| "Depression is a psychiatric disorder with several comorbidities that has a complicated pathophysiology." | 1.62 | Exercise and fluoxetine treatment during adolescence protect against early life stress-induced behavioral abnormalities in adult rats. ( Amiri, S; Gauvin, E; Peeri, M; Pirri, F; Zolfaghari, FS, 2021) |
| "Fluoxetine (FLX) is a common selective serotonin reuptake inhibitor, which is used in adolescents with psychiatric disorders." | 1.56 | Effects of adolescent administration of fluoxetine on novel object recognition memory, anxiety-like behaviors, and hippocampal brain-derived neurotrophic factor level. ( Adak, O; Dehghany, R; Saadati, H; Sadegzadeh, F; Sakhaie, N, 2020) |
| "The etiology of major depressive disorder (MDD), the leading cause of worldwide disability, is unknown." | 1.51 | Activating newborn neurons suppresses depression and anxiety-like behaviors. ( Contractor, A; Dunlop, SR; Kessler, JA; Peng, CY; Tunc-Ozcan, E; Zhu, Y, 2019) |
| "Pretreatments of pyridoxine (90 mg/kg, i." | 1.51 | Lithium potentiated, pyridoxine abolished and fluoxetine attenuated the anxiolytic effect of diazepam in mice. ( Garg, C; Garg, M; Walia, V, 2019) |
| " At the end of dosing schedule, neurobehavioral tests were conducted; followed by mechanistic evaluation through biochemical analysis, RTPCR and western blot in serum and hippocampus." | 1.48 | Antidepressant activity of vorinostat is associated with amelioration of oxidative stress and inflammation in a corticosterone-induced chronic stress model in mice. ( Js, IC; Kv, A; Lahkar, M; Madhana, RM; Naidu, VGM; Sinha, S, 2018) |
| "Women with major depressive disorder during pregnancy often use selective serotonin reuptake inhibitors (SSRIs) antidepressants." | 1.46 | Prenatal fluoxetine modifies the behavioral and hormonal responses to stress in male mice: role for glucocorticoid insensitivity. ( Avitsur, R, 2017) |
| "Fluoxetine (Flx) is a first-line treatment for depression; however, its downstream mechanisms of action beyond serotonergic signaling remain ill-defined." | 1.46 | Fluoxetine reverses behavior changes in socially isolated rats: role of the hippocampal GSH-dependent defense system and proinflammatory cytokines. ( Filipović, D; Gass, P; Perić, I; Stanisavljević, A, 2017) |
| "Fluoxetine and melatonin treatments decreased TBARS in both cortices." | 1.46 | The antidepressant effect of melatonin and fluoxetine in diabetic rats is associated with a reduction of the oxidative stress in the prefrontal and hippocampal cortices. ( Boudah, A; Jasmin, L; Rebai, R, 2017) |
| "Fluoxetine (FLX) has paradoxical anxiogenic-like effects during the acute phase of treatment." | 1.46 | Anxiogenic-like effects of fluoxetine render adult male rats vulnerable to the effects of a novel stress. ( García-García, L; Gomez, F, 2017) |
| "Pretreatment with diazepam (1 mg kg(-1) intraperitoneal (i." | 1.43 | Short term, low dose fluoxetine blocks estrous cycle-linked changes in responsiveness to diazepam in female rats. ( André, E; de Sousa Pinto, ÍA; Gavioli, EC; Lovick, T; Santos, RO; Soares-Rachetti, Vde P, 2016) |
| "Fluoxetine treatment exerted antidepressant effect in all rat lines irrespective of its effect on AS." | 1.43 | Effect of chronic fluoxetine treatment on audiogenic epilepsy, symptoms of anxiety and depression in rats of four lines. ( Fedotova, IB; Nikolaev, GM; Perepelkina, OV; Poletaeva, II; Sarkissova, KY; Surina, NM, 2016) |
| "Laquinimod is a novel oral immunomodulatory drug for the treatment of multiple sclerosis (MS)." | 1.42 | Effects of the anti-multiple sclerosis immunomodulator laquinimod on anxiety and depression in rodent behavioral models. ( Amit, BH; Gil-Ad, I; Gueta, RU; Hayardeni, L; Taler, M; Tarasenko, I; Weizman, A, 2015) |
| " On the basis of these data, novel dosing strategies were developed for five antidepressants to mimic the pharmacological profile of the antidepressant with the longest half-life, fluoxetine." | 1.42 | The role of 5-HT1A receptors in mediating acute negative effects of antidepressants: implications in pediatric depression. ( Cao, YJ; Hendrix, CW; Kaplin, AI; Rahn, KA, 2015) |
| "Fluoxetine treatment did not affect these behavioral alterations, but it did increase the social dominance of the injured mice, as assessed by the tube test." | 1.42 | The effects of chronic fluoxetine treatment following injury of medial frontal cortex in mice. ( Barneto, AA; Dyck, RH; McAllister, BB; Patel, PP; Spanswick, SC, 2015) |
| "Ketamine is an anesthetic with antidepressant properties." | 1.42 | The positive effect on ketamine as a priming adjuvant in antidepressant treatment. ( Dalla, C; Ferreira, C; Kokras, N; Melo, A; Pêgo, JM; Sousa, N; Ventura-Silva, AP, 2015) |
| "Ketamine (Ketalar®) is a non-competitive glutamatergic antagonist classically used to induce sedation." | 1.42 | Behavioral, endocrine, and neuronal alterations in zebrafish (Danio rerio) following sub-chronic coadministration of fluoxetine and ketamine. ( Hylton, A; Pittman, J, 2015) |
| "A single injected dose of the antidepressant fluoxetine had no significant effect on animals' activity in the open-arm test, neither in a small dosage (5 mg/kgbw) nor in a higher one (10 mg/kgbw), whereas a single high dose of buspirone significantly impeded the open-arm activity of the rats." | 1.40 | Dose dependent effects of serotonergic agents on anxiety. ( Dogaru, MT; Gáll, Z; Kolcsar, M, 2014) |
| " Furthermore, we show that the serotonin transporter polyadenylation profile associated with the STPP risk allele is altered through the chronic administration of fluoxetine, a treatment that also facilitates retention of extinction learning." | 1.38 | Serotonin transporter polyadenylation polymorphism modulates the retention of fear extinction memory. ( Casey, BJ; Glatt, CE; Hartley, CA; Holmes, A; McKenna, MC; Phelps, EA; Salman, R, 2012) |
| " However, although the NPS anxiolytic dose-response curve displayed the classical sigmoidal shape, the dose-response curve of the putative panicolytic-like effect was bell shaped with peak effect at 0." | 1.38 | Anxiolytic- and panicolytic-like effects of Neuropeptide S in the mouse elevated T-maze. ( Calo, G; Guerrini, R; Pulga, A; Rizzi, A; Ruzza, C, 2012) |
| "Pre-treatment with diazepam (0." | 1.37 | Acute anxiogenic-like effects of selective serotonin reuptake inhibitors are attenuated by the benzodiazepine diazepam in BALB/c mice. ( Birkett, MA; Kessler, EJ; Meyer, JS; Ritchie, S; Rowlett, JK; Shinday, NM, 2011) |
| "Fluoxetine-treated dams gave birth to litters 15% smaller than usual and to pups of reduced weight (until postnatal day 7)." | 1.37 | Fluoxetine administration to pregnant rats increases anxiety-related behavior in the offspring. ( Afrasiab-Middelman, A; Dederen, JP; Homberg, JR; Jonkers, M; Kiliaan, AJ; Korte-Bouws, GA; Martens, GJ; Olivier, JD; Peeters, EJ; Roelofs, JJ; Schubert, D; Vallès, A; van Heesch, F, 2011) |
| "We present the results of a comparative analysis of the effects of the chronic administration of the selective serotonin reuptake inhibitors fluoxetine (5." | 1.37 | [Influence of fluoxetine and paroxetine on anxiety-like behavior in young and adult prenatally stressed male rats]. ( Akulova, VK; Fedotova, YO; Ordian, NÉ; Pivina, SG, 2011) |
| " Dam dosing was adjusted to reflect the 50th and 85th percentiles of serum concentrations observed in pregnant women." | 1.37 | Serotonin transporter occupancy in rats exposed to serotonin reuptake inhibitors in utero or via breast milk. ( Bourke, CH; Capello, CF; Nemeroff, A; Newport, DJ; Owens, MJ; Ritchie, JC; Stowe, ZN, 2011) |
| "It has been postulated that chronic administration of antidepressant drugs induces delayed structural and molecular adaptations at glutamatergic forebrain synapses that might underlie mood improvement." | 1.36 | Chronic fluoxetine treatment induces structural plasticity and selective changes in glutamate receptor subunits in the rat cerebral cortex. ( Aboitiz, F; Ampuero, E; Dagnino-Subiabre, A; Diaz-Veliz, G; Earle, N; Falcon, R; Gonzalez, RE; Orrego, F; Rubio, FJ; Sandoval, M; Wyneken, U, 2010) |
| "Effects of the chronic administration of selective serotonin reuptake inhibitors (SSRIs) fluoxetine (daily 5." | 1.36 | [Comparative efficacy of selective serotonin reuptake inhibitors in young prenatally stressed female rats]. ( Akulova, VK; Fedotova, IuO; Ordian, NÉ; Pivina, SG, 2010) |
| " Dose-response studies using two classes of anxiolytics (chlordiazepoxide: 2." | 1.35 | Modelling the anxiety-depression continuum in chicks. ( Acevedo, EO; Huang, CJ; Sufka, KJ; Warnick, JE, 2009) |
| "Treatment with fluoxetine between postnatal days P4 and P21 resulted in a significant loss of body weight and long-lasting behavioural inhibition in adult mice in response to stressful events such as the light-dark or open field tests." | 1.35 | Long-lasting behavioural and molecular alterations induced by early postnatal fluoxetine exposure are restored by chronic fluoxetine treatment in adult mice. ( Castrén, E; Karpova, NN; Lindholm, J; Pruunsild, P; Timmusk, T, 2009) |
| "Fluoxetine-treated fish seemed less active in their home tanks than controls or blocker-treated fish." | 1.35 | Fish on Prozac: effect of serotonin reuptake inhibitors on cognition in goldfish. ( Beulig, A; Fowler, J, 2008) |
| "Preclinical and clinical evidence suggests that anxiolytic effects are observed after chronic administration of the selective serotonin reuptake inhibitor fluoxetine." | 1.34 | Effects of acute and chronic treatment with fluoxetine on stress-induced hyperthermia in telemetered rats and mice. ( Conley, RK; Hutson, PH, 2007) |
| "Fluoxetine treatment reversed MDMA-induced anxiety in the emergence test and depressive-like effects in the forced swim test, yet exhibited no effects on the social interaction test." | 1.32 | Chronic fluoxetine treatment partly attenuates the long-term anxiety and depressive symptoms induced by MDMA ('Ecstasy') in rats. ( Clemens, KJ; Cornish, JL; Gurtman, CG; Hunt, GE; Li, KM; McGregor, IS; Thompson, MR, 2004) |
| "Therapy reduced PTSD symptoms, provoked anxiety and heart rate." | 1.31 | Brain function in a patient with torture related post-traumatic stress disorder before and after fluoxetine treatment: a positron emission tomography provocation study. ( Fernandez, M; Fischer, H; Frans, O; Fredrikson, M; Pissiota, A; von Knorring, L, 2001) |
| " The dose-response curve was biphasic for citalopram with a maximum of 64% inhibition." | 1.30 | Behavioral profiles of SSRIs in animal models of depression, anxiety and aggression. Are they all alike? ( Meier, E; Sánchez, C, 1997) |
| "Fluoxetine (alone) treatment of rats for 1 or 15 days had no effect on open-arm activity and cortical CRE-DNA-binding activity." | 1.30 | Potential role of the gene transcription factor cyclic AMP-responsive element binding protein in ethanol withdrawal-related anxiety. ( Mittal, N; Nayyar, D; Pandey, SC; Zhang, D, 1999) |
| "The treatment of fluoxetine significantly correlated with body mass index (T1: p < 0." | 1.30 | [The combined effect of psychotherapy and fluoxetine on obesity]. ( Haász, P; Jákó, P; Resch, M; Sidó, Z, 1999) |
| " In addition, long-term administration with both SRIs produced a reliable attenuation of predator assessment activities." | 1.29 | Differential modulation of antipredator defensive behavior in Swiss-Webster mice following acute or chronic administration of imipramine and fluoxetine. ( Agnes, RS; Blanchard, DC; Blanchard, RJ; Griebel, G, 1995) |
| "Fluoxetine is a selective serotonin re-uptake inhibitor and thus being a specific antidepressant has its specific responder." | 1.29 | Fluoxetine in patients with major depressive disorder--a responder analysis. ( Heinrich, K; Klieser, E; Lehmann, E, 1995) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 8 (2.31) | 18.7374 |
| 1990's | 33 (9.54) | 18.2507 |
| 2000's | 81 (23.41) | 29.6817 |
| 2010's | 174 (50.29) | 24.3611 |
| 2020's | 50 (14.45) | 2.80 |
| Authors | Studies |
|---|---|
| Rephaeli, A | 1 |
| Gil-Ad, I | 2 |
| Aharoni, A | 1 |
| Tarasenko, I | 2 |
| Tarasenko, N | 1 |
| Geffen, Y | 1 |
| Halbfinger, E | 1 |
| Nisemblat, Y | 1 |
| Weizman, A | 2 |
| Nudelman, A | 1 |
| Sagahón-Azúa, J | 1 |
| Medellín-Garibay, SE | 1 |
| Chávez-Castillo, CE | 1 |
| González-Salinas, CG | 1 |
| Milán-Segovia, RDC | 1 |
| Romano-Moreno, S | 1 |
| Ferreira-Garcia, R | 1 |
| Costa, MA | 1 |
| Gonçalves, FG | 1 |
| de Nonohay, RG | 1 |
| Nardi, AE | 1 |
| Freire, RCDR | 1 |
| Manfro, GG | 1 |
| Leussis, MP | 1 |
| Thanos, JM | 1 |
| Powers, A | 1 |
| Peterson, E | 1 |
| Head, JP | 1 |
| McGovern, NJ | 1 |
| Malarkey, FJ | 1 |
| Drake, A | 1 |
| Legg, LA | 1 |
| Rudberg, AS | 1 |
| Hua, X | 1 |
| Wu, S | 2 |
| Hackett, ML | 2 |
| Tilney, R | 1 |
| Lindgren, L | 1 |
| Kutlubaev, MA | 2 |
| Hsieh, CF | 2 |
| Barugh, AJ | 1 |
| Hankey, GJ | 2 |
| Lundström, E | 1 |
| Dennis, M | 1 |
| Mead, GE | 2 |
| Kanno, Y | 1 |
| Tsuchida, K | 1 |
| Maruyama, C | 1 |
| Hori, K | 1 |
| Teramura, H | 1 |
| Asahi, S | 1 |
| Matsuo, O | 1 |
| Ozaki, KI | 1 |
| Gao, K | 1 |
| Farzi, A | 1 |
| Ke, X | 1 |
| Yu, Y | 1 |
| Chen, C | 1 |
| Chen, S | 1 |
| Yu, T | 1 |
| Wang, H | 3 |
| Li, Y | 2 |
| Dos Santos, BM | 1 |
| Pereira, GC | 1 |
| Piton, E | 1 |
| Fialho, MFP | 1 |
| Becker, G | 1 |
| da Silva Carlotto, M | 1 |
| Camargo, LFM | 1 |
| Ramanzini, LG | 1 |
| Oliveira, SM | 1 |
| Trevisan, G | 1 |
| Zanchet, EM | 1 |
| Pillat, MM | 1 |
| Bochi, GV | 1 |
| Li, Q | 1 |
| Zhao, B | 1 |
| Li, W | 2 |
| He, Y | 1 |
| Tang, X | 2 |
| Zhang, T | 1 |
| Zhong, Z | 1 |
| Pan, Q | 1 |
| Zhang, Y | 4 |
| Kalbouneh, HM | 1 |
| Toubasi, AA | 1 |
| Albustanji, FH | 1 |
| Obaid, YY | 1 |
| Al-Harasis, LM | 1 |
| Kryst, J | 1 |
| Majcher-Maślanka, I | 1 |
| Chocyk, A | 1 |
| Sadeghi, MA | 1 |
| Hemmati, S | 1 |
| Yousefi-Manesh, H | 1 |
| Fekrvand, S | 1 |
| Foroutani, L | 1 |
| Nassireslami, E | 1 |
| Yousefi Zoshk, M | 1 |
| Hosseini, Y | 1 |
| Dehpour, AR | 1 |
| Chamanara, M | 1 |
| Shintani, Y | 1 |
| Yamano, Y | 1 |
| Kuta, M | 1 |
| Takeshita, R | 1 |
| Takuma, K | 2 |
| Okada, T | 1 |
| Toyooka, N | 1 |
| Takasaki, I | 1 |
| Miyata, A | 1 |
| Kurihara, T | 1 |
| Hashimoto, H | 1 |
| Hayata-Takano, A | 1 |
| Linhares, SSG | 1 |
| Meurer, YDSR | 1 |
| de Aquino, ACQ | 1 |
| Câmara, DA | 1 |
| Brandão, LEM | 1 |
| Fiuza, FP | 1 |
| Lima, RH | 1 |
| Engelberth, RCJG | 1 |
| Cavalcante, JS | 1 |
| Thanos, PK | 1 |
| McCarthy, M | 1 |
| Senior, D | 1 |
| Watts, S | 1 |
| Connor, C | 1 |
| Hammond, N | 1 |
| Blum, K | 1 |
| Hadjiargyrou, M | 1 |
| Komatsu, D | 1 |
| Steiner, H | 1 |
| Kurita, JPF | 1 |
| Leão, AHFF | 1 |
| Bioni, VS | 1 |
| Wuo-Silva, R | 1 |
| Lima, AC | 1 |
| Paiva-Santos, MA | 1 |
| Marinho, GF | 1 |
| Cunha, DMG | 1 |
| Becegato, M | 1 |
| Lopes-Silva, LB | 1 |
| Ribeiro, AM | 2 |
| Silva, RH | 2 |
| Shafia, S | 1 |
| Nikkhah, F | 1 |
| Akhoundzadeh, K | 1 |
| Maza, FJ | 1 |
| Urbano, FJ | 1 |
| Delorenzi, A | 1 |
| Sedighi, F | 1 |
| Zarghami, M | 1 |
| Alizadeh Arimi, F | 1 |
| Moosazadeh, M | 1 |
| Ala, S | 1 |
| Ghasemian, R | 1 |
| Mehravaran, H | 1 |
| Elyasi, F | 1 |
| Wu, J | 1 |
| Qin, G | 1 |
| Lemes, JA | 1 |
| Silva, MSCF | 1 |
| Gonçalves, BSM | 1 |
| Céspedes, IC | 1 |
| Viana, MB | 1 |
| Joo, MK | 1 |
| Kim, DH | 1 |
| Gohar, A | 1 |
| Ali, G | 1 |
| Rashid, U | 1 |
| Rauf, K | 1 |
| Arif, M | 1 |
| Khan, MS | 1 |
| Alkahramaan, YMSA | 1 |
| Sewell, RDE | 1 |
| Szala-Rycaj, J | 1 |
| Szewczyk, A | 1 |
| Zagaja, M | 1 |
| Kaczmarczyk-Ziemba, A | 1 |
| Maj, M | 1 |
| Andres-Mach, M | 1 |
| Pestana, JE | 1 |
| Graham, BM | 2 |
| Gallo, MT | 1 |
| Brivio, P | 1 |
| Dolci, B | 1 |
| Fumagalli, F | 1 |
| Calabrese, F | 1 |
| Yuan, P | 1 |
| Zhang, J | 1 |
| Li, L | 1 |
| Song, Z | 1 |
| Tunc-Ozcan, E | 1 |
| Peng, CY | 2 |
| Zhu, Y | 1 |
| Dunlop, SR | 1 |
| Contractor, A | 1 |
| Kessler, JA | 2 |
| Yang, C | 2 |
| Si, J | 1 |
| Suo, L | 1 |
| Li, J | 1 |
| Yohn, CN | 1 |
| Ashamalla, SA | 1 |
| Bokka, L | 1 |
| Gergues, MM | 1 |
| Garino, A | 1 |
| Samuels, BA | 2 |
| Giacomini, ACVV | 1 |
| Piassetta, AS | 1 |
| Genario, R | 1 |
| Bonan, CD | 1 |
| Piato, A | 1 |
| Barcellos, LJG | 1 |
| de Abreu, MS | 2 |
| Sun, L | 1 |
| Zhang, H | 1 |
| Cao, Y | 2 |
| Wang, C | 1 |
| Zhao, C | 1 |
| Cui, G | 1 |
| Wang, M | 1 |
| Pan, Y | 1 |
| Shi, Y | 1 |
| Nie, Y | 1 |
| Orrico-Sanchez, A | 1 |
| Chausset-Boissarie, L | 1 |
| Alves de Sousa, R | 1 |
| Coutens, B | 1 |
| Rezai Amin, S | 1 |
| Vialou, V | 1 |
| Louis, F | 1 |
| Hessani, A | 1 |
| Dansette, PM | 1 |
| Zornoza, T | 1 |
| Gruszczynski, C | 1 |
| Giros, B | 1 |
| Guiard, BP | 6 |
| Acher, F | 1 |
| Pietrancosta, N | 1 |
| Gautron, S | 1 |
| Reddihough, DS | 1 |
| Marraffa, C | 1 |
| Mouti, A | 1 |
| O'Sullivan, M | 1 |
| Lee, KJ | 1 |
| Orsini, F | 1 |
| Hazell, P | 1 |
| Granich, J | 1 |
| Whitehouse, AJO | 1 |
| Wray, J | 1 |
| Dossetor, D | 1 |
| Santosh, P | 1 |
| Silove, N | 1 |
| Kohn, M | 1 |
| de Souza, JA | 1 |
| do Amaral Almeida, LC | 1 |
| Tavares, GA | 1 |
| Falcão, LAL | 1 |
| Beltrão, LC | 1 |
| Costa, FCO | 1 |
| de Souza, FL | 1 |
| da Silva, MC | 1 |
| de Souza, SL | 1 |
| Holanda, DKR | 1 |
| Wurlitzer, NJ | 1 |
| Dionisio, AP | 1 |
| Campos, AR | 1 |
| Moreira, RA | 1 |
| Sousa, PHM | 1 |
| Brito, ES | 1 |
| Ribeiro, PRV | 1 |
| Iunes, MF | 1 |
| Costa, AM | 1 |
| Liao, XM | 1 |
| Su, YA | 1 |
| Wang, Y | 1 |
| Yu, X | 1 |
| Si, TM | 1 |
| Houwing, DJ | 3 |
| Schuttel, K | 1 |
| Struik, EL | 1 |
| Arling, C | 1 |
| Ramsteijn, AS | 1 |
| Heinla, I | 1 |
| Olivier, JDA | 1 |
| Zhou, Y | 1 |
| Arend, J | 1 |
| Mufson, L | 1 |
| Gunlicks-Stoessel, M | 1 |
| Christodoulos, IN | 1 |
| Chyou, TY | 1 |
| Nishtala, PS | 1 |
| Wang, D | 1 |
| Tian, HL | 1 |
| Cui, X | 1 |
| Wang, Q | 1 |
| Guo, F | 1 |
| Zhang, W | 2 |
| Tang, QS | 1 |
| Amaral, JMX | 1 |
| Padilha, MC | 1 |
| Chagas, SV | 1 |
| Baker, JS | 1 |
| Mullen, C | 1 |
| Vieira Neto, L | 1 |
| Aquino Neto, FR | 1 |
| Cruz, MS | 1 |
| Laureano-Melo, R | 1 |
| Dos-Santos, RC | 1 |
| da Conceição, RR | 1 |
| de Souza, JS | 1 |
| da Silva Lau, R | 1 |
| da Silva Souza Silva, S | 1 |
| Marinho, BG | 1 |
| Giannocco, G | 1 |
| Ahmed, RG | 1 |
| da Silva Côrtes, W | 1 |
| Sadegzadeh, F | 1 |
| Sakhaie, N | 1 |
| Dehghany, R | 1 |
| Adak, O | 1 |
| Saadati, H | 1 |
| Tikker, L | 1 |
| Casarotto, P | 1 |
| Singh, P | 1 |
| Biojone, C | 1 |
| Piepponen, TP | 1 |
| Estartús, N | 1 |
| Seelbach, A | 1 |
| Sridharan, R | 1 |
| Laukkanen, L | 1 |
| Castrén, E | 2 |
| Partanen, J | 1 |
| Demin, KA | 1 |
| Lakstygal, AM | 1 |
| Krotova, NA | 1 |
| Masharsky, A | 1 |
| Tagawa, N | 1 |
| Chernysh, MV | 1 |
| Ilyin, NP | 1 |
| Taranov, AS | 1 |
| Galstyan, DS | 1 |
| Derzhavina, KA | 1 |
| Levchenko, NA | 1 |
| Kolesnikova, TO | 1 |
| Mor, MS | 1 |
| Vasyutina, ML | 1 |
| Efimova, EV | 1 |
| Katolikova, N | 1 |
| Prjibelski, AD | 1 |
| Gainetdinov, RR | 1 |
| Amstislavskaya, TG | 1 |
| Strekalova, T | 1 |
| Kalueff, AV | 4 |
| Terstege, DJ | 1 |
| MacDonald, DS | 1 |
| Tasker, RA | 1 |
| Cavalcanti, CCL | 1 |
| Da Silva Aragão, R | 1 |
| Cadena-Burbano, EV | 1 |
| Oliveira, TRDP | 1 |
| Silva, JM | 1 |
| Benjamim, RAC | 1 |
| Lago, AB | 1 |
| Silva, EHM | 1 |
| Costa, TL | 1 |
| Manhães-De-Castro, R | 3 |
| Flores-Ramirez, FJ | 1 |
| Themann, A | 1 |
| Sierra-Fonseca, JA | 1 |
| Garcia-Carachure, I | 1 |
| Castillo, SA | 1 |
| Rodriguez, M | 1 |
| Lira, O | 1 |
| Preciado-Piña, J | 1 |
| Warren, BL | 4 |
| Robison, AJ | 1 |
| Iñiguez, SD | 4 |
| Zolfaghari, FS | 1 |
| Pirri, F | 1 |
| Gauvin, E | 1 |
| Peeri, M | 1 |
| Amiri, S | 1 |
| Bashiri, H | 1 |
| Homberg, JR | 6 |
| Salari, AA | 3 |
| Amigo, J | 2 |
| Garro-Martinez, E | 1 |
| Vidal Casado, R | 1 |
| Compan, V | 2 |
| Pilar-Cuéllar, F | 2 |
| Pazos, A | 2 |
| Díaz, A | 2 |
| Castro, E | 2 |
| Liu, K | 1 |
| Garcia, A | 1 |
| Park, JJ | 1 |
| Toliver, AA | 1 |
| Ramos, L | 1 |
| Aizenman, CD | 1 |
| Panayotis, N | 1 |
| Freund, PA | 1 |
| Marvaldi, L | 1 |
| Shalit, T | 1 |
| Brandis, A | 1 |
| Mehlman, T | 1 |
| Tsoory, MM | 1 |
| Fainzilber, M | 1 |
| Amani, M | 1 |
| Moraga-Amaro, R | 1 |
| Díaz-Galarce, R | 1 |
| Donoso-Ramos, JP | 1 |
| Ugalde, V | 1 |
| Linsambarth, S | 1 |
| Doorduin, J | 1 |
| de Vries, EF | 1 |
| Ampuero, E | 2 |
| Peña, F | 1 |
| Pacheco, R | 1 |
| Wyneken, U | 2 |
| Stehberg, J | 1 |
| Isa Kara, M | 1 |
| Ertaş, ET | 1 |
| Ozen, E | 1 |
| Atıcı, M | 1 |
| Aksoy, S | 1 |
| Erdogan, MS | 1 |
| Kelebek, S | 1 |
| Avitsur, R | 2 |
| Perić, I | 1 |
| Stanisavljević, A | 1 |
| Gass, P | 1 |
| Filipović, D | 2 |
| Benham, RS | 1 |
| Hewage, NB | 1 |
| Suckow, RF | 1 |
| Engin, E | 1 |
| Rudolph, U | 1 |
| Gemmel, M | 1 |
| Hazlett, M | 1 |
| Bögi, E | 2 |
| De Lacalle, S | 1 |
| Hill, LA | 1 |
| Kokras, N | 2 |
| Hammond, GL | 1 |
| Dalla, C | 2 |
| Charlier, TD | 1 |
| Pawluski, JL | 4 |
| Rebai, R | 1 |
| Jasmin, L | 1 |
| Boudah, A | 1 |
| Connor, DA | 1 |
| Gould, TJ | 1 |
| Song, C | 1 |
| Liu, BP | 1 |
| Zhang, YP | 1 |
| Peng, Z | 1 |
| Wang, J | 1 |
| Collier, AD | 1 |
| Echevarria, DJ | 1 |
| Savelieva, KV | 1 |
| Lawrence, RF | 1 |
| Rex, CS | 1 |
| Meshalkina, DA | 1 |
| Mitra, S | 1 |
| Mucha, M | 1 |
| Owen, S | 1 |
| Bult-Ito, A | 2 |
| Todorović, N | 1 |
| Zewde, AM | 1 |
| Yu, F | 1 |
| Nayak, S | 1 |
| Tallarida, C | 1 |
| Reitz, AB | 1 |
| Kirby, LG | 1 |
| Rawls, SM | 2 |
| Dincheva, I | 1 |
| Yang, J | 3 |
| Li, A | 1 |
| Marinic, T | 1 |
| Freilingsdorf, H | 1 |
| Huang, C | 1 |
| Casey, BJ | 2 |
| Hempstead, B | 1 |
| Glatt, CE | 2 |
| Lee, FS | 2 |
| Bath, KG | 2 |
| Jing, D | 2 |
| Pu, ZP | 1 |
| Xia, JM | 1 |
| Xie, W | 1 |
| He, JC | 1 |
| JiaWen, W | 1 |
| Hong, S | 1 |
| ShengXiang, X | 1 |
| Jing, L | 1 |
| Kv, A | 1 |
| Madhana, RM | 1 |
| Js, IC | 1 |
| Lahkar, M | 1 |
| Sinha, S | 1 |
| Naidu, VGM | 1 |
| Belovicová, K | 1 |
| Ujhazy, E | 1 |
| Mach, M | 1 |
| Koprdova, R | 1 |
| Zilava, L | 1 |
| Garafová, A | 1 |
| Jezova, D | 1 |
| Dubovicky, M | 1 |
| Zoric, B | 1 |
| Jankovic, L | 1 |
| Kuzmanovic Pficer, J | 1 |
| Zidverc-Trajkovic, J | 1 |
| Mijajlovic, M | 1 |
| Stanimirovic, D | 1 |
| Gobinath, AR | 2 |
| Wong, S | 1 |
| Chow, C | 2 |
| Lieblich, SE | 2 |
| Barr, AM | 1 |
| Galea, LAM | 1 |
| Butkevich, IP | 2 |
| Mikhailenko, VA | 2 |
| Pereira, MM | 1 |
| de Morais, H | 1 |
| Dos Santos Silva, E | 1 |
| Corso, CR | 1 |
| Adami, ER | 1 |
| Carlos, RM | 1 |
| Acco, A | 1 |
| Zanoveli, JM | 1 |
| Aguilar-Valles, A | 1 |
| Haji, N | 1 |
| De Gregorio, D | 1 |
| Matta-Camacho, E | 1 |
| Eslamizade, MJ | 1 |
| Popic, J | 1 |
| Sharma, V | 1 |
| Cao, R | 1 |
| Rummel, C | 1 |
| Tanti, A | 2 |
| Wiebe, S | 1 |
| Nuñez, N | 1 |
| Comai, S | 1 |
| Nadon, R | 1 |
| Luheshi, G | 1 |
| Mechawar, N | 1 |
| Turecki, G | 1 |
| Lacaille, JC | 1 |
| Gobbi, G | 1 |
| Sonenberg, N | 1 |
| Zhuang, X | 1 |
| Xu, H | 1 |
| Fang, Z | 1 |
| Xu, C | 1 |
| Xue, C | 1 |
| Hong, X | 1 |
| Dong, V | 1 |
| Richardson, R | 1 |
| Micheli, L | 1 |
| Ceccarelli, M | 1 |
| D'Andrea, G | 1 |
| Tirone, F | 1 |
| Martin, JM | 2 |
| Bertram, MG | 2 |
| Saaristo, M | 2 |
| Ecker, TE | 1 |
| Hannington, SL | 2 |
| Tanner, JL | 1 |
| Michelangeli, M | 1 |
| O'Bryan, MK | 1 |
| Wong, BBM | 2 |
| Gan, H | 1 |
| Zhang, Q | 1 |
| Zhu, B | 1 |
| Chai, D | 1 |
| Wei, CL | 1 |
| Wang, S | 2 |
| Yen, JT | 1 |
| Cheng, YF | 1 |
| Liao, CL | 1 |
| Hsu, CC | 1 |
| Wu, CC | 1 |
| Tsai, YC | 1 |
| Millard, SJ | 1 |
| Lum, JS | 1 |
| Fernandez, F | 1 |
| Weston-Green, K | 1 |
| Newell, KA | 1 |
| Garabadu, D | 1 |
| Kumar, V | 1 |
| Mao, M | 1 |
| Li, S | 1 |
| Zong, M | 1 |
| Qiu, L | 1 |
| Xia, J | 1 |
| Ji, M | 1 |
| Walden, J | 1 |
| Cho, M | 1 |
| Nayak, SU | 1 |
| Jennings, T | 1 |
| Tallarida, CS | 1 |
| Machado Figueiredo, R | 1 |
| de Carvalho, MC | 1 |
| Brandão, ML | 2 |
| Lovick, TA | 1 |
| Hudd, TR | 1 |
| Blake, CS | 1 |
| Rimola-Dejesus, Y | 1 |
| Nguyen, TT | 1 |
| Zaiken, K | 1 |
| Fursdon, JB | 1 |
| Brooks, BW | 1 |
| Burket, SR | 1 |
| Mole, RA | 1 |
| Deal, NDS | 1 |
| Walia, V | 1 |
| Garg, C | 1 |
| Garg, M | 1 |
| Davey, CG | 1 |
| Chanen, AM | 1 |
| Hetrick, SE | 1 |
| Cotton, SM | 1 |
| Ratheesh, A | 1 |
| Amminger, GP | 1 |
| Koutsogiannis, J | 1 |
| Phelan, M | 1 |
| Mullen, E | 1 |
| Harrison, BJ | 1 |
| Rice, S | 1 |
| Parker, AG | 1 |
| Dean, OM | 1 |
| Weller, A | 1 |
| Kerr, M | 1 |
| Quinn, AL | 1 |
| Catania, L | 1 |
| Kazantzis, N | 1 |
| McGorry, PD | 1 |
| Berk, M | 1 |
| Aguiar, JC | 1 |
| Gomes, EP | 1 |
| Fonseca-Silva, T | 1 |
| Velloso, NA | 1 |
| Vieira, LT | 1 |
| Fernandes, MF | 1 |
| Santos, SH | 1 |
| Neto, JF | 1 |
| De-Paula, AM | 1 |
| Guimarães, AL | 1 |
| Maximino, C | 2 |
| Puty, B | 2 |
| Benzecry, R | 1 |
| Araújo, J | 1 |
| Lima, MG | 1 |
| de Jesus Oliveira Batista, E | 1 |
| Renata de Matos Oliveira, K | 1 |
| Crespo-Lopez, ME | 1 |
| Herculano, AM | 2 |
| Hilton, RC | 1 |
| Rengasamy, M | 1 |
| Mansoor, B | 1 |
| He, J | 1 |
| Mayes, T | 1 |
| Emslie, GJ | 3 |
| Porta, G | 1 |
| Clarke, GN | 1 |
| Wagner, KD | 2 |
| Birmaher, B | 1 |
| Keller, MB | 1 |
| Ryan, N | 1 |
| Shamseddeen, W | 1 |
| Asarnow, JR | 1 |
| Brent, DA | 1 |
| Quesseveur, G | 2 |
| David, DJ | 9 |
| Gaillard, MC | 1 |
| Pla, P | 1 |
| Wu, MV | 2 |
| Nguyen, HT | 2 |
| Nicolas, V | 1 |
| Auregan, G | 1 |
| David, I | 1 |
| Dranovsky, A | 1 |
| Hantraye, P | 1 |
| Hen, R | 6 |
| Gardier, AM | 9 |
| Déglon, N | 1 |
| Morozova, AY | 1 |
| Zubkov, EA | 1 |
| Storozheva, ZI | 1 |
| Kekelidze, ZI | 1 |
| Chekhonin, VP | 1 |
| Majidi-Zolbanin, J | 1 |
| Azarfarin, M | 1 |
| Samadi, H | 1 |
| Enayati, M | 1 |
| Trofimiuk, E | 1 |
| Braszko, JJ | 1 |
| Matos Oliveira, KR | 1 |
| Wong, RY | 1 |
| Oxendine, SE | 1 |
| Godwin, J | 1 |
| Lapmanee, S | 1 |
| Charoenphandhu, J | 2 |
| Charoenphandhu, N | 2 |
| Arrant, AE | 1 |
| Coburn, E | 1 |
| Jacobsen, J | 1 |
| Kuhn, CM | 1 |
| Shen, J | 1 |
| Malison, RT | 1 |
| Luo, X | 1 |
| Bhatt, S | 1 |
| Mahesh, R | 1 |
| Devadoss, T | 1 |
| Jindal, A | 1 |
| El Yacoubi, M | 1 |
| Rappeneau, V | 1 |
| Champion, E | 1 |
| Malleret, G | 1 |
| Vaugeois, JM | 1 |
| Sachs, BD | 1 |
| Jacobsen, JP | 1 |
| Thomas, TL | 1 |
| Siesser, WB | 1 |
| Roberts, WL | 1 |
| Caron, MG | 1 |
| Kangussu, LM | 1 |
| Almeida-Santos, AF | 1 |
| Bader, M | 1 |
| Alenina, N | 1 |
| Fontes, MA | 1 |
| Santos, RA | 1 |
| Aguiar, DC | 1 |
| Campagnole-Santos, MJ | 1 |
| Hoeffer, CA | 1 |
| Wong, H | 1 |
| Cain, P | 1 |
| Levenga, J | 1 |
| Cowansage, KK | 1 |
| Choi, Y | 1 |
| Davy, C | 1 |
| Majmundar, N | 1 |
| McMillan, DR | 1 |
| Rothermel, BA | 1 |
| Klann, E | 1 |
| Pittman, JT | 1 |
| Lott, CS | 1 |
| Kiryanova, V | 2 |
| McAllister, BB | 2 |
| Dyck, RH | 3 |
| Vicente, MA | 1 |
| Zangrossi, H | 1 |
| Mendez-David, I | 2 |
| Darcet, F | 2 |
| Kerdine-Römer, S | 2 |
| Sarkar, A | 1 |
| Chachra, P | 1 |
| Vaidya, VA | 1 |
| da Silva, AI | 1 |
| Monteiro Galindo, LC | 1 |
| Nascimento, L | 1 |
| Moura Freitas, C | 1 |
| Lagranha, CJ | 1 |
| Lopes de Souza, S | 1 |
| Anderson, ST | 1 |
| Commins, S | 1 |
| Moynagh, PN | 1 |
| Coogan, AN | 1 |
| Amit, BH | 1 |
| Hayardeni, L | 1 |
| Taler, M | 1 |
| Gueta, RU | 1 |
| Jałocha, W | 1 |
| Walecka-Kapica, E | 2 |
| Tomaszewska-Warda, K | 1 |
| Chojnacki, J | 2 |
| Klupińska, G | 2 |
| Gupta, D | 1 |
| Radhakrishnan, M | 1 |
| Kurhe, Y | 1 |
| Margiotta-Casaluci, L | 1 |
| Owen, SF | 1 |
| Cumming, RI | 1 |
| de Polo, A | 1 |
| Winter, MJ | 1 |
| Panter, GH | 1 |
| Rand-Weaver, M | 1 |
| Sumpter, JP | 1 |
| Tan, L | 1 |
| Zhou, J | 1 |
| Liang, B | 1 |
| Lei, F | 1 |
| Du, L | 1 |
| Yang, L | 1 |
| Li, T | 1 |
| McEwen, BS | 2 |
| Gomez, F | 2 |
| Venero, C | 1 |
| Viveros, MP | 1 |
| García-García, L | 2 |
| Kolcsar, M | 1 |
| Gáll, Z | 1 |
| Dogaru, MT | 1 |
| Xiong, GJ | 1 |
| Yang, Y | 2 |
| Cao, J | 1 |
| Mao, RR | 1 |
| Xu, L | 1 |
| Ruan, CS | 1 |
| Zhou, FH | 1 |
| He, ZY | 1 |
| Wang, SF | 1 |
| Yang, CR | 1 |
| Shen, YJ | 1 |
| Guo, Y | 1 |
| Zhao, HB | 1 |
| Chen, L | 1 |
| Liu, D | 1 |
| Liu, J | 2 |
| Baune, BT | 1 |
| Xiao, ZC | 1 |
| Zhou, XF | 1 |
| Shannonhouse, JL | 2 |
| Grater, DM | 1 |
| York, D | 1 |
| Wellman, PJ | 2 |
| Morgan, C | 2 |
| Tritschler, L | 1 |
| Ali, ZE | 1 |
| Damiens, MH | 1 |
| Pallardy, M | 1 |
| Rahn, KA | 1 |
| Cao, YJ | 1 |
| Hendrix, CW | 1 |
| Kaplin, AI | 1 |
| Spanswick, SC | 1 |
| Patel, PP | 1 |
| Barneto, AA | 1 |
| Almeida-Souza, TH | 1 |
| Goes, TC | 1 |
| Teixeira-Silva, F | 1 |
| García-Cárdenas, N | 1 |
| Olvera-Hernández, S | 1 |
| Gómez-Quintanar, BN | 1 |
| Fernández-Guasti, A | 1 |
| Melo, A | 1 |
| Ferreira, C | 1 |
| Ventura-Silva, AP | 1 |
| Sousa, N | 1 |
| Pêgo, JM | 1 |
| Amodeo, LR | 1 |
| Greenfield, VY | 1 |
| Humphrey, DE | 1 |
| Varela, V | 1 |
| Pipkin, JA | 1 |
| Eaton, SE | 1 |
| Johnson, JD | 1 |
| Plant, CP | 1 |
| Harmony, ZR | 1 |
| Wang, L | 2 |
| Crawford, CA | 1 |
| Qin, J | 1 |
| Chen, W | 1 |
| Sui, N | 1 |
| Chen, H | 1 |
| Li, M | 1 |
| Gorenstein, G | 1 |
| Gorenstein, C | 1 |
| de Oliveira, MC | 1 |
| Asbahr, FR | 1 |
| Shavitt, RG | 1 |
| Stan, TL | 1 |
| Sousa, VC | 1 |
| Zhang, X | 1 |
| Ono, M | 1 |
| Svenningsson, P | 1 |
| Pittman, J | 1 |
| Hylton, A | 1 |
| Mittal, N | 2 |
| Pan, J | 1 |
| Palmateer, J | 1 |
| Martin, L | 1 |
| Pandya, A | 1 |
| Kumar, S | 1 |
| Ofomata, A | 1 |
| Hurn, PD | 1 |
| Schallert, T | 1 |
| Abuhamdah, RM | 1 |
| Hussain, MD | 1 |
| Chazot, PL | 1 |
| Ennaceur, A | 1 |
| Workman, JL | 1 |
| Galea, LA | 1 |
| Yu, XB | 1 |
| Dong, RR | 1 |
| Lin, JR | 1 |
| An, YQ | 1 |
| Du, Y | 1 |
| Tang, SS | 1 |
| Hu, M | 1 |
| Long, Y | 1 |
| Sun, HB | 1 |
| Kong, LY | 1 |
| Hong, H | 1 |
| Chojnacki, C | 1 |
| Pawlowicz, M | 1 |
| Blonska, A | 1 |
| Boulle, F | 2 |
| Machiels, B | 2 |
| Kroeze, Y | 2 |
| Kumar, N | 2 |
| Steinbusch, HW | 2 |
| Kenis, G | 2 |
| Van den Hove, DL | 2 |
| Schaufler, J | 1 |
| Ronovsky, M | 1 |
| Savalli, G | 1 |
| Cabatic, M | 1 |
| Sartori, SB | 2 |
| Singewald, N | 3 |
| Pollak, DD | 1 |
| Siopi, E | 1 |
| Denizet, M | 1 |
| Gabellec, MM | 1 |
| de Chaumont, F | 1 |
| Olivo-Marin, JC | 1 |
| Guilloux, JP | 4 |
| Lledo, PM | 1 |
| Lazarini, F | 1 |
| Hamilton, TJ | 1 |
| Kwan, GT | 1 |
| Gallup, J | 1 |
| Tresguerres, M | 1 |
| Abreu, MS | 2 |
| Giacomini, AC | 3 |
| Barcellos, LJ | 2 |
| Ansai, S | 1 |
| Hosokawa, H | 1 |
| Maegawa, S | 1 |
| Kinoshita, M | 1 |
| Nemeth, CL | 1 |
| Miller, AH | 1 |
| Tansey, MG | 1 |
| Neigh, GN | 1 |
| Steinbusch, HWM | 1 |
| van den Hove, DLA | 1 |
| Soares-Rachetti, Vde P | 1 |
| de Sousa Pinto, ÍA | 1 |
| Santos, RO | 1 |
| André, E | 1 |
| Gavioli, EC | 1 |
| Lovick, T | 1 |
| Koakoski, G | 1 |
| Piato, AL | 1 |
| DuBois, DW | 1 |
| Fincher, AS | 1 |
| Vela, AM | 1 |
| Henry, MM | 1 |
| Frye, GD | 1 |
| Bozzatello, P | 1 |
| Bellino, S | 2 |
| Sarkissova, KY | 1 |
| Fedotova, IB | 2 |
| Surina, NM | 2 |
| Nikolaev, GM | 2 |
| Perepelkina, OV | 2 |
| Poletaeva, II | 2 |
| Grinshpahet, R | 1 |
| Goren, N | 1 |
| Weinstein, I | 1 |
| Kirshenboim, O | 1 |
| Chlebowski, N | 1 |
| Marcinkiewcz, CA | 1 |
| Mazzone, CM | 1 |
| D'Agostino, G | 1 |
| Halladay, LR | 1 |
| Hardaway, JA | 1 |
| DiBerto, JF | 1 |
| Navarro, M | 1 |
| Burnham, N | 1 |
| Cristiano, C | 1 |
| Dorrier, CE | 1 |
| Tipton, GJ | 1 |
| Ramakrishnan, C | 1 |
| Kozicz, T | 1 |
| Deisseroth, K | 1 |
| Thiele, TE | 1 |
| McElligott, ZA | 1 |
| Holmes, A | 4 |
| Heisler, LK | 1 |
| Kash, TL | 1 |
| Vidal, R | 1 |
| Martín, A | 1 |
| Zhou, L | 1 |
| Ma, SL | 1 |
| Yeung, PK | 1 |
| Wong, YH | 1 |
| Tsim, KW | 1 |
| So, KF | 1 |
| Lam, LC | 1 |
| Chung, SK | 1 |
| Islas-Preciado, D | 1 |
| López-Rubalcava, C | 1 |
| González-Olvera, J | 1 |
| Gallardo-Tenorio, A | 1 |
| Estrada-Camarena, E | 1 |
| Holman, HJ | 1 |
| Brooker, SM | 1 |
| Gobeske, KT | 1 |
| Chen, J | 1 |
| Flevari, P | 1 |
| Leftheriotis, D | 1 |
| Repasos, E | 1 |
| Katsaras, D | 1 |
| Katsimardos, A | 1 |
| Lekakis, J | 1 |
| Amin, R | 1 |
| Sarkisova, KY | 1 |
| Kostina, ZA | 1 |
| Aswar, U | 1 |
| Chepurwar, S | 1 |
| Shintre, S | 1 |
| Aswar, M | 1 |
| Warnick, JE | 1 |
| Huang, CJ | 1 |
| Acevedo, EO | 1 |
| Sufka, KJ | 1 |
| Khazaie, H | 1 |
| Moradi, M | 1 |
| Tahmasian, M | 1 |
| Ahmadi, A | 1 |
| Yalcin, I | 1 |
| Belzung, C | 3 |
| Surget, A | 2 |
| Bespalov, AY | 1 |
| van Gaalen, MM | 1 |
| Sukhotina, IA | 1 |
| Wicke, K | 1 |
| Mezler, M | 1 |
| Schoemaker, H | 1 |
| Gross, G | 1 |
| Noorlander, CW | 2 |
| Ververs, FF | 1 |
| Nikkels, PG | 1 |
| van Echteld, CJ | 1 |
| Visser, GH | 1 |
| Smidt, MP | 2 |
| Karpova, NN | 1 |
| Lindholm, J | 1 |
| Pruunsild, P | 1 |
| Timmusk, T | 1 |
| Parise, EM | 2 |
| Alcantara, LF | 3 |
| Schuh, B | 1 |
| Maffeo, ML | 1 |
| Manojlovic, Z | 1 |
| Bolaños-Guzmán, CA | 3 |
| Ribas, VR | 1 |
| Aniceto, HK | 1 |
| Martins, HA | 1 |
| Ribas, KH | 1 |
| Guerra-Ribas, Rde M | 1 |
| Fraga, Sdo N | 1 |
| Ribeiro-Ribas, V | 1 |
| Vasconcelos, CM | 1 |
| Viana, MT | 1 |
| Serafini, P | 1 |
| Lobo, DS | 1 |
| Grosman, A | 1 |
| Seibel, D | 1 |
| Rocha, AM | 1 |
| Motta, EL | 1 |
| Oh, JE | 1 |
| Zupan, B | 1 |
| Gross, S | 1 |
| Toth, M | 2 |
| Koike, H | 1 |
| Ibi, D | 1 |
| Mizoguchi, H | 1 |
| Nagai, T | 1 |
| Nitta, A | 1 |
| Nabeshima, T | 1 |
| Yoneda, Y | 1 |
| Yamada, K | 1 |
| Rainer, Q | 4 |
| Wang, JW | 1 |
| Marsteller, D | 1 |
| Mendez, I | 1 |
| Drew, M | 1 |
| Craig, DA | 1 |
| Artymyshyn, RP | 1 |
| Gerald, C | 1 |
| Antonijevic, IA | 1 |
| Leonardo, ED | 1 |
| Egan, RJ | 1 |
| Bergner, CL | 1 |
| Hart, PC | 1 |
| Cachat, JM | 1 |
| Canavello, PR | 1 |
| Elegante, MF | 1 |
| Elkhayat, SI | 1 |
| Bartels, BK | 1 |
| Tien, AK | 1 |
| Tien, DH | 1 |
| Mohnot, S | 1 |
| Beeson, E | 1 |
| Glasgow, E | 1 |
| Amri, H | 1 |
| Zukowska, Z | 1 |
| Zhang, WJ | 1 |
| Yang, XB | 1 |
| Zhong, BL | 1 |
| Martin, AL | 1 |
| Brown, RE | 1 |
| Garza, JC | 1 |
| Bronner, J | 1 |
| Kim, CS | 1 |
| Lu, XY | 1 |
| Andó, RD | 1 |
| Adori, C | 1 |
| Kirilly, E | 1 |
| Molnár, E | 1 |
| Kovács, GG | 1 |
| Ferrington, L | 1 |
| Kelly, PA | 1 |
| Bagdy, G | 4 |
| Papakostas, GI | 3 |
| Clain, A | 1 |
| Ameral, VE | 1 |
| Baer, L | 2 |
| Brintz, C | 1 |
| Smith, WT | 4 |
| Londborg, PD | 3 |
| Glaudin, V | 4 |
| Painter, JR | 3 |
| Fava, M | 8 |
| Popa, D | 1 |
| Cerdan, J | 1 |
| Repérant, C | 1 |
| Sziray, N | 1 |
| Kuki, Z | 1 |
| Nagy, KM | 1 |
| Markó, B | 1 |
| Kompagne, H | 1 |
| Lévay, G | 1 |
| Conboy, L | 1 |
| Varea, E | 1 |
| Castro, JE | 1 |
| Sakouhi-Ouertatani, H | 1 |
| Calandra, T | 1 |
| Lashuel, HA | 1 |
| Sandi, C | 1 |
| Rinaldi, C | 1 |
| Bogetto, F | 1 |
| Farabaugh, AH | 1 |
| Bitran, S | 1 |
| Witte, J | 1 |
| Alpert, J | 1 |
| Chuzi, S | 1 |
| Clain, AJ | 1 |
| McGrath, PJ | 2 |
| Dording, C | 1 |
| Mischoulon, D | 3 |
| Rubio, FJ | 1 |
| Falcon, R | 1 |
| Sandoval, M | 1 |
| Diaz-Veliz, G | 1 |
| Gonzalez, RE | 1 |
| Earle, N | 1 |
| Dagnino-Subiabre, A | 1 |
| Aboitiz, F | 1 |
| Orrego, F | 1 |
| Goddard, M | 1 |
| Smith, PF | 1 |
| Ashton, JC | 1 |
| Olivier, JD | 2 |
| Blom, T | 1 |
| Arentsen, T | 1 |
| Schaefer, K | 1 |
| Huang, H | 1 |
| Wilson, A | 1 |
| Iosifescu, DV | 1 |
| Wessel, TC | 1 |
| Ordian, NÉ | 2 |
| Pivina, SG | 2 |
| Fedotova, IuO | 1 |
| Akulova, VK | 2 |
| Robert, G | 1 |
| Drapier, D | 1 |
| Bentué-Ferrer, D | 1 |
| Renault, A | 1 |
| Reymann, JM | 1 |
| Greene-Schloesser, DM | 1 |
| Van der Zee, EA | 1 |
| Sheppard, DK | 1 |
| Castillo, MR | 1 |
| Gregg, KA | 1 |
| Burrow, T | 1 |
| Foltz, H | 1 |
| Slater, M | 1 |
| Jiao, J | 1 |
| Dulawa, SC | 2 |
| Teerapornpuntakit, J | 1 |
| Nuntapornsak, A | 1 |
| Krishnamra, N | 1 |
| Birkett, MA | 1 |
| Shinday, NM | 1 |
| Kessler, EJ | 1 |
| Meyer, JS | 1 |
| Ritchie, S | 1 |
| Rowlett, JK | 1 |
| Kobayashi, K | 1 |
| Ikeda, Y | 1 |
| Suzuki, H | 1 |
| Matatiashvili, TTs | 1 |
| Domianidze, TR | 1 |
| Chichinadze, KN | 1 |
| Pantsulaia, IN | 1 |
| Khananashvili, MM | 1 |
| Vallès, A | 1 |
| van Heesch, F | 1 |
| Afrasiab-Middelman, A | 1 |
| Roelofs, JJ | 1 |
| Jonkers, M | 1 |
| Peeters, EJ | 1 |
| Korte-Bouws, GA | 1 |
| Dederen, JP | 1 |
| Kiliaan, AJ | 1 |
| Martens, GJ | 1 |
| Schubert, D | 1 |
| Hansen, F | 1 |
| de Oliveira, DL | 1 |
| Amaral, FU | 1 |
| Guedes, FS | 1 |
| Schneider, TJ | 1 |
| Tumelero, AC | 1 |
| Hansel, G | 1 |
| Schmidt, KH | 1 |
| Torres, FV | 1 |
| Fedotova, YO | 1 |
| Wright, KN | 2 |
| Weakley, SK | 1 |
| Capello, CF | 1 |
| Bourke, CH | 1 |
| Ritchie, JC | 1 |
| Stowe, ZN | 1 |
| Newport, DJ | 1 |
| Nemeroff, A | 1 |
| Owens, MJ | 1 |
| Crespi, F | 1 |
| Rayen, I | 1 |
| Prickaerts, J | 1 |
| Aggarwal, A | 1 |
| Sharma, DD | 1 |
| Sharma, RC | 1 |
| Kumar, R | 1 |
| Frančišković, T | 1 |
| Suković, Z | 1 |
| Janović, S | 1 |
| Stevanović, A | 1 |
| Nemčić-Moro, I | 1 |
| Rončević-Gržeta, I | 1 |
| Letica-Crepulja, M | 1 |
| Smit-Rigter, LA | 1 |
| von Oerthel, L | 1 |
| Chameau, P | 1 |
| van Hooft, JA | 1 |
| Pinna, G | 1 |
| Rasmusson, AM | 1 |
| Barbosa Júnior, A | 1 |
| Alves, FL | 1 |
| Pereira, Ade S | 1 |
| Ide, LM | 1 |
| Hoffmann, A | 1 |
| Richendrfer, H | 1 |
| Pelkowski, SD | 1 |
| Colwill, RM | 1 |
| Creton, R | 1 |
| Rickards, H | 1 |
| Cavanna, AE | 1 |
| Worrall, R | 1 |
| Lin, YL | 1 |
| Lin, SY | 1 |
| Melo, TG | 1 |
| Izídio, GS | 1 |
| Ferreira, LS | 1 |
| Sousa, DS | 1 |
| Macedo, PT | 1 |
| Cabral, A | 1 |
| Rogóż, Z | 1 |
| Skuza, G | 1 |
| Hartley, CA | 1 |
| McKenna, MC | 1 |
| Salman, R | 1 |
| Phelps, EA | 1 |
| Aykaç, A | 1 |
| Aydın, B | 1 |
| Cabadak, H | 1 |
| Gören, MZ | 1 |
| Hache, G | 1 |
| Le Dantec, Y | 1 |
| Orvoën, S | 1 |
| Coudoré, F | 1 |
| Minier, F | 1 |
| Venzala, E | 1 |
| García-García, AL | 1 |
| Elizalde, N | 1 |
| Delagrange, P | 1 |
| Tordera, RM | 1 |
| Vialou, VF | 1 |
| Feng, J | 1 |
| Kennedy, PJ | 1 |
| Laplant, Q | 1 |
| Shen, L | 1 |
| Nestler, EJ | 1 |
| Pulga, A | 1 |
| Ruzza, C | 1 |
| Rizzi, A | 1 |
| Guerrini, R | 1 |
| Calo, G | 1 |
| Spencer, S | 1 |
| Falcon, E | 1 |
| Kumar, J | 1 |
| Krishnan, V | 1 |
| Mukherjee, S | 1 |
| Birnbaum, SG | 1 |
| McClung, CA | 1 |
| Sah, A | 1 |
| Schmuckermair, C | 1 |
| Gaburro, S | 1 |
| Kandasamy, M | 1 |
| Irschick, R | 1 |
| Klimaschewski, L | 1 |
| Landgraf, R | 1 |
| Aigner, L | 1 |
| Lee, R | 1 |
| Claxton, A | 1 |
| Burhans, LB | 1 |
| Smith-Bell, CA | 1 |
| Schreurs, BG | 1 |
| Ravinder, S | 1 |
| Burghardt, NS | 1 |
| Brodsky, R | 1 |
| Bauer, EP | 1 |
| Chattarji, S | 1 |
| Kuo, JR | 1 |
| Cheng, YH | 1 |
| Chen, YS | 1 |
| Chio, CC | 1 |
| Gean, PW | 1 |
| Mineur, YS | 1 |
| Obayemi, A | 1 |
| Wigestrand, MB | 1 |
| Fote, GM | 1 |
| Calarco, CA | 1 |
| Li, AM | 1 |
| Picciotto, MR | 1 |
| Mar, A | 1 |
| Spreekmeester, E | 1 |
| Rochford, J | 1 |
| Jones, N | 1 |
| King, SM | 1 |
| Duxon, MS | 1 |
| Berger, I | 1 |
| Jaworowski, S | 1 |
| Gross-Tsur, V | 1 |
| Rodgers, RJ | 1 |
| Salchner, P | 1 |
| Giorgi, O | 1 |
| Piras, G | 1 |
| Lecca, D | 1 |
| Hansson, S | 1 |
| Driscoll, P | 1 |
| Corda, MG | 1 |
| Thompson, MR | 1 |
| Li, KM | 1 |
| Clemens, KJ | 1 |
| Gurtman, CG | 1 |
| Hunt, GE | 1 |
| Cornish, JL | 1 |
| McGregor, IS | 1 |
| Kotler, LA | 1 |
| Devlin, MJ | 1 |
| Davies, M | 1 |
| Walsh, BT | 1 |
| Starcevic, V | 1 |
| Linden, M | 1 |
| Uhlenhuth, EH | 1 |
| Kolar, D | 1 |
| Latas, M | 1 |
| Roberts, NJ | 1 |
| Bowskill, RJ | 1 |
| Rafferty, PG | 1 |
| Holick, KA | 1 |
| Gundersen, B | 1 |
| Joliat, MJ | 1 |
| Schmidt, ME | 1 |
| Zhang, S | 1 |
| Michelson, D | 3 |
| Trapp, NJ | 1 |
| Miner, CM | 1 |
| Seibert, LM | 1 |
| Petersen, T | 1 |
| Hughes, ME | 1 |
| Nierenberg, AA | 2 |
| Alpert, JE | 3 |
| Emery, M | 1 |
| Senn, A | 1 |
| Wisard, M | 1 |
| Germond, M | 1 |
| OZdel, O | 2 |
| Oğuzhanoğlu, A | 1 |
| Oğuzhanoğlu, NK | 2 |
| Karadağ, F | 1 |
| CUlha Atecí, F | 1 |
| Aybek, Z | 2 |
| Bruder, GE | 1 |
| Stewart, JW | 1 |
| Deliyannides, D | 1 |
| Quitkin, FM | 2 |
| Licinio, J | 1 |
| O'Kirwan, F | 1 |
| Irizarry, K | 1 |
| Merriman, B | 1 |
| Thakur, S | 1 |
| Jepson, R | 1 |
| Lake, S | 1 |
| Tantisira, KG | 1 |
| Weiss, ST | 1 |
| Wong, ML | 1 |
| Holden, C | 1 |
| Ansorge, MS | 1 |
| Zhou, M | 1 |
| Lira, A | 1 |
| Gingrich, JA | 1 |
| Martijena, ID | 1 |
| Bustos, SG | 1 |
| Bertotto, ME | 1 |
| Molina, VA | 1 |
| De Vry, J | 1 |
| Schreiber, R | 1 |
| Melon, C | 1 |
| Dalmus, M | 1 |
| Jentzsch, KR | 1 |
| Degroot, A | 1 |
| Nomikos, GG | 1 |
| Farabaugh, A | 1 |
| Wu, SL | 1 |
| Mascarini, A | 1 |
| Tossani, E | 1 |
| Kratochvil, CJ | 1 |
| Newcorn, JH | 1 |
| Arnold, LE | 1 |
| Duesenberg, D | 1 |
| Quintana, H | 1 |
| Sarkis, EH | 1 |
| Gao, H | 1 |
| Biederman, J | 1 |
| Li, X | 1 |
| Morrow, D | 1 |
| Witkin, JM | 1 |
| Goeldner, FO | 1 |
| Pigatto, G | 1 |
| Ribeiro, AF | 1 |
| Machado, HB | 1 |
| Boerngen-Lacerda, R | 1 |
| Gameiro, GH | 1 |
| Gameiro, PH | 1 |
| Andrade, Ada S | 1 |
| Pereira, LF | 1 |
| Arthuri, MT | 1 |
| Marcondes, FK | 1 |
| Veiga, MC | 1 |
| Csoka, AB | 1 |
| Shipko, S | 1 |
| Hogg, S | 1 |
| Michan, L | 1 |
| Jessa, M | 1 |
| Schroeder, FA | 1 |
| Lin, CL | 1 |
| Crusio, WE | 1 |
| Akbarian, S | 1 |
| Chen, ZY | 1 |
| Ieraci, A | 1 |
| Khan, T | 1 |
| Siao, CJ | 1 |
| Herrera, DG | 1 |
| Hempstead, BL | 1 |
| Gobshtis, N | 1 |
| Ben-Shabat, S | 1 |
| Fride, E | 1 |
| Conley, RK | 1 |
| Hutson, PH | 2 |
| Coffey, B | 1 |
| Wieland, N | 1 |
| Karlsson, RM | 1 |
| Choe, JS | 1 |
| Cameron, HA | 1 |
| Thorsell, A | 1 |
| Crawley, JN | 1 |
| Heilig, M | 1 |
| Aylwin, S | 1 |
| Al-Zaman, Y | 1 |
| Murray, F | 1 |
| Smith, DW | 1 |
| Leonard, SK | 1 |
| Dwyer, JM | 1 |
| Sukoff Rizzo, SJ | 1 |
| Platt, B | 1 |
| Logue, SF | 1 |
| Neal, SJ | 1 |
| Malberg, JE | 1 |
| Beyer, CE | 1 |
| Schechter, LE | 1 |
| Rosenzweig-Lipson, S | 1 |
| Ring, RH | 1 |
| Kovalenko, IL | 1 |
| Avgustinovich, DF | 1 |
| Tolstikova, TG | 1 |
| Beulig, A | 1 |
| Fowler, J | 1 |
| Brambilla, F | 2 |
| Draisci, A | 2 |
| Peirone, A | 2 |
| Brunetta, M | 2 |
| Griebel, G | 3 |
| Blanchard, DC | 1 |
| Agnes, RS | 1 |
| Blanchard, RJ | 1 |
| Klieser, E | 1 |
| Lehmann, E | 1 |
| Heinrich, K | 1 |
| Smulevich, AB | 1 |
| Andriushchenko, AV | 1 |
| Morkovkina, IV | 1 |
| Tkhostov, ASh | 1 |
| Koliutskaia, EV | 1 |
| Wolfe, F | 1 |
| Cathey, MA | 1 |
| Hawley, DJ | 1 |
| Tollefson, GD | 1 |
| Souetre, E | 1 |
| Thomander, L | 1 |
| Potvin, JH | 2 |
| Rapaport, M | 1 |
| Coccaro, E | 1 |
| Sheline, Y | 1 |
| Perse, T | 1 |
| Holland, P | 1 |
| Fabre, L | 1 |
| Bradford, D | 1 |
| Petkov, VD | 1 |
| Belcheva, S | 1 |
| Konstantinova, E | 1 |
| Sánchez, C | 1 |
| Meier, E | 1 |
| Uebelacker, LA | 1 |
| Pava, JA | 1 |
| Rosenbaum, JF | 3 |
| Tiller, JW | 1 |
| Bouwer, C | 1 |
| Behnke, K | 1 |
| Rush, AJ | 1 |
| Weinberg, WA | 1 |
| Kowatch, RA | 1 |
| Carmody, T | 1 |
| Mayes, TL | 1 |
| Labbate, LA | 1 |
| Grimes, JB | 1 |
| Arana, GW | 1 |
| Jenck, F | 1 |
| Moreau, JL | 1 |
| Berendsen, HH | 1 |
| Boes, M | 1 |
| Broekkamp, CL | 1 |
| Martin, JR | 1 |
| Wichmann, J | 1 |
| Van Delft, AM | 1 |
| Pandey, SC | 1 |
| Zhang, D | 1 |
| Nayyar, D | 1 |
| File, SE | 1 |
| Ouagazzal, AM | 1 |
| Gonzalez, LE | 1 |
| Overstreet, DH | 1 |
| To, CT | 2 |
| Anheuer, ZE | 2 |
| Zajecka, J | 1 |
| Amsterdam, JD | 1 |
| Reimherr, FW | 1 |
| Tamura, RN | 1 |
| Sundell, KL | 1 |
| Beasley, CM | 3 |
| Chouinard, G | 2 |
| Saxena, B | 1 |
| Bélanger, MC | 1 |
| Ravindran, A | 1 |
| Bakish, D | 1 |
| Beauclair, L | 1 |
| Morris, P | 1 |
| Vasavan Nair, NP | 1 |
| Manchanda, R | 1 |
| Reesal, R | 1 |
| Remick, R | 1 |
| O'Neill, MC | 1 |
| Durand, M | 1 |
| Berton, O | 1 |
| Aguerre, S | 1 |
| Edno, L | 1 |
| Combourieu, I | 1 |
| Mormède, P | 1 |
| Chaouloff, F | 1 |
| Cohen, C | 1 |
| Perrault, G | 1 |
| Sanger, DJ | 1 |
| Ackerman, DL | 1 |
| Greenland, S | 1 |
| Bystritsky, A | 1 |
| Flament, MF | 1 |
| Lane, RM | 1 |
| Zhu, R | 1 |
| Ying, Z | 1 |
| Resch, M | 1 |
| Jákó, P | 1 |
| Sidó, Z | 1 |
| Haász, P | 1 |
| Raap, DK | 1 |
| Garcia, F | 1 |
| Serres, F | 1 |
| Ma, Q | 1 |
| Battaglia, G | 1 |
| Van de Kar, LD | 1 |
| Wilkinson, D | 1 |
| Silva, RC | 1 |
| Hoog, SL | 1 |
| Tepner, RG | 1 |
| Kopp, JB | 1 |
| Nilsson, ME | 1 |
| Hackmann, A | 1 |
| Clark, DM | 1 |
| McManus, F | 1 |
| Kurt, M | 1 |
| Arik, AC | 1 |
| Celik, S | 1 |
| Harris, GC | 1 |
| Aston-Jones, G | 1 |
| Fernandez, M | 1 |
| Pissiota, A | 1 |
| Frans, O | 1 |
| von Knorring, L | 1 |
| Fischer, H | 1 |
| Fredrikson, M | 1 |
| Krishnan, KR | 1 |
| Doraiswamy, PM | 1 |
| Clary, CM | 1 |
| Parsons, LH | 1 |
| Kerr, TM | 1 |
| Tecott, LH | 1 |
| Schramm, NL | 1 |
| McDonald, MP | 1 |
| Limbird, LE | 1 |
| Le Guisquet, AM | 1 |
| Barreau, S | 1 |
| Calatayud, F | 1 |
| Friede, M | 1 |
| Henneicke von Zepelin, HH | 1 |
| Freudenstein, J | 1 |
| Wellington, K | 1 |
| Perry, CM | 1 |
| Voznesenskaia, TG | 1 |
| Venault, P | 1 |
| Rudrauf, D | 1 |
| Lepicard, EM | 1 |
| Berthoz, A | 1 |
| Jouvent, R | 1 |
| Chapouthier, G | 1 |
| Rios, M | 1 |
| Fan, G | 1 |
| Fekete, C | 1 |
| Kelly, J | 1 |
| Bates, B | 1 |
| Kuehn, R | 1 |
| Lechan, RM | 1 |
| Jaenisch, R | 1 |
| Graf, M | 1 |
| Modos, EA | 1 |
| Kantor, S | 1 |
| Simiand, J | 1 |
| Serradeil-Le Gal, C | 1 |
| Wagnon, J | 1 |
| Pascal, M | 1 |
| Scatton, B | 1 |
| Maffrand, JP | 1 |
| Soubrie, P | 1 |
| King, JA | 1 |
| Messenger, T | 1 |
| Ferris, CF | 1 |
| Spalletta, G | 1 |
| Pasini, A | 1 |
| Caltagirone, C | 1 |
| Sayler, ME | 2 |
| Weiss, AM | 1 |
| Winchel, RM | 1 |
| Jones, JS | 1 |
| Stanley, B | 1 |
| Molcho, A | 1 |
| Stanley, M | 1 |
| Hoehn-Saric, R | 1 |
| Pearlson, GD | 1 |
| Harris, GJ | 1 |
| Machlin, SR | 1 |
| Camargo, EE | 1 |
| Dornseif, BE | 1 |
| Pultz, JA | 1 |
| Bosomworth, JC | 1 |
| Hansen, TE | 1 |
| Dieter, K | 1 |
| Keepers, GA | 1 |
| Bodkin, JA | 1 |
| Teicher, MH | 1 |
| Durcan, MJ | 2 |
| Lister, RG | 2 |
| Eckardt, MJ | 2 |
| Linnoila, M | 2 |
| Feighner, JP | 1 |
| Cohn, JB | 2 |
| Wilcox, C | 1 |
| Rickels, K | 1 |
| Amsterdam, JB | 1 |
| Weise, C | 1 |
| Settle, GP | 1 |
| Stark, P | 1 |
| Hardison, CD | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Establishing the Effect(s) and Safety of Fluoxetine Initiated in the Acute Phase of Stroke[NCT02683213] | Phase 3 | 1,500 participants (Actual) | Interventional | 2014-10-20 | Completed | ||
| Treatment of SSRI-Resistant Depression in Adolescents (TORDIA)[NCT00018902] | Phase 2/Phase 3 | 334 participants (Actual) | Interventional | 2001-01-31 | Completed | ||
| The Efficacy of Eszopiclone 3 mg as Adjunctive Therapy in Subjects With Insomnia Related to Generalized Anxiety Disorder.[NCT00235508] | Phase 4 | 420 participants (Actual) | Interventional | 2005-06-30 | Completed | ||
| Depression Response to Eszopiclone in Adults With Major Depressive Disorder (DREAMDD): A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 8-Week, Safety & Efficacy Study of Eszopiclone 3 mg Compared to Placebo in Subjects With Insomnia Relate[NCT00368030] | Phase 3 | 545 participants (Actual) | Interventional | 2004-01-31 | Completed | ||
| Perinatal Stress and Gene Influences: Pathways to Infant Vulnerability[NCT00525226] | 1,431 participants (Actual) | Observational | 2007-09-30 | Completed | |||
| Escitalopram and Language Intervention for Subacute Aphasia (ELISA)[NCT03843463] | Phase 2 | 88 participants (Anticipated) | Interventional | 2021-07-18 | Recruiting | ||
| Medication Treatment Following Neuropsychologic, Dichotic and f-MRI Tests in Depressed Outpatients With Repeat f-MRI Following Treatment[NCT00296777] | Phase 4 | 28 participants (Actual) | Interventional | 2004-12-31 | Completed | ||
| Dichotic Listening as a Predictor of Placebo and Medication Response in Depression[NCT00296725] | Phase 1/Phase 2 | 25 participants (Actual) | Interventional | 1994-04-30 | Completed | ||
| [NCT00265291] | Phase 2 | 700 participants (Actual) | Interventional | 1999-11-30 | Completed | ||
| Model for Early Prediction of Clinical Response in Patients With Major Depression Receiving Fluoxetine[NCT01075529] | Phase 4 | 140 participants (Actual) | Interventional | 2007-03-31 | Completed | ||
| Evaluation of the Efficiency of a Therapeutic Education Program in Standardized Thermal Cure for Fibromyalgia Patients[NCT02406313] | 152 participants (Actual) | Interventional | 2015-03-31 | Active, not recruiting | |||
| Imagery-based CBT for Social Anxiety Disorder: Piloting a Treatment Augmentation Protocol[NCT02659436] | 9 participants (Actual) | Interventional | 2016-01-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"The HAM-D is a commonly used measure of the severity of depression. While several versions exist consisting of different numbers of items, virtually all include the original 17. Each item is scored from on a 3 or 5 point scale (so, from 0-2 or 0-4), with 0 indicating the item is not present and the highest item score indicating it is present nearly all the time to the severest extent. Item scores are added to obtain a total HAM-D score. Minimum possible score is 0 (indicating none of the 17 items is present), maximal possible score is 52. By convention, scores of <=7 are accepted as indicating remission and scores that have decreased >= 50% from pre-treatment indicate positive response. Higher scores indicate worse depression, while lower scores indicate milder depression or lack of depressive symptoms." (NCT00296725)
Timeframe: 6 weeks
| Intervention | score on a scale (Mean) |
|---|---|
| Fluoxetine | 10 |
| Imipramine | 9 |
"The CGI consists of two ratings: 1) Global Severity (CGI-S) and 2) Global Improvement (CGI-I), both having seven possible ratings, each from 1-7. Ratings on the CGI-S are: 1=No psychopathology 2=Minimal psychopathology 3=Mild psychopathology 4=Moderate psychopathology 5=Moderately severe psychopathology 6=Severe psychopathology 7 Extreme psychopathology. CGI-I ratings are rated for how the past week's psychopathology compares to the week immediately prior to start of treatment and includes: 1=Very much improved 2=much improved 3=minimally improved 4=Unchanged 5=minimally worse 6=much worse 7=very much worse. Scores on both thus range from 1-7 with lower scores indicating less psychopathology/greater improvement, respectively, and higher scores indicating more psychopathology/less improvement, respectively. We define response as a CGI-I of 1 or 2; nonresponse is all other ratings (i.e., CGI-I = 3 or higher." (NCT00296725)
Timeframe: 6 weeks.
| Intervention | Participants (Count of Participants) |
|---|---|
| Fluoxetine | 7 |
| Imipramine | 4 |
14 reviews available for fluoxetine and Anxiety
| Article | Year |
|---|---|
Selective serotonin reuptake inhibitors (SSRIs) for stroke recovery.
Topics: Anxiety; Anxiety Disorders; Fluoxetine; Humans; Selective Serotonin Reuptake Inhibitors; Stroke | 2021 |
Safety and Efficacy of SSRIs in Improving Poststroke Recovery: A Systematic Review and Meta-Analysis.
Topics: Anxiety; Citalopram; Fluoxetine; Humans; Selective Serotonin Reuptake Inhibitors; Stroke; United Sta | 2022 |
Effects of chronic fluoxetine treatment on anxiety- and depressive-like behaviors in adolescent rodents - systematic review and meta-analysis.
Topics: Animals; Antidepressive Agents; Anxiety; Behavior, Animal; Depression; Fluoxetine; Plastics; Rodenti | 2022 |
The efficacy and safety of fluoxetine versus placebo for stroke recovery: a meta-analysis of randomized controlled trials.
Topics: Anxiety; Fluoxetine; Humans; Randomized Controlled Trials as Topic; Selective Serotonin Reuptake Inh | 2023 |
Depression and adult neurogenesis: Positive effects of the antidepressant fluoxetine and of physical exercise.
Topics: Adult; Animals; Antidepressive Agents; Anxiety; Cell Differentiation; Cell Proliferation; Dentate Gy | 2018 |
Long-term outcomes of developmental exposure to fluoxetine: a review of the animal literature.
Topics: Animals; Anxiety; Brain; Depression; Female; Fluoxetine; Humans; Pregnancy; Prenatal Exposure Delaye | 2013 |
Biomarkers for assessing population and individual health and disease related to stress and adaptation.
Topics: Adaptation, Psychological; Allostasis; Animals; Antidepressive Agents, Second-Generation; Anxiety; A | 2015 |
The age-dependent effects of selective serotonin reuptake inhibitors in humans and rodents: A review.
Topics: Age Factors; Animals; Anxiety; Behavior, Animal; Depression; Disease Models, Animal; Fluoxetine; Hum | 2011 |
Up-regulation of neurosteroid biosynthesis as a pharmacological strategy to improve behavioural deficits in a putative mouse model of post-traumatic stress disorder.
Topics: Animals; Anxiety; Behavior, Animal; Brain; Disease Models, Animal; Fluoxetine; Mice; Neurotransmitte | 2012 |
Selective serotonin reuptake inhibitors (SSRIs) for stroke recovery.
Topics: Adult; Anxiety; Citalopram; Cognition; Depression; Fluoxetine; Humans; Nervous System Diseases; Paro | 2012 |
Selective serotonin reuptake inhibitors (SSRIs) for stroke recovery.
Topics: Adult; Anxiety; Citalopram; Cognition; Depression; Fluoxetine; Humans; Nervous System Diseases; Paro | 2012 |
Selective serotonin reuptake inhibitors (SSRIs) for stroke recovery.
Topics: Adult; Anxiety; Citalopram; Cognition; Depression; Fluoxetine; Humans; Nervous System Diseases; Paro | 2012 |
Selective serotonin reuptake inhibitors (SSRIs) for stroke recovery.
Topics: Adult; Anxiety; Citalopram; Cognition; Depression; Fluoxetine; Humans; Nervous System Diseases; Paro | 2012 |
Selective mutism: a review of the concept and treatment.
Topics: Anxiety; Fluoxetine; Humans; Monoamine Oxidase Inhibitors; Mutism; Phenelzine; Phobic Disorders; Pre | 2002 |
Long-term treatment outcomes of depression with associated anxiety: efficacy of continuation treatment with fluoxetine.
Topics: Adult; Anxiety; Depressive Disorder, Major; Diagnostic and Statistical Manual of Mental Disorders; F | 2004 |
Emerging concepts in the medical and surgical treatment of obesity.
Topics: Adipose Tissue; Amyloid; Anticonvulsants; Antidepressive Agents; Anxiety; Appetite Regulation; Baria | 2008 |
Venlafaxine extended-release: a review of its use in the management of major depression.
Topics: Antidepressive Agents, Second-Generation; Anxiety; Cyclohexanols; Delayed-Action Preparations; Depre | 2001 |
51 trials available for fluoxetine and Anxiety
| Article | Year |
|---|---|
Efficacy and safety of adding fluoxetine to the treatment regimen of hospitalized patients with non-critical COVID-19 pneumonia: A double-blind randomized, placebo-controlled clinical trial.
Topics: Antidepressive Agents, Second-Generation; Anxiety; C-Reactive Protein; COVID-19; Depression; Double- | 2023 |
Effect of Fluoxetine on Obsessive-Compulsive Behaviors in Children and Adolescents With Autism Spectrum Disorders: A Randomized Clinical Trial.
Topics: Adolescent; Anxiety; Autism Spectrum Disorder; Child; Confounding Factors, Epidemiologic; Female; Fl | 2019 |
Change in dysfunctional attitudes and attachment in interpersonal psychotherapy for depressed adolescents.
Topics: Adolescent; Anxiety; Anxiety Disorders; Attitude; Child; Fluoxetine; Humans; Interpersonal Psychothe | 2021 |
The efficacy of fluoxetine in BMS-A cross-over study.
Topics: Aged; Anxiety; Burning Mouth Syndrome; Cross-Over Studies; Depression; Female; Fluoxetine; Humans; M | 2018 |
The addition of fluoxetine to cognitive behavioural therapy for youth depression (YoDA-C): a randomised, double-blind, placebo-controlled, multicentre clinical trial.
Topics: Adolescent; Adult; Anxiety; Australia; Cognitive Behavioral Therapy; Combined Modality Therapy; Como | 2019 |
Impact of treatments for depression on comorbid anxiety, attentional, and behavioral symptoms in adolescents with selective serotonin reuptake inhibitor-resistant depression.
Topics: Adolescent; Anxiety; Attention Deficit and Disruptive Behavior Disorders; Behavioral Symptoms; Cital | 2013 |
Health-related quality of life and symptom severity in Chinese patients with major depressive disorder.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Anxiety; Asian People; China; Depressive Disorder, M | 2013 |
Child-focused treatment of pediatric OCD affects parental behavior and family environment.
Topics: Adolescent; Adult; Antidepressive Agents, Second-Generation; Anxiety; Child; Cognitive Behavioral Th | 2015 |
Effects of fluoxetine and melatonin on mood, sleep quality and body mass index in postmenopausal women.
Topics: Affect; Aged; Anxiety; Appetite; Body Mass Index; Depression; Double-Blind Method; Drug Therapy, Com | 2015 |
Combined therapy with interpersonal psychotherapy adapted for borderline personality disorder: A two-years follow-up.
Topics: Adolescent; Adult; Antidepressive Agents, Second-Generation; Anxiety; Borderline Personality Disorde | 2016 |
Fluoxetine vs. placebo for the treatment of recurrent vasovagal syncope with anxiety sensitivity.
Topics: Adult; Anti-Anxiety Agents; Anxiety; Cardiovascular Agents; Female; Fluoxetine; Greece; Humans; Male | 2017 |
Fluoxetine treatment for anxiety in women undergoing in vitro fertilization.
Topics: Adult; Anxiety; Double-Blind Method; Female; Fertilization in Vitro; Fluoxetine; Folic Acid; Humans; | 2009 |
Combination of acupuncture and fluoxetine for depression: a randomized, double-blind, sham-controlled trial.
Topics: Acupuncture Therapy; Adult; Antidepressive Agents; Anxiety; Combined Modality Therapy; Depressive Di | 2009 |
Fluoxetine-clonazepam cotherapy for anxious depression: an exploratory, post-hoc analysis of a randomized, double blind study.
Topics: Adult; Anti-Anxiety Agents; Antidepressive Agents; Anxiety; Clonazepam; Depressive Disorder, Major; | 2010 |
Adaptation of interpersonal psychotherapy to borderline personality disorder: a comparison of combined therapy and single pharmacotherapy.
Topics: Adolescent; Adult; Affective Symptoms; Antidepressive Agents, Second-Generation; Anxiety; Combined M | 2010 |
Anxious depression and early changes in the HAMD-17 anxiety-somatization factor items and antidepressant treatment outcome.
Topics: Adult; Antidepressive Agents, Second-Generation; Anxiety; Depressive Disorder, Major; Female; Fluoxe | 2010 |
A post hoc analysis of the effect of nightly administration of eszopiclone and a selective serotonin reuptake inhibitor in patients with insomnia and anxious depression.
Topics: Adult; Anxiety; Azabicyclo Compounds; Depressive Disorder, Major; Double-Blind Method; Drug Therapy, | 2011 |
A post hoc analysis of the effect of nightly administration of eszopiclone and a selective serotonin reuptake inhibitor in patients with insomnia and anxious depression.
Topics: Adult; Anxiety; Azabicyclo Compounds; Depressive Disorder, Major; Double-Blind Method; Drug Therapy, | 2011 |
A post hoc analysis of the effect of nightly administration of eszopiclone and a selective serotonin reuptake inhibitor in patients with insomnia and anxious depression.
Topics: Adult; Anxiety; Azabicyclo Compounds; Depressive Disorder, Major; Double-Blind Method; Drug Therapy, | 2011 |
A post hoc analysis of the effect of nightly administration of eszopiclone and a selective serotonin reuptake inhibitor in patients with insomnia and anxious depression.
Topics: Adult; Anxiety; Azabicyclo Compounds; Depressive Disorder, Major; Double-Blind Method; Drug Therapy, | 2011 |
Is extended clonazepam cotherapy of fluoxetine effective for outpatients with major depression?
Topics: Administration, Oral; Adult; Antidepressive Agents, Second-Generation; Anxiety; Clonazepam; Depressi | 2002 |
An open trial of fluoxetine for adolescents with bulimia nervosa.
Topics: Adolescent; Antidepressive Agents, Second-Generation; Anxiety; Body Mass Index; Bulimia; Depressive | 2003 |
Long-term treatment outcomes of depression with associated anxiety: efficacy of continuation treatment with fluoxetine.
Topics: Adult; Anxiety; Depressive Disorder, Major; Diagnostic and Statistical Manual of Mental Disorders; F | 2004 |
Dichotic listening tests of functional brain asymmetry predict response to fluoxetine in depressed women and men.
Topics: Adolescent; Adult; Aged; Antidepressive Agents, Second-Generation; Anxiety; Auditory Perception; Dep | 2004 |
Dichotic listening tests of functional brain asymmetry predict response to fluoxetine in depressed women and men.
Topics: Adolescent; Adult; Aged; Antidepressive Agents, Second-Generation; Anxiety; Auditory Perception; Dep | 2004 |
Dichotic listening tests of functional brain asymmetry predict response to fluoxetine in depressed women and men.
Topics: Adolescent; Adult; Aged; Antidepressive Agents, Second-Generation; Anxiety; Auditory Perception; Dep | 2004 |
Dichotic listening tests of functional brain asymmetry predict response to fluoxetine in depressed women and men.
Topics: Adolescent; Adult; Aged; Antidepressive Agents, Second-Generation; Anxiety; Auditory Perception; Dep | 2004 |
Association of a corticotropin-releasing hormone receptor 1 haplotype and antidepressant treatment response in Mexican-Americans.
Topics: Adult; Antidepressive Agents; Anxiety; Depressive Disorder; Desipramine; Double-Blind Method; Female | 2004 |
The relationship between early changes in the HAMD-17 anxiety/somatization factor items and treatment outcome among depressed outpatients.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Antidepressive Agents, Second-Generation; Anxiety; D | 2005 |
Atomoxetine alone or combined with fluoxetine for treating ADHD with comorbid depressive or anxiety symptoms.
Topics: Adolescent; Anxiety; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child | 2005 |
Combined cognitive-behavioral, psychopharmacological and nutritional therapy in eating disorders. 1. Anorexia nervosa--restricted type.
Topics: Adolescent; Adult; Anorexia Nervosa; Antidepressive Agents, Second-Generation; Antidepressive Agents | 1995 |
Combined cognitive-behavioral, psychopharmacological and nutritional therapy in eating disorders. 2. Anorexia nervosa--binge-eating/purging type.
Topics: Adolescent; Adult; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Anxie | 1995 |
[The psychopharmacotherapy of anxious-depressive states (the interrelationship of the structure of the comorbidity to the choice of drug therapy)].
Topics: Adult; Alprazolam; Anxiety; Comorbidity; Depression; Double-Blind Method; Female; Fluoxetine; Humans | 1994 |
A double-blind placebo controlled trial of fluoxetine in fibromyalgia.
Topics: Adult; Aged; Anxiety; Depression; Double-Blind Method; Female; Fibromyalgia; Fluoxetine; Humans; Mid | 1994 |
A comparison of fluvoxamine and fluoxetine in the treatment of major depression.
Topics: Adult; Antidepressive Agents, Second-Generation; Anxiety; Depressive Disorder; Double-Blind Method; | 1996 |
Major depressive subtypes and treatment response.
Topics: Adolescent; Adult; Aged; Antidepressive Agents, Second-Generation; Anxiety; Depressive Disorder; Fem | 1997 |
Moclobemide for anxiety disorders: a focus on moclobemide for panic disorder.
Topics: Adult; Anxiety; Benzamides; Blood Pressure; Female; Fluoxetine; Humans; Male; Moclobemide; Monoamine | 1997 |
Fluoxetine in child and adolescent depression: acute and maintenance treatment.
Topics: Acute Disease; Adolescent; Antidepressive Agents, Second-Generation; Anxiety; Chi-Square Distributio | 1998 |
Serotonin reuptake antidepressant effects on sexual function in patients with anxiety disorders.
Topics: 1-Naphthylamine; Adult; Anxiety; Ejaculation; Female; Fluoxetine; Humans; Libido; Male; Middle Aged; | 1998 |
Changes in adverse events reported by patients during 6 months of fluoxetine therapy.
Topics: Anxiety; Depressive Disorder; Double-Blind Method; Drug Administration Schedule; Fluoxetine; Follow- | 1999 |
A Canadian multicenter, double-blind study of paroxetine and fluoxetine in major depressive disorder.
Topics: Adult; Anxiety; Depressive Disorder, Major; Dose-Response Relationship, Drug; Female; Fluoxetine; Hu | 1999 |
Side effects as predictors of drug response in obsessive-compulsive disorder.
Topics: Adolescent; Adult; Anxiety; Clomipramine; Dose-Response Relationship, Drug; Ejaculation; Female; Flu | 1999 |
Predictors of an acute antidepressant response to fluoxetine and sertraline.
Topics: Adult; Antidepressive Agents; Antidepressive Agents, Second-Generation; Anxiety; Depressive Disorder | 1999 |
Fluoxetine versus sertraline and paroxetine in major depression: tolerability and efficacy in anxious depression.
Topics: Adult; Antidepressive Agents, Second-Generation; Anxiety; Depressive Disorder; Double-Blind Method; | 2000 |
Recurrent images and early memories in social phobia.
Topics: Adult; Anxiety; Cognition; Cognitive Behavioral Therapy; Conditioning, Psychological; Eidetic Imager | 2000 |
Short-term cotherapy with clonazepam and fluoxetine: anxiety, sleep disturbance and core symptoms of depression.
Topics: Adult; Aged; Anxiety; Clonazepam; Depressive Disorder, Major; Dose-Response Relationship, Drug; Drug | 2000 |
Clinical and treatment response characteristics of late-life depression associated with vascular disease: a pooled analysis of two multicenter trials with sertraline.
Topics: Age of Onset; Aged; Antidepressive Agents; Anxiety; Cardiovascular Diseases; Comorbidity; Depressive | 2001 |
Differential therapy of mild to moderate depressive episodes (ICD-10 F 32.0; F 32.1) with St. John's wort.
Topics: Adult; Aged; Antidepressive Agents, Second-Generation; Anxiety; Depressive Disorder; Female; Fluoxet | 2001 |
Fluoxetine alone in the treatment of first episode anxious-depression: an open clinical trial.
Topics: Adult; Aged; Analysis of Variance; Anxiety; Comorbidity; Depressive Disorder, Major; Fluoxetine; Hum | 2002 |
Fluoxetine: activating and sedating effects at multiple fixed doses.
Topics: Adult; Akathisia, Drug-Induced; Ambulatory Care; Anxiety; Asthenia; Depressive Disorder; Dose-Respon | 1992 |
Clinical characteristics of trichotillomania and its response to fluoxetine.
Topics: Adult; Anxiety; Comorbidity; Depressive Disorder; Female; Fluoxetine; Humans; Male; Middle Aged; Obs | 1992 |
Fluoxetine versus trazodone: efficacy and activating-sedating effects.
Topics: Adult; Akathisia, Drug-Induced; Ambulatory Care; Anxiety; Depressive Disorder; Dizziness; Double-Bli | 1991 |
Double-blind comparative trials of fluoxetine and doxepin in geriatric patients with major depressive disorder.
Topics: Age Factors; Aged; Anxiety; Blood Pressure; Body Weight; Clinical Trials as Topic; Depressive Disord | 1985 |
A comparison of fluoxetine, imipramine, and placebo in patients with major depressive disorder.
Topics: Adult; Ambulatory Care; Anxiety; Body Weight; Clinical Trials as Topic; Depressive Disorder; Dizzine | 1985 |
A double-blind controlled clinical trial of fluoxetine and amitriptyline in the treatment of outpatients with major depressive disorder.
Topics: Adult; Ambulatory Care; Amitriptyline; Anxiety; Body Weight; Clinical Trials as Topic; Depressive Di | 1985 |
Comparison of two dosage regimens of fluoxetine in major depression.
Topics: Adult; Akathisia, Drug-Induced; Anxiety; Clinical Trials as Topic; Depressive Disorder; Dose-Respons | 1985 |
A review of multicenter controlled studies of fluoxetine vs. imipramine and placebo in outpatients with major depressive disorder.
Topics: Adolescent; Adult; Aged; Akathisia, Drug-Induced; Ambulatory Care; Anxiety; Clinical Trials as Topic | 1985 |
282 other studies available for fluoxetine and Anxiety
| Article | Year |
|---|---|
Gamma-aminobutyric acid amides of nortriptyline and fluoxetine display improved pain suppressing activity.
Topics: Analgesics; Animals; Antidepressive Agents; Anxiety; Behavior, Animal; Fluoxetine; Formaldehyde; gam | 2009 |
Factors associated with fluoxetine and norfluoxetine plasma concentrations and clinical response in Mexican patients with mental disorders.
Topics: Adult; Antipsychotic Agents; Anxiety; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2D6; Cytochrome | 2021 |
Heart rate variability: A biomarker of selective response to mindfulness-based treatment versus fluoxetine in generalized anxiety disorder.
Topics: Anxiety; Anxiety Disorders; Biomarkers; Fluoxetine; Heart Rate; Humans; Mindfulness | 2021 |
Sex differences in long-term behavioral alterations, especially anxiety, following prenatal fluoxetine exposure in C57BL/6 mice.
Topics: Animals; Anxiety; Autism Spectrum Disorder; Behavior, Animal; Communication; Depression; Female; Flu | 2021 |
Alpha2-antiplasmin deficiency affects depression and anxiety-like behavior and apoptosis induced by stress in mice.
Topics: alpha-2-Antiplasmin; Animals; Anxiety; Apoptosis; Behavior, Animal; Cytokines; Depression; Fibrinoly | 2022 |
Oral administration of
Topics: Administration, Oral; Animals; Anxiety; Cell Line; Depression; Feces; Fluoxetine; Lactococcus lactis | 2022 |
Lower antidepressant response to fluoxetine is associated with anxiety-like behavior, hippocampal oxidative imbalance, and increase on peripheral IL-17 and IFN-γ levels.
Topics: Animals; Antidepressive Agents; Anxiety; Behavior, Animal; Corticosterone; Depression; Disease Model | 2022 |
Effects of repeated drug administration on behaviors in normal mice and fluoxetine efficacy in chronic unpredictable mild stress mice.
Topics: Animals; Anxiety; Behavior, Animal; Depression; Disease Models, Animal; Fluoxetine; Hippocampus; Hum | 2022 |
Neuronal nitric oxide synthase inhibition accelerated the removal of fluoxetine's anxiogenic activity in an animal model of PTSD.
Topics: Animals; Anti-Anxiety Agents; Anxiety; Disease Models, Animal; Drug Therapy, Combination; Enzyme Inh | 2023 |
Small-molecule non-peptide antagonists of the PACAP receptor attenuate acute restraint stress-induced anxiety-like behaviors in mice.
Topics: Animals; Anti-Anxiety Agents; Anxiety; Fluoxetine; Mice; Pituitary Adenylate Cyclase-Activating Poly | 2022 |
Prenatal exposure to fluoxetine modulates emotionality and aversive memory in male and female rat offspring.
Topics: Animals; Anxiety; Female; Fluoxetine; Humans; Male; Placenta; Pregnancy; Prenatal Exposure Delayed E | 2022 |
Combined Chronic Oral Methylphenidate and Fluoxetine Treatment During Adolescence: Effects on Behavior.
Topics: Animals; Anxiety; Attention Deficit Disorder with Hyperactivity; Fluoxetine; Methylphenidate; Rats; | 2023 |
Memory and anxiety-like behavior of rats in the plus-maze discriminative avoidance task: Role of serotonergic transmission in the basolateral amygdala.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Anxiety; Avoidance Learning; Basolateral Nuclear Co | 2023 |
Effect of combination fluoxetine and exercise on prefrontal BDNF, anxiety-like behavior and fear extinction in a female rat model of post-traumatic stress disorder (PTSD): a comparison with male animals.
Topics: Animals; Anxiety; Brain-Derived Neurotrophic Factor; Disease Models, Animal; Extinction, Psychologic | 2023 |
Aversive memory conditioning induces fluoxetine-dependent anxiety-like states in the crab Neohelice granulata.
Topics: Animals; Anxiety; Brachyura; Conditioning, Psychological; Fluoxetine; Memory | 2023 |
Deep brain stimulation of the dorsal raphe induces anxiolytic and panicolytic-like effects and alters serotonin immunoreactivity.
Topics: Animals; Anti-Anxiety Agents; Anxiety; Deep Brain Stimulation; Dorsal Raphe Nucleus; Escape Reaction | 2023 |
Vagus nerve-dependent effects of fluoxetine on anxiety- and depression-like behaviors in mice.
Topics: Animals; Anxiety; Depression; Fluoxetine; Hippocampus; Mice; Serotonin; Vagus Nerve | 2023 |
Effect of Gabapentin-Fluoxetine Derivative GBP1F in a Murine Model of Depression, Anxiety and Cognition.
Topics: Animals; Anti-Anxiety Agents; Antidepressive Agents; Anxiety; Ascorbic Acid; Behavior, Animal; Cogni | 2023 |
The Influence of Topinambur and Inulin Preventive Supplementation on Microbiota, Anxious Behavior, Cognitive Functions and Neurogenesis in Mice Exposed to the Chronic Unpredictable Mild Stress.
Topics: Animals; Anxiety; Cognition; Dietary Supplements; Dysbiosis; Fluoxetine; Inulin; Mice; Microbiota; N | 2023 |
Reproductive experience alters the effects of diazepam and fluoxetine on anxiety-like behaviour, fear extinction, and corticosterone levels in female rats.
Topics: Animals; Anti-Anxiety Agents; Anxiety; Corticosterone; Diazepam; Estradiol; Extinction, Psychologica | 2023 |
Perinatal serotonergic manipulation shapes anhedonic and cognitive behaviors in a sex- and age-dependent manner: Identification of related biological functions at central and peripheral level.
Topics: Animals; Anxiety; Behavior, Animal; Biomarkers; Brain; Cognition; Female; Fluoxetine; Humans; Male; | 2023 |
Fluoxetine Attenuated Anxiety-Like Behaviors in Streptozotocin-Induced Diabetic Mice by Mitigating the Inflammation.
Topics: Animals; Antidepressive Agents; Anxiety; Blotting, Western; Diabetes Mellitus, Experimental; Disease | 2019 |
Activating newborn neurons suppresses depression and anxiety-like behaviors.
Topics: Animals; Antidepressive Agents; Anxiety; Behavior, Animal; Dentate Gyrus; Depression; Depressive Dis | 2019 |
Chronic exposure to fluoxetine of female mice before mating causes impaired stress resilience in female offspring.
Topics: Animals; Antidepressive Agents, Second-Generation; Anxiety; Behavior, Animal; Depression; Disease Mo | 2019 |
Social instability is an effective chronic stress paradigm for both male and female mice.
Topics: Animals; Antidepressive Agents, Second-Generation; Anxiety; Behavior, Animal; Corticosterone; Diseas | 2019 |
Tryptophan alleviates neuroendocrine and behavioral responses to stress in zebrafish.
Topics: Animals; Anxiety; Behavior, Animal; Disease Models, Animal; Female; Fluoxetine; Hydrocortisone; Male | 2020 |
Fluoxetine ameliorates dysbiosis in a depression model induced by chronic unpredicted mild stress in mice.
Topics: Animals; Antidepressive Agents, Second-Generation; Anxiety; Depressive Disorder; Disease Models, Ani | 2019 |
Antidepressant efficacy of a selective organic cation transporter blocker in a mouse model of depression.
Topics: Anhedonia; Animals; Antidepressive Agents; Anxiety; Depression; Disease Models, Animal; Fluoxetine; | 2020 |
Dual exposure to stress in different stages of development affects eating behavior of male Wistar rats.
Topics: Age Factors; Animals; Animals, Newborn; Anxiety; Drug Resistance; Eating; Female; Fluoxetine; Food D | 2020 |
Garlic passion fruit (Passiflora tenuifila Killip): Assessment of eventual acute toxicity, anxiolytic, sedative, and anticonvulsant effects using in vivo assays.
Topics: Animals; Anti-Anxiety Agents; Anticonvulsants; Antidepressive Agents; Anxiety; Behavior, Animal; Dia | 2020 |
Antidepressant treatment strategy with an early onset of action improves the clinical outcome in patients with major depressive disorder and high anxiety: a multicenter and 6-week follow-up study.
Topics: Antidepressive Agents; Anxiety; Citalopram; Depressive Disorder, Major; Fluoxetine; Fluvoxamine; Fol | 2020 |
Perinatal fluoxetine treatment and dams' early life stress history alter affective behavior in rat offspring depending on serotonin transporter genotype and sex.
Topics: Affect; Animals; Animals, Newborn; Antidepressive Agents; Anxiety; Anxiety Disorders; Behavior, Anim | 2020 |
Safety of fluoxetine use in children and adolescents: a disproportionality analysis of the Food and Drug Administration Adverse Event Reporting System (FAERS) database.
Topics: Adolescent; Adverse Drug Reaction Reporting Systems; Antidepressive Agents, Second-Generation; Anxie | 2020 |
Effects of Jian-Pi-Zhi-Dong Decoction on the Expression of 5-HT and Its Receptor in a Rat Model of Tourette Syndrome and Comorbid Anxiety.
Topics: Animals; Antidepressive Agents, Second-Generation; Anxiety; Behavior, Animal; Cerebral Cortex; Corpu | 2020 |
Effective treatment and prevention of attempted suicide, anxiety, and aggressiveness with fluoxetine, despite proven use of androgenic anabolic steroids.
Topics: Adult; Aggression; Antidepressive Agents, Second-Generation; Anxiety; Depression; Fluoxetine; Humans | 2021 |
Perinatal fluoxetine treatment promotes long-term behavioral changes in adult mice.
Topics: Animals; Animals, Newborn; Anxiety; Cognitive Dysfunction; Female; Fluoxetine; Hippocampus; Male; Mi | 2020 |
Effects of adolescent administration of fluoxetine on novel object recognition memory, anxiety-like behaviors, and hippocampal brain-derived neurotrophic factor level.
Topics: Animals; Anxiety; Brain-Derived Neurotrophic Factor; Female; Fluoxetine; Hippocampus; Male; Memory D | 2020 |
Inactivation of the GATA Cofactor ZFPM1 Results in Abnormal Development of Dorsal Raphe Serotonergic Neuron Subtypes and Increased Anxiety-Like Behavior.
Topics: Animals; Anxiety; Behavior, Animal; Brain Chemistry; Dorsal Raphe Nucleus; Fear; Female; Fluoxetine; | 2020 |
Understanding complex dynamics of behavioral, neurochemical and transcriptomic changes induced by prolonged chronic unpredictable stress in zebrafish.
Topics: Animals; Antidepressive Agents; Anxiety; Behavior, Animal; Brain; Disease Models, Animal; Female; Fl | 2020 |
Standardised ginseng extract G115® potentiates the antidepressant-like properties of fluoxetine in the forced swim test.
Topics: Animals; Anxiety; Autopsy; Behavior, Animal; Brain-Derived Neurotrophic Factor; Depressive Disorder, | 2021 |
High-caloric or isocaloric maternal high-fat diets differently affect young-adult offspring behavior in anxiety-related tests and offspring sensitivity to acute fluoxetine.
Topics: Animals; Anxiety; Behavior, Animal; Diet, High-Fat; Disease Models, Animal; Energy Intake; Female; F | 2021 |
Adolescent fluoxetine treatment mediates a persistent anxiety-like outcome in female C57BL/6 mice that is ameliorated by fluoxetine re-exposure in adulthood.
Topics: Animals; Anxiety; Behavior, Animal; Female; Fluoxetine; Mice; Mice, Inbred C57BL; Selective Serotoni | 2021 |
Exercise and fluoxetine treatment during adolescence protect against early life stress-induced behavioral abnormalities in adult rats.
Topics: Animals; Animals, Newborn; Antidepressive Agents, Second-Generation; Anxiety; Behavior, Animal; Cort | 2021 |
The combination of fluoxetine and environmental enrichment reduces postpartum stress-related behaviors through the oxytocinergic system and HPA axis in mice.
Topics: Animals; Anxiety; Anxiety Disorders; Brain; Depression, Postpartum; Disease Models, Animal; Female; | 2021 |
5-HT
Topics: Animals; Anxiety; Corticosterone; Depression; Fluoxetine; Hippocampus; Mice; Serotonin | 2021 |
Early Developmental Exposure to Fluoxetine and Citalopram Results in Different Neurodevelopmental Outcomes.
Topics: Anxiety; Citalopram; Female; Fluoxetine; Humans; Patch-Clamp Techniques; Pregnancy; Selective Seroto | 2021 |
β-sitosterol reduces anxiety and synergizes with established anxiolytic drugs in mice.
Topics: Animals; Anti-Anxiety Agents; Anxiety; Anxiety Disorders; Fear; Fluoxetine; Mice, Inbred C57BL; Moto | 2021 |
Perinatal fluoxetine dose-dependently affects prenatal stress-induced neurobehavioural abnormalities, HPA-axis functioning and underlying brain alterations in rat dams and their offspring.
Topics: Animals; Antidepressive Agents; Anxiety; Behavior, Animal; Brain; Female; Fluoxetine; Hippocampus; L | 2021 |
Prenatal fluoxetine impairs non-hippocampal but not hippocampal memory in adult male rat offspring.
Topics: Animals; Antidepressive Agents, Second-Generation; Anxiety; Depression; Female; Fluoxetine; Food Pre | 2021 |
BiteStrip analysis of the effect of fluoxetine and paroxetine on sleep bruxism.
Topics: Adult; Anxiety; Dental Devices, Home Care; Depression; Female; Fluoxetine; Humans; Male; Paroxetine; | 2017 |
Prenatal fluoxetine modifies the behavioral and hormonal responses to stress in male mice: role for glucocorticoid insensitivity.
Topics: Animals; Antidepressive Agents; Anxiety; Anxiety Disorders; Behavior, Animal; Corticosterone; Depres | 2017 |
Fluoxetine reverses behavior changes in socially isolated rats: role of the hippocampal GSH-dependent defense system and proinflammatory cytokines.
Topics: Animals; Anxiety; Behavior, Animal; Catalase; Depression; Disease Models, Animal; Fluoxetine; Glutat | 2017 |
Prodepressant- and anxiogenic-like effects of serotonin-selective, but not noradrenaline-selective, antidepressant agents in mice lacking α2-containing GABA
Topics: Adrenergic Uptake Inhibitors; Animals; Antidepressive Agents; Anxiety; Depression; Desipramine; Dose | 2017 |
Perinatal fluoxetine effects on social play, the HPA system, and hippocampal plasticity in pre-adolescent male and female rats: Interactions with pre-gestational maternal stress.
Topics: Animals; Anxiety; Behavior, Animal; Depression; Female; Fluoxetine; Hippocampus; Hypothalamo-Hypophy | 2017 |
The antidepressant effect of melatonin and fluoxetine in diabetic rats is associated with a reduction of the oxidative stress in the prefrontal and hippocampal cortices.
Topics: Animals; Antidepressive Agents; Anxiety; Depression; Diabetes Mellitus, Experimental; Fluoxetine; Gl | 2017 |
Chronic fluoxetine ameliorates adolescent chronic nicotine exposure-induced long-term adult deficits in trace conditioning.
Topics: Aging; Animals; Anxiety; Brain-Derived Neurotrophic Factor; Conditioning, Psychological; Fear; Fluox | 2017 |
Modeling consequences of prolonged strong unpredictable stress in zebrafish: Complex effects on behavior and physiology.
Topics: Animals; Animals, Outbred Strains; Antidepressive Agents, Second-Generation; Anxiety; Behavior, Anim | 2018 |
Postpartum Lactation-Mediated Behavioral Outcomes and Drug Responses in a Spontaneous Mouse Model of Obsessive-Compulsive Disorder.
Topics: Animals; Anxiety; Disease Models, Animal; Female; Fluoxetine; Lactation; Lactation Disorders; Mental | 2017 |
The antidepressant- and anxiolytic-like effects of fluoxetine and clozapine in chronically isolated rats involve inhibition of hippocampal TNF-α.
Topics: Animals; Anti-Anxiety Agents; Antidepressive Agents, Second-Generation; Anxiety; Clozapine; Fluoxeti | 2017 |
PLDT (planarian light/dark test): an invertebrate assay to quantify defensive responding and study anxiety-like effects.
Topics: Analysis of Variance; Animals; Anxiety; Behavior, Animal; Benzodiazepines; Carbolines; Darkness; Dos | 2018 |
Effect of Early-Life Fluoxetine on Anxiety-Like Behaviors in BDNF Val66Met Mice.
Topics: Age Factors; Animals; Anti-Anxiety Agents; Anxiety; Brain-Derived Neurotrophic Factor; Dorsal Raphe | 2017 |
[Exploring the clinical characters of Shugan Jieyu capsule through text mining].
Topics: Anxiety; Data Mining; Depression; Drug Therapy, Combination; Drugs, Chinese Herbal; Female; Fluoxeti | 2017 |
Depression- and anxiety-like behaviour is related to BDNF/TrkB signalling in a mouse model of psoriasis.
Topics: Animals; Anxiety; Behavior, Animal; Brain-Derived Neurotrophic Factor; Depression; Disease Models, A | 2018 |
Antidepressant activity of vorinostat is associated with amelioration of oxidative stress and inflammation in a corticosterone-induced chronic stress model in mice.
Topics: Animals; Anti-Inflammatory Agents; Antidepressive Agents; Antioxidants; Anxiety; Chronic Disease; Co | 2018 |
Perinatal exposure to venlafaxine leads to lower anxiety and depression-like behavior in the adult rat offspring.
Topics: Adrenal Cortex Hormones; Aldosterone; Animals; Animals, Newborn; Anxiety; Anxiety Disorders; Behavio | 2018 |
Maternal exercise increases but concurrent maternal fluoxetine prevents the increase in hippocampal neurogenesis of adult offspring.
Topics: Animals; Anxiety; Corticosterone; Depression, Postpartum; Disease Models, Animal; Doublecortin Domai | 2018 |
Effect of Fluoxetine in Prenatal Period on Nociceptive System Reactivity and Psychoemotional Behavior in Young Female Rats.
Topics: Animals; Animals, Newborn; Anxiety; Behavior, Animal; Body Weight; Cognition; Female; Fluoxetine; Ma | 2018 |
The antioxidant gallic acid induces anxiolytic-, but not antidepressant-like effect, in streptozotocin-induced diabetes.
Topics: Animals; Anti-Anxiety Agents; Antidepressive Agents; Antioxidants; Anxiety; Behavior, Animal; Depres | 2018 |
Translational control of depression-like behavior via phosphorylation of eukaryotic translation initiation factor 4E.
Topics: Animals; Antidepressive Agents; Anxiety; Behavior, Animal; Benzofurans; Citalopram; Depression; Depr | 2018 |
Platelet serotonin and serotonin transporter as peripheral surrogates in depression and anxiety patients.
Topics: Adult; Anxiety; Blood Platelets; Depression; Dose-Response Relationship, Drug; Female; Fluoxetine; H | 2018 |
The impact of chronic fluoxetine on conditioned fear expression and hippocampal FGF2 in rats: Short- and long-term effects.
Topics: Animals; Anxiety; Behavior, Animal; Conditioning, Classical; Fear; Fibroblast Growth Factor 2; Fluox | 2018 |
Impact of the widespread pharmaceutical pollutant fluoxetine on behaviour and sperm traits in a freshwater fish.
Topics: Animals; Antidepressive Agents; Anxiety; Cyprinodontiformes; Dose-Response Relationship, Drug; Fluox | 2019 |
Fluoxetine reverses brain radiation and temozolomide-induced anxiety and spatial learning and memory defect in mice.
Topics: Animals; Anti-Anxiety Agents; Antineoplastic Agents, Alkylating; Anxiety; Brain Diseases; Chemoradio | 2019 |
Prenatal Stimulation of 5-HT
Topics: Adaptation, Psychological; Animals; Animals, Newborn; Anxiety; Behavior, Animal; Buspirone; Depressi | 2019 |
Antidepressant-like activities of live and heat-killed Lactobacillus paracasei PS23 in chronic corticosterone-treated mice and possible mechanisms.
Topics: Animals; Antidepressive Agents; Anxiety; Anxiety Disorders; Behavior, Animal; Brain; Corticosterone; | 2019 |
Perinatal exposure to fluoxetine increases anxiety- and depressive-like behaviours and alters glutamatergic markers in the prefrontal cortex and hippocampus of male adolescent rats: A comparison between Sprague-Dawley rats and the Wistar-Kyoto rat model o
Topics: Animals; Anxiety; Depression; Disease Models, Animal; Female; Fluoxetine; Hippocampus; Male; Prefron | 2019 |
Celecoxib potentiates the antianxiety and anticompulsive-like activity of fluoxetine against chronic unpredictable mild stress in experimental animals.
Topics: Animals; Anti-Anxiety Agents; Anxiety; Behavior, Animal; Celecoxib; Compulsive Behavior; Disease Mod | 2019 |
Two-hit model of postintensive care syndrome induced by lipopolysaccharide challenge and subsequent chronic unpredictable stress in mice.
Topics: Animals; Anxiety; Chronic Disease; Cognition Disorders; Corticosterone; Critical Care; Critical Illn | 2019 |
Fear.
Topics: Anticonvulsants; Anxiety; Clonazepam; Depression; Family Practice; Fear; Female; Fluoxetine; Humans; | 2019 |
Predator odor produces anxiety-like behavioral phenotype in planarians that is counteracted by fluoxetine.
Topics: Animals; Anxiety; Avoidance Learning; Behavior, Animal; Fluoxetine; Odorants; Planarians | 2019 |
Short-term, low-dose fluoxetine prevents oestrous cycle-linked increase in anxiety-like behaviour in female rats.
Topics: Animals; Anxiety; Behavior, Animal; Disease Models, Animal; Estrous Cycle; Fear; Female; Fluoxetine; | 2019 |
A Case Report of Serotonin Syndrome in a Patient on Selective Serotonin Reuptake Inhibitor (SSRI) Monotherapy.
Topics: Anxiety; Depressive Disorder, Major; Female; Fluoxetine; Humans; Hydroxyzine; Paroxetine; Selective | 2020 |
Antidepressants in Surface Waters: Fluoxetine Influences Mosquitofish Anxiety-Related Behavior at Environmentally Relevant Levels.
Topics: Animals; Antidepressive Agents; Anxiety; Behavior, Animal; Cyprinodontiformes; Female; Fluoxetine; M | 2019 |
Lithium potentiated, pyridoxine abolished and fluoxetine attenuated the anxiolytic effect of diazepam in mice.
Topics: Animals; Anti-Anxiety Agents; Anxiety; Behavior, Animal; Brain; Diazepam; Fluoxetine; Glutamate Deca | 2019 |
Fluoxetine reduces periodontal disease progression in a conditioned fear stress model in rats.
Topics: Alveolar Bone Loss; Animals; Anxiety; Chronic Periodontitis; Conditioning, Psychological; Disease Mo | 2013 |
Role of serotonin in zebrafish (Danio rerio) anxiety: relationship with serotonin levels and effect of buspirone, WAY 100635, SB 224289, fluoxetine and para-chlorophenylalanine (pCPA) in two behavioral models.
Topics: Animals; Anti-Anxiety Agents; Anxiety; Behavior, Animal; Brain; Buspirone; Disease Models, Animal; D | 2013 |
BDNF overexpression in mouse hippocampal astrocytes promotes local neurogenesis and elicits anxiolytic-like activities.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Antidepressive Agents, Second-Generation; Anxiety; | 2013 |
Effect of ultrasonic irradiation on the development of symptoms of depression and anxiety in rats.
Topics: Anhedonia; Animals; Antidepressive Agents; Anxiety; Behavior, Animal; Depression; Disease Models, An | 2013 |
Adolescent fluoxetine treatment decreases the effects of neonatal immune activation on anxiety-like behavior in mice.
Topics: Age Factors; Analysis of Variance; Animals; Animals, Newborn; Antidepressive Agents, Second-Generati | 2013 |
Concomitant docosahexaenoic acid administration ameliorates stress-induced cognitive impairment in rats.
Topics: Animals; Antidepressive Agents, Second-Generation; Anxiety; Cognition Disorders; Docosahexaenoic Aci | 2013 |
Behavioral and neurochemical changes in the zebrafish leopard strain.
Topics: Animals; Anxiety; Fluoxetine; Monoamine Oxidase; Motor Activity; Mutation; Phenotype; Selective Sero | 2013 |
Behavioral and neurogenomic transcriptome changes in wild-derived zebrafish with fluoxetine treatment.
Topics: Animals; Anxiety; Behavior, Animal; Fluoxetine; Humans; Male; Nervous System; Selective Serotonin Re | 2013 |
Beneficial effects of fluoxetine, reboxetine, venlafaxine, and voluntary running exercise in stressed male rats with anxiety- and depression-like behaviors.
Topics: Analysis of Variance; Animals; Anti-Anxiety Agents; Anxiety; Cyclohexanols; Depression; Disease Mode | 2013 |
Lower anxiogenic effects of serotonin agonists are associated with lower activation of amygdala and lateral orbital cortex in adolescent male rats.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Age Factors; Amygdala; Animals; Anxiety; Behavior, Animal; D | 2013 |
Anti-depressant like activity of N-n-butyl-3-methoxyquinoxaline-2-carboxamide (6o) a 5-HT3 receptor antagonist.
Topics: Animals; Antidepressive Agents; Anxiety; Behavior, Animal; Depression; Fluoxetine; Guinea Pigs; Mice | 2013 |
The H/Rouen mouse model displays depression-like and anxiety-like behaviors.
Topics: Anhedonia; Animals; Antidepressive Agents, Second-Generation; Anxiety; Comorbidity; Depressive Disor | 2013 |
The effects of congenital brain serotonin deficiency on responses to chronic fluoxetine.
Topics: 5-Hydroxytryptophan; Animals; Antidepressive Agents, Second-Generation; Anxiety; Behavior, Animal; F | 2013 |
Angiotensin-(1-7) attenuates the anxiety and depression-like behaviors in transgenic rats with low brain angiotensinogen.
Topics: Angiotensin I; Angiotensinogen; Animals; Anxiety; Brain; Depression; Disease Models, Animal; Drug Ad | 2013 |
Regulator of calcineurin 1 modulates expression of innate anxiety and anxiogenic responses to selective serotonin reuptake inhibitor treatment.
Topics: Animals; Anxiety; Brain; Brain-Derived Neurotrophic Factor; Calcineurin; Calcium-Binding Proteins; C | 2013 |
Startle response memory and hippocampal changes in adult zebrafish pharmacologically-induced to exhibit anxiety/depression-like behaviors.
Topics: Analysis of Variance; Animals; Antidepressive Agents, Second-Generation; Anxiety; Central Nervous Sy | 2014 |
Involvement of 5-HT2C and 5-HT1A receptors of the basolateral nucleus of the amygdala in the anxiolytic effect of chronic antidepressant treatment.
Topics: Amygdala; Animals; Anti-Anxiety Agents; Antidepressive Agents, Second-Generation; Antidepressive Age | 2014 |
Rapid anxiolytic effects of a 5-HT₄ receptor agonist are mediated by a neurogenesis-independent mechanism.
Topics: Aniline Compounds; Animals; Anti-Anxiety Agents; Antidepressive Agents, Second-Generation; Anxiety; | 2014 |
Postnatal fluoxetine-evoked anxiety is prevented by concomitant 5-HT2A/C receptor blockade and mimicked by postnatal 5-HT2A/C receptor stimulation.
Topics: Animals; Anxiety; Depression; Fluoxetine; Gene Expression; Male; Motor Activity; Prefrontal Cortex; | 2014 |
Fluoxetine treatment of rat neonates significantly reduces oxidative stress in the hippocampus and in behavioral indicators of anxiety later in postnatal life.
Topics: Animals; Animals, Newborn; Anti-Anxiety Agents; Anxiety; Behavior, Animal; Body Weight; Eating; Fluo | 2014 |
Lipopolysaccharide-induced sepsis induces long-lasting affective changes in the mouse.
Topics: Animals; Antidepressive Agents; Anxiety; Behavior, Animal; Cytoskeletal Proteins; Depression; Diseas | 2015 |
Effects of the anti-multiple sclerosis immunomodulator laquinimod on anxiety and depression in rodent behavioral models.
Topics: Animals; Antidepressive Agents; Anxiety; Brain-Derived Neurotrophic Factor; Depression; Fluoxetine; | 2015 |
Increased aggression, improved spatial memory, and reduced anxiety-like behaviour in adult male mice exposed to fluoxetine early in life.
Topics: Aggression; Animals; Anxiety; Behavior, Animal; Conditioning, Classical; Fear; Female; Fluoxetine; M | 2014 |
[The effect of fluoxetine and tianeptine on emotional and eating disorders in postmenopausal women].
Topics: Aged; Antidepressive Agents, Tricyclic; Anxiety; Body Mass Index; Depression; Drug Administration Sc | 2014 |
Ondansetron, a 5HT3 receptor antagonist reverses depression and anxiety-like behavior in streptozotocin-induced diabetic mice: possible implication of serotonergic system.
Topics: Animals; Antidepressive Agents; Antiemetics; Anxiety; Behavior, Animal; Brain; Depression; Depressiv | 2014 |
Quantitative cross-species extrapolation between humans and fish: the case of the anti-depressant fluoxetine.
Topics: Animals; Antidepressive Agents, Second-Generation; Anxiety; Behavior, Animal; Biotransformation; Cyp | 2014 |
A Case of Quetiapine-Induced Rapid Eye Movement Sleep Behavior Disorder.
Topics: Antipsychotic Agents; Anxiety; Depression; Female; Fluoxetine; Humans; Middle Aged; Polysomnography; | 2016 |
Short-term fluoxetine treatment induces neuroendocrine and behavioral anxiogenic-like responses in adolescent male rats.
Topics: Animals; Anxiety; Behavior, Animal; Corticosterone; Dorsal Raphe Nucleus; Fluoxetine; Hypothalamo-Hy | 2015 |
Dose dependent effects of serotonergic agents on anxiety.
Topics: Animals; Anti-Anxiety Agents; Anxiety; Behavior, Animal; Buspirone; Disease Models, Animal; Dose-Res | 2014 |
Fluoxetine treatment reverses the intergenerational impact of maternal separation on fear and anxiety behaviors.
Topics: Analysis of Variance; Animals; Antidepressive Agents, Second-Generation; Anxiety; Conditioning, Clas | 2015 |
Mice deficient for wild-type p53-induced phosphatase 1 display elevated anxiety- and depression-like behaviors.
Topics: Animals; Antidepressive Agents, Second-Generation; Anxiety; Depression; Exploratory Behavior; Fluoxe | 2015 |
Sex differences in motivational responses to dietary fat in Syrian hamsters.
Topics: Analysis of Variance; Animals; Antidepressive Agents; Anxiety; Calorimetry; Cohort Studies; Cricetin | 2015 |
Nrf2-signaling and BDNF: A new target for the antidepressant-like activity of chronic fluoxetine treatment in a mouse model of anxiety/depression.
Topics: Animals; Antidepressive Agents; Anxiety; Brain-Derived Neurotrophic Factor; Cerebral Cortex; Cortico | 2015 |
The role of 5-HT1A receptors in mediating acute negative effects of antidepressants: implications in pediatric depression.
Topics: Adrenergic Uptake Inhibitors; Animals; Antidepressive Agents; Anxiety; Behavior, Animal; Child; Depr | 2015 |
The effects of chronic fluoxetine treatment following injury of medial frontal cortex in mice.
Topics: Animals; Anxiety; Behavior, Animal; Brain Injuries; Disease Models, Animal; Fluoxetine; Male; Mice; | 2015 |
Pharmacological validation of the free-exploratory paradigm in male Wistar rats: A proposed test of trait anxiety.
Topics: Animals; Anti-Anxiety Agents; Anxiety; Diazepam; Drug Evaluation, Preclinical; Exploratory Behavior; | 2015 |
Male rats with same sex preference show high experimental anxiety and lack of anxiogenic-like effect of fluoxetine in the plus maze test.
Topics: Animals; Anti-Anxiety Agents; Anxiety; Enzyme Inhibitors; Exploratory Behavior; Female; Fluoxetine; | 2015 |
The positive effect on ketamine as a priming adjuvant in antidepressant treatment.
Topics: Animals; Antidepressive Agents; Anxiety; Aspartic Acid; Behavior, Animal; Brain; Depression; Depress | 2015 |
Effects of acute or repeated paroxetine and fluoxetine treatment on affective behavior in male and female adolescent rats.
Topics: Age Factors; Animals; Antidepressive Agents, Second-Generation; Anxiety; Depressive Disorder; Drug A | 2015 |
Behavioral and pharmacological investigation of anxiety and maternal responsiveness of postpartum female rats in a pup elevated plus maze.
Topics: Animals; Anti-Anxiety Agents; Anxiety; Diazepam; Dopamine D2 Receptor Antagonists; Female; Fluoxetin | 2015 |
Lurasidone and fluoxetine reduce novelty-induced hypophagia and NMDA receptor subunit and PSD-95 expression in mouse brain.
Topics: Administration, Oral; Animals; Anti-Anxiety Agents; Antidepressive Agents; Antipsychotic Agents; Anx | 2015 |
Behavioral, endocrine, and neuronal alterations in zebrafish (Danio rerio) following sub-chronic coadministration of fluoxetine and ketamine.
Topics: Animals; Antidepressive Agents, Second-Generation; Anxiety; Behavior, Animal; Brain; Depression; Dis | 2015 |
So you think you can jump? A novel long jump assessment to detect deficits in stroked mice.
Topics: Animals; Anxiety; Disease Models, Animal; Female; Fluoxetine; Hindlimb; Infarction, Middle Cerebral | 2015 |
Effects of chronic fluoxetine treatment on anxious behaviour of BALB/c mice in a 3-dimensional maze.
Topics: Animals; Anti-Anxiety Agents; Anxiety; Behavior, Animal; Fear; Fluoxetine; Male; Maze Learning; Mice | 2015 |
Maternal postpartum corticosterone and fluoxetine differentially affect adult male and female offspring on anxiety-like behavior, stress reactivity, and hippocampal neurogenesis.
Topics: Animals; Animals, Newborn; Anti-Anxiety Agents; Anxiety; Corticosterone; Dexamethasone; Disease Mode | 2016 |
Knockdown of hippocampal cysteinyl leukotriene receptor 1 prevents depressive behavior and neuroinflammation induced by chronic mild stress in mice.
Topics: Animals; Antidepressive Agents, Second-Generation; Anxiety; Cytokines; Depression; Eating; Fluoxetin | 2016 |
Prenatal stress and early-life exposure to fluoxetine have enduring effects on anxiety and hippocampal BDNF gene expression in adult male offspring.
Topics: Animals; Anxiety; Behavior, Animal; Brain-Derived Neurotrophic Factor; Disease Models, Animal; Femal | 2016 |
Fluoxetine normalizes disrupted light-induced entrainment, fragmented ultradian rhythms and altered hippocampal clock gene expression in an animal model of high trait anxiety- and depression-related behavior.
Topics: Animals; Anxiety; Circadian Rhythm; Cryptochromes; Depressive Disorder; Disease Models, Animal; Fema | 2016 |
Anxiety- and Depression-Like States Lead to Pronounced Olfactory Deficits and Impaired Adult Neurogenesis in Mice.
Topics: Animals; Anti-Inflammatory Agents; Antidepressive Agents, Second-Generation; Anxiety; Cell Prolifera | 2016 |
Acute fluoxetine exposure alters crab anxiety-like behaviour, but not aggressiveness.
Topics: Aggression; Animals; Antidepressive Agents; Anxiety; Behavior, Animal; Brachyura; Disease Models, An | 2016 |
The smell of "anxiety": Behavioral modulation by experimental anosmia in zebrafish.
Topics: Analysis of Variance; Anesthetics, Local; Animals; Antidepressive Agents, Second-Generation; Anxiety | 2016 |
Chronic fluoxetine treatment induces anxiolytic responses and altered social behaviors in medaka, Oryzias latipes.
Topics: Animals; Anti-Anxiety Agents; Antidepressive Agents, Second-Generation; Anxiety; Behavior, Animal; F | 2016 |
Inflammatory mechanisms contribute to microembolism-induced anxiety-like and depressive-like behaviors.
Topics: Animals; Anxiety; B-Lymphocytes; Cyclooxygenase Inhibitors; Cytokines; Depression; Encephalitis; Flu | 2016 |
Developmental fluoxetine exposure increases behavioral despair and alters epigenetic regulation of the hippocampal BDNF gene in adult female offspring.
Topics: Animals; Anxiety; Brain-Derived Neurotrophic Factor; Depression; Disease Models, Animal; Epigenesis, | 2016 |
Chronic 5-HT4 receptor agonist treatment restores learning and memory deficits in a neuroendocrine mouse model of anxiety/depression.
Topics: Aniline Compounds; Animals; Antidepressive Agents; Anxiety; Association Learning; Corticosterone; De | 2016 |
Short term, low dose fluoxetine blocks estrous cycle-linked changes in responsiveness to diazepam in female rats.
Topics: Animals; Anti-Anxiety Agents; Anxiety; Brain; Diazepam; Estrous Cycle; Estrus; Female; Fluoxetine; g | 2016 |
Evaluating "anxiety" and social behavior in jundiá (Rhamdia quelen).
Topics: Analysis of Variance; Animals; Antidepressive Agents, Second-Generation; Anxiety; Catfishes; Disease | 2016 |
Fluoxetine disrupts motivation and GABAergic signaling in adolescent female hamsters.
Topics: Anhedonia; Animals; Anxiety; Brain-Derived Neurotrophic Factor; Conflict, Psychological; Cricetinae; | 2016 |
Effect of chronic fluoxetine treatment on audiogenic epilepsy, symptoms of anxiety and depression in rats of four lines.
Topics: Animals; Anxiety; Depression; Epilepsy, Reflex; Fluoxetine; Rats; Rats, Wistar; Species Specificity | 2016 |
Prenatal SSRI alters the hormonal and behavioral responses to stress in female mice: Possible role for glucocorticoid resistance.
Topics: Animals; Anxiety; Behavior, Animal; Corticosterone; Female; Fluoxetine; Hypothalamo-Hypophyseal Syst | 2016 |
Serotonin engages an anxiety and fear-promoting circuit in the extended amygdala.
Topics: Amygdala; Animals; Anxiety; Anxiety Disorders; Corticotropin-Releasing Hormone; Dorsal Raphe Nucleus | 2016 |
The absence of 5-HT
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Anhedonia; Animals; Antidepressive Agents, Second-Generation | 2016 |
Anxiety and depression with neurogenesis defects in exchange protein directly activated by cAMP 2-deficient mice are ameliorated by a selective serotonin reuptake inhibitor, Prozac.
Topics: Affect; Aged; Aged, 80 and over; Alzheimer Disease; Animals; Anxiety; Asian People; Behavior, Animal | 2016 |
Environmental enrichment prevents anxiety-like behavior induced by progesterone withdrawal in two strains of rats.
Topics: Animals; Anti-Anxiety Agents; Anxiety; Behavior, Animal; Environment; Female; Fluoxetine; Progestero | 2016 |
COMBINATION THERAPY WITH FLUOXETINE AND ALPRAZOLAM TO CONTROL ANXIETY IN A HAND-REARED SNOW LEOPARD (UNCIA UNCIA).
Topics: Adrenergic Uptake Inhibitors; Alprazolam; Animals; Animals, Zoo; Anti-Anxiety Agents; Anxiety; Behav | 2016 |
Hippocampal bone morphogenetic protein signaling mediates behavioral effects of antidepressant treatment.
Topics: Animals; Anti-Anxiety Agents; Antidepressive Agents; Anxiety; Bone Morphogenetic Protein 4; Bone Mor | 2017 |
Fluoxetine and Trazodone Combination Pharmacotherapy Resulting in Severe Irritability, Anger, Anxiety, and Anorexia: Probable Adverse Drug Interaction.
Topics: Adult; Anger; Anorexia; Antidepressive Agents, Second-Generation; Anxiety; Drug Interactions; Drug T | 2016 |
Anxiogenic-like effects of fluoxetine render adult male rats vulnerable to the effects of a novel stress.
Topics: Animals; Anxiety; Corticosterone; Corticotropin-Releasing Hormone; Energy Metabolism; Fluoxetine; Hy | 2017 |
Genetic background contributes to the co-morbidity of anxiety and depression with audiogenic seizure propensity and responses to fluoxetine treatment.
Topics: Animals; Antidepressive Agents; Anxiety; Depression; Disease Models, Animal; Epilepsy, Reflex; Fluox | 2017 |
Telmisartan attenuates diabetes induced depression in rats.
Topics: Animals; Antidepressive Agents; Anxiety; Behavior, Animal; Benzimidazoles; Benzoates; Brain; Depress | 2017 |
Modelling the anxiety-depression continuum in chicks.
Topics: Animals; Animals, Newborn; Anti-Anxiety Agents; Antidepressive Agents; Anxiety; Chickens; Chlordiaze | 2009 |
Treatment of idiopathic recurrent priapism with fluoxetine and low dose Perphenazine.
Topics: Adult; Antipsychotic Agents; Anxiety; Depression; Fluoxetine; Humans; Male; Perphenazine; Priapism; | 2008 |
Mouse strain differences in the unpredictable chronic mild stress: a four-antidepressant survey.
Topics: Animals; Animals, Outbred Strains; Antidepressive Agents; Antidepressive Agents, Second-Generation; | 2008 |
Behavioral characterization of the mGlu group II/III receptor antagonist, LY-341495, in animal models of anxiety and depression.
Topics: Amino Acids; Amphetamine; Animals; Anti-Anxiety Agents; Antidepressive Agents, Second-Generation; An | 2008 |
Modulation of serotonin transporter function during fetal development causes dilated heart cardiomyopathy and lifelong behavioral abnormalities.
Topics: Animals; Antidepressive Agents; Anxiety; Behavior, Animal; Cardiomyopathy, Dilated; Female; Fluoxeti | 2008 |
Long-lasting behavioural and molecular alterations induced by early postnatal fluoxetine exposure are restored by chronic fluoxetine treatment in adult mice.
Topics: Animals; Animals, Newborn; Anxiety; Behavior, Animal; Body Weight; Brain Chemistry; Brain-Derived Ne | 2009 |
Nicotine exposure during adolescence induces a depression-like state in adulthood.
Topics: Aging; Animals; Antidepressive Agents, Second-Generation; Anxiety; Bupropion; Cholinergic Agents; De | 2009 |
Neonatal administration of fluoxetine did not alter the anxiety indicators, but decreased the locomotor activity in adult rats in the elevated plus-maze.
Topics: Animals; Animals, Newborn; Anxiety; Fluoxetine; Male; Maze Learning; Motor Activity; Rats; Rats, Wis | 2008 |
Paradoxical anxiogenic response of juvenile mice to fluoxetine.
Topics: Age Factors; Analysis of Variance; Animals; Animals, Newborn; Anxiety; Behavior, Animal; Cell Prolif | 2009 |
Behavioral abnormality and pharmacologic response in social isolation-reared mice.
Topics: Aggression; Animals; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Anxiety; Behavi | 2009 |
Neurogenesis-dependent and -independent effects of fluoxetine in an animal model of anxiety/depression.
Topics: Analysis of Variance; Animals; Antidepressive Agents, Second-Generation; Anxiety; Arrestins; beta-Ar | 2009 |
Understanding behavioral and physiological phenotypes of stress and anxiety in zebrafish.
Topics: Animals; Antidepressive Agents, Second-Generation; Anxiety; Behavior, Animal; Caffeine; Central Nerv | 2009 |
The lonely mouse: verification of a separation-induced model of depression in female mice.
Topics: Acoustic Stimulation; Analysis of Variance; Animals; Anxiety; Behavior, Animal; Conditioning, Classi | 2010 |
Acute administration of leptin produces anxiolytic-like effects: a comparison with fluoxetine.
Topics: Animals; Antidepressive Agents, Second-Generation; Anxiety; Disease Models, Animal; Exploratory Beha | 2010 |
Acute SSRI-induced anxiogenic and brain metabolic effects are attenuated 6 months after initial MDMA-induced depletion.
Topics: Animals; Anxiety; Axons; Brain; Citalopram; Fluoxetine; Male; N-Methyl-3,4-methylenedioxyamphetamine | 2010 |
[Neurogenesis-dependent and independent effects of anti-depressant drugs].
Topics: Animals; Anti-Anxiety Agents; Anxiety; Depression; Fluoxetine; Hippocampus; Humans; Mice; Models, An | 2009 |
A longitudinal study of 5-HT outflow during chronic fluoxetine treatment using a new technique of chronic microdialysis in a highly emotional mouse strain.
Topics: Administration, Oral; Animals; Antidepressive Agents; Anxiety; Behavior, Animal; Depressive Disorder | 2010 |
Effects of single and simultaneous lesions of serotonergic and noradrenergic pathways on open-space and bright-space anxiety-like behavior in two animal models.
Topics: 5,7-Dihydroxytryptamine; Adaptation, Physiological; Adrenergic Agents; Adrenergic Uptake Inhibitors; | 2010 |
Macrophage migration inhibitory factor is critically involved in basal and fluoxetine-stimulated adult hippocampal cell proliferation and in anxiety, depression, and memory-related behaviors.
Topics: Acoustic Stimulation; Animals; Antidepressive Agents, Second-Generation; Anxiety; Bromodeoxyuridine; | 2011 |
Chronic fluoxetine treatment induces structural plasticity and selective changes in glutamate receptor subunits in the rat cerebral cortex.
Topics: Animals; Antidepressive Agents; Anxiety; Behavior, Animal; Dendritic Spines; Fluoxetine; Gene Expres | 2010 |
Behavioural effects of co-administration of delta9-tetrahydrocannabinol with fluoxetine in rats.
Topics: Animals; Anti-Anxiety Agents; Antidepressive Agents, Second-Generation; Anxiety; Behavior, Animal; D | 2010 |
[Comparative efficacy of selective serotonin reuptake inhibitors in young prenatally stressed female rats].
Topics: Animals; Anti-Anxiety Agents; Anxiety; Behavior, Animal; Female; Fluoxetine; Paroxetine; Rats; Rats, | 2010 |
Acute and chronic anxiogenic-like response to fluoxetine in rats in the elevated plus-maze: modulation by stressful handling.
Topics: Analysis of Variance; Angiogenesis Inhibitors; Animals; Anxiety; Disease Models, Animal; Fluoxetine; | 2011 |
Predictive validity of a non-induced mouse model of compulsive-like behavior.
Topics: Animals; Anxiety; Behavior, Animal; Clomipramine; Compulsive Behavior; Desipramine; Disease Models, | 2011 |
Infant maternal separation impairs adult cognitive performance in BALB/cJ mice.
Topics: Age Factors; Animals; Animals, Newborn; Anxiety; Behavior, Animal; Cognition Disorders; Depression; | 2011 |
Anxiety-like behaviors and expression of SERT and TPH in the dorsal raphé of estrogen- and fluoxetine-treated ovariectomized rats.
Topics: Animals; Anti-Anxiety Agents; Anxiety; Base Sequence; DNA Primers; Estradiol; Female; Fluoxetine; Ma | 2011 |
Acute anxiogenic-like effects of selective serotonin reuptake inhibitors are attenuated by the benzodiazepine diazepam in BALB/c mice.
Topics: Animals; Anti-Anxiety Agents; Anxiety; Behavior, Animal; Citalopram; Corticosterone; Diazepam; Drug | 2011 |
Behavioral destabilization induced by the selective serotonin reuptake inhibitor fluoxetine.
Topics: Animals; Anxiety; Behavior, Animal; Depression; Fluoxetine; Male; Mice; Mice, Inbred C57BL; Motor Ac | 2011 |
[Study of self-regulating behavior at different stages of psychogenic stress before the formation of depressive-like state in rats].
Topics: Animals; Antidepressive Agents; Anxiety; Behavior, Animal; Depression; Escape Reaction; Fluoxetine; | 2011 |
Fluoxetine administration to pregnant rats increases anxiety-related behavior in the offspring.
Topics: Animals; Anxiety; Behavior, Animal; Brain; Chromatography, High Pressure Liquid; Female; Fluoxetine; | 2011 |
Effects of chronic administration of tryptophan with or without concomitant fluoxetine in depression-related and anxiety-like behaviors on adult rat.
Topics: Age Factors; Animals; Anxiety; Depression; Drug Therapy, Combination; Fluoxetine; Male; Rats; Rats, | 2011 |
[Influence of fluoxetine and paroxetine on anxiety-like behavior in young and adult prenatally stressed male rats].
Topics: Age Factors; Animals; Anti-Anxiety Agents; Antidepressive Agents, Second-Generation; Anxiety; Behavi | 2011 |
Juvenile administration of concomitant methylphenidate and fluoxetine alters behavioral reactivity to reward- and mood-related stimuli and disrupts ventral tegmental area gene expression in adulthood.
Topics: Animals; Anxiety; Cyclic AMP Response Element-Binding Protein; Extracellular Signal-Regulated MAP Ki | 2011 |
Serotonin transporter occupancy in rats exposed to serotonin reuptake inhibitors in utero or via breast milk.
Topics: Aging; Animals; Anxiety; Brain; Central Nervous System; Female; Fetus; Fluoxetine; Image Processing, | 2011 |
Influence of Neuropeptide Y and antidepressants upon cerebral monoamines involved in depression: an in vivo electrochemical study.
Topics: Amygdala; Animals; Anti-Anxiety Agents; Antidepressive Agents; Antidepressive Agents, Tricyclic; Anx | 2011 |
Fluoxetine during development reverses the effects of prenatal stress on depressive-like behavior and hippocampal neurogenesis in adolescence.
Topics: Animals; Antidepressive Agents; Anxiety; Behavior, Animal; Body Weight; Depression; Doublecortin Dom | 2011 |
Hypomania as a genuine side effect of fluoxetine.
Topics: Adolescent; Antidepressive Agents, Second-Generation; Anxiety; Bipolar Disorder; Fluoxetine; Humans; | 2011 |
Tianeptine in the combined treatment of combat related posttraumatic stress disorder.
Topics: Adult; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Anxiety; Combat D | 2011 |
Prenatal fluoxetine exposure induces life-long serotonin 5-HT₃ receptor-dependent cortical abnormalities and anxiety-like behaviour.
Topics: Animals; Anxiety; Behavior, Animal; Cerebral Cortex; Female; Fluoxetine; Mice; Neurons; Pregnancy; P | 2012 |
Functional status of somatodendritic serotonin 1A autoreceptor after long-term treatment with fluoxetine in a mouse model of anxiety/depression based on repeated corticosterone administration.
Topics: Animals; Anxiety; Autoreceptors; Corticosterone; Depression; Drug Resistance; Drug Therapy, Combinat | 2012 |
Behavioral characterization of the alarm reaction and anxiolytic-like effect of acute treatment with fluoxetine in piauçu fish.
Topics: Animals; Anti-Anxiety Agents; Anxiety; Behavior, Animal; Epidermis; Escape Reaction; Fishes; Fluoxet | 2012 |
On the edge: pharmacological evidence for anxiety-related behavior in zebrafish larvae.
Topics: Animals; Anxiety; Caffeine; Cues; Diazepam; Disease Models, Animal; Dose-Response Relationship, Drug | 2012 |
Treatment practices in Tourette syndrome: the European perspective.
Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Anxiety; Aripiprazole; Atomoxetine Hydrochloride | 2012 |
Prenatal lipopolysaccharide exposure increases anxiety-like behaviors and enhances stress-induced corticosterone responses in adult rats.
Topics: Animals; Anxiety; Anxiety Disorders; Brain; Corticosterone; Dopamine; Female; Fluoxetine; Hippocampu | 2012 |
Antidepressants differentially modify the extinction of an aversive memory task in female rats.
Topics: Animals; Antidepressive Agents; Anxiety; Avoidance Learning; Extinction, Psychological; Female; Fluo | 2012 |
Anxiolytic-like effects of olanzapine, risperidone and fluoxetine in the elevated plus-maze test in rats.
Topics: Animals; Anti-Anxiety Agents; Anxiety; Benzodiazepines; Drug Interactions; Drug Therapy, Combination | 2011 |
Serotonin transporter polyadenylation polymorphism modulates the retention of fear extinction memory.
Topics: Alleles; Animals; Anxiety; Depression; Fear; Fluoxetine; Genetic Variation; Humans; Memory; Mice; Po | 2012 |
The change in muscarinic receptor subtypes in different brain regions of rats treated with fluoxetine or propranolol in a model of post-traumatic stress disorder.
Topics: Adrenergic beta-Antagonists; Amygdala; Animals; Anxiety; Blotting, Western; Brain Chemistry; Explora | 2012 |
Antinociceptive effects of fluoxetine in a mouse model of anxiety/depression.
Topics: Animals; Antidepressive Agents, Second-Generation; Anxiety; Chronic Pain; Cold Temperature; Corticos | 2012 |
Differential environmental regulation of neurogenesis along the septo-temporal axis of the hippocampus.
Topics: Animals; Animals, Newborn; Antidepressive Agents, Second-Generation; Antimetabolites; Anxiety; Bromo | 2012 |
Chronic social defeat stress model: behavioral features, antidepressant action, and interaction with biological risk factors.
Topics: Animals; Antidepressive Agents; Anxiety; Behavior, Animal; Cyclohexanols; Depression; Depressive Dis | 2012 |
Neurobiological sequelae of witnessing stressful events in adult mice.
Topics: Animals; Anxiety; Behavior, Animal; Corticosterone; Depression; Disease Models, Animal; Fluoxetine; | 2013 |
Anxiolytic- and panicolytic-like effects of Neuropeptide S in the mouse elevated T-maze.
Topics: Animals; Anti-Anxiety Agents; Antidepressive Agents, Second-Generation; Anxiety; Diazepam; Dose-Resp | 2012 |
Circadian genes Period 1 and Period 2 in the nucleus accumbens regulate anxiety-related behavior.
Topics: Animals; Antidepressive Agents, Second-Generation; Anxiety; Avoidance Learning; Fluoxetine; Maze Lea | 2013 |
Anxiety- rather than depression-like behavior is associated with adult neurogenesis in a female mouse model of higher trait anxiety- and comorbid depression-like behavior.
Topics: Analysis of Variance; Animals; Antidepressive Agents; Anxiety; Behavior, Animal; Biomarkers; Dentate | 2012 |
Subacute fluoxetine enhances conditioned responding and conditioning-specific reflex modification of the rabbit nictitating membrane response: implications for drug treatment with selective serotonin reuptake inhibitors.
Topics: Animals; Antidepressive Agents; Anxiety; Conditioning, Classical; Conditioning, Eyelid; Dose-Respons | 2013 |
A role for the extended amygdala in the fear-enhancing effects of acute selective serotonin reuptake inhibitor treatment.
Topics: Amygdala; Analysis of Variance; Animals; Antidepressive Agents; Anxiety; Conditioning, Psychological | 2013 |
Involvement of extracellular signal regulated kinases in traumatic brain injury-induced depression in rodents.
Topics: Animals; Anxiety; Blotting, Western; Brain Injuries; Coloring Agents; Depression; Extracellular Sign | 2013 |
Cholinergic signaling in the hippocampus regulates social stress resilience and anxiety- and depression-like behavior.
Topics: Acetylcholinesterase; Animals; Antidepressive Agents; Anxiety; Behavior, Animal; Cholinergic Antagon | 2013 |
Fluoxetine-induced increases in open-field habituation in the olfactory bulbectomized rat depend on test aversiveness but not on anxiety.
Topics: Animals; Anti-Anxiety Agents; Anxiety; Avoidance Learning; Environment; Fluoxetine; Habituation, Psy | 2002 |
Further evidence for the predictive validity of the unstable elevated exposed plus-maze, a behavioural model of extreme anxiety in rats: differential effects of fluoxetine and chlordiazepoxide.
Topics: Animals; Anti-Anxiety Agents; Anxiety; Chlordiazepoxide; Dose-Response Relationship, Drug; Escape Re | 2002 |
Prior exposure to the elevated plus-maze sensitizes mice to the acute behavioral effects of fluoxetine and phenelzine.
Topics: Animals; Anxiety; Fluoxetine; Male; Maze Learning; Mice; Phenelzine | 2003 |
Neuroanatomical substrates involved in the anxiogenic-like effect of acute fluoxetine treatment.
Topics: Animals; Anti-Anxiety Agents; Anxiety; Brain; Escape Reaction; Fluoxetine; Genes, fos; Immobilizatio | 2002 |
Differential neurochemical properties of central serotonergic transmission in Roman high- and low-avoidance rats.
Topics: Animals; Anxiety; Autoradiography; Avoidance Learning; Behavior, Animal; Binding, Competitive; Brain | 2003 |
Which SSRI?
Topics: Adolescent; Anxiety; Child; Depressive Disorder; Drug Interactions; Fluoxetine; Half-Life; Humans; M | 2003 |
Chronic fluoxetine treatment partly attenuates the long-term anxiety and depressive symptoms induced by MDMA ('Ecstasy') in rats.
Topics: Animals; Antidepressive Agents, Second-Generation; Anxiety; Body Fluids; Body Temperature; Body Weig | 2004 |
Treatment of panic disorder with agoraphobia in an anxiety disorders clinic: factors influencing psychiatrists' treatment choices.
Topics: Adult; Agoraphobia; Anxiety; Benzodiazepines; Choice Behavior; Cognitive Behavioral Therapy; Combine | 2004 |
Self-induced hyperemesis in pregnancy.
Topics: Adult; Antidepressive Agents, Second-Generation; Anxiety; Depression; Female; Fluoxetine; Humans; Hy | 2004 |
Effects of chronic fluoxetine in animal models of anxiety and depression.
Topics: Analysis of Variance; Animals; Anxiety; Behavior, Animal; Depression; Disease Models, Animal; Dose-R | 2004 |
Animal behavior case of the month. Urine spraying and inappropriate urination for the past 10 years.
Topics: Alprazolam; Animals; Anti-Anxiety Agents; Antidepressive Agents, Second-Generation; Anxiety; Behavio | 2004 |
Anxiety and somatic symptoms as predictors of treatment-related adverse events in major depressive disorder.
Topics: Adult; Anxiety; Depressive Disorder, Major; Female; Fluoxetine; Humans; Male; Prospective Studies; S | 2004 |
Ejaculation failure on the day of oocyte retrieval for IVF: case report.
Topics: Adult; Antidepressive Agents, Second-Generation; Anxiety; Cryopreservation; Depression; Ejaculation; | 2004 |
A follow-up study of male sexual disorders: the neurophysiological assessments, anxiety-depression levels, and response to fluoxetine treatment.
Topics: Adult; Aged; Anxiety; Depression; Fluoxetine; Follow-Up Studies; Humans; Male; Middle Aged; Sexual D | 2004 |
Drugs vs. talk therapy: 3,079 readers rate their care for depression and anxiety.
Topics: Antidepressive Agents; Anxiety; Anxiety Disorders; Bupropion; Citalopram; Cyclohexanols; Depression; | 2004 |
Neuroscience. Prozac treatment of newborn mice raises anxiety.
Topics: Animals; Animals, Newborn; Anxiety; Brain; Child; Fluoxetine; Humans; Membrane Glycoproteins; Membra | 2004 |
Early-life blockade of the 5-HT transporter alters emotional behavior in adult mice.
Topics: Animals; Animals, Newborn; Anxiety; Avoidance Learning; Behavior, Animal; Brain; Central Nervous Sys | 2004 |
Antidepressants attenuate both the enhanced ethanol intake and ethanol-induced anxiolytic effects in diazepam withdrawn rats.
Topics: Alcohol Drinking; Analysis of Variance; Animals; Anti-Anxiety Agents; Antidepressive Agents; Anxiety | 2005 |
5-HT1A receptors are differentially involved in the anxiolytic- and antidepressant-like effects of 8-OH-DPAT and fluoxetine in the rat.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Anti-Anxiety Agents; Antidepressive Agents; Antidep | 2004 |
Fluoxetine disrupts the integration of anxiety and aversive memories.
Topics: Acetylcholine; Animals; Antidepressive Agents, Second-Generation; Anxiety; Dose-Response Relationshi | 2005 |
The efficacy of fluoxetine and a stop-start technique in the treatment of premature ejaculation and anxiety.
Topics: Adult; Anxiety; Ejaculation; Fluoxetine; Humans; Male; Middle Aged; Sexual Dysfunctions, Psychologic | 2005 |
Decreases in nestlet shredding of mice by serotonin uptake inhibitors: comparison with marble burying.
Topics: Animals; Anxiety; Disease Models, Animal; Dose-Response Relationship, Drug; Fluoxetine; Habituation, | 2006 |
Influence of fluoxetine and paroxetine in behavioral sensitization induced by ethanol in mice.
Topics: Animals; Antidepressive Agents, Second-Generation; Anxiety; Behavior, Animal; Central Nervous System | 2005 |
Nociception- and anxiety-like behavior in rats submitted to different periods of restraint stress.
Topics: Acute Disease; Adrenocorticotropic Hormone; Analgesics, Opioid; Animals; Anxiety; Chronic Disease; C | 2006 |
Persistent sexual side effects after SSRI discontinuation.
Topics: Adult; Androgens; Anxiety; Bupropion; Cabergoline; Citalopram; Depressive Disorder; Dopamine Agonist | 2006 |
Prediction of anti-panic properties of escitalopram in the dorsal periaqueductal grey model of panic anxiety.
Topics: Adrenergic alpha-Antagonists; Alprazolam; Animals; Anxiety; Citalopram; Dose-Response Relationship, | 2006 |
Antidepressant-like effects of the histone deacetylase inhibitor, sodium butyrate, in the mouse.
Topics: Animals; Antidepressive Agents; Anxiety; Behavior, Animal; Brain-Derived Neurotrophic Factor; Butyra | 2007 |
Genetic variant BDNF (Val66Met) polymorphism alters anxiety-related behavior.
Topics: Alleles; Animals; Anxiety; Behavior, Animal; Brain-Derived Neurotrophic Factor; Conditioning, Psycho | 2006 |
Antidepressant-induced undesirable weight gain: prevention with rimonabant without interference with behavioral effectiveness.
Topics: Analysis of Variance; Animals; Antidepressive Agents; Anxiety; Behavior, Animal; Desipramine; Female | 2007 |
Effects of acute and chronic treatment with fluoxetine on stress-induced hyperthermia in telemetered rats and mice.
Topics: Animals; Anxiety; Body Temperature; Dose-Response Relationship, Drug; Fever; Fluoxetine; Male; Mice; | 2007 |
Tics, anxiety, and possible PANDAS in an adolescent.
Topics: Adolescent; Adrenergic alpha-Agonists; Antidepressive Agents, Second-Generation; Anxiety; Autoimmune | 2007 |
The neuropeptide Y Y1 receptor subtype is necessary for the anxiolytic-like effects of neuropeptide Y, but not the antidepressant-like effects of fluoxetine, in mice.
Topics: Animals; Antidepressive Agents, Second-Generation; Anxiety; Arousal; Cell Count; Cell Division; Cond | 2008 |
Chronic low dose corticosterone exposure decreased hippocampal cell proliferation, volume and induced anxiety and depression like behaviours in mice.
Topics: Adrenal Glands; Animals; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; | 2008 |
Pharmacology of neuropeptide S in mice: therapeutic relevance to anxiety disorders.
Topics: Alprazolam; Animals; Anti-Anxiety Agents; Antidepressive Agents; Anxiety; Anxiety Disorders; Arousal | 2008 |
[Effects of acute and chronic introduction of fluoxetine on anxiety-depressive condition of male and female mice].
Topics: Animals; Antidepressive Agents, Second-Generation; Anxiety; Behavior, Animal; Depression; Female; Fl | 2007 |
Fish on Prozac: effect of serotonin reuptake inhibitors on cognition in goldfish.
Topics: Animals; Anxiety; Avoidance Learning; Escape Reaction; Fluoxetine; Goldfish; Piperazines; Pyridines; | 2008 |
Differential modulation of antipredator defensive behavior in Swiss-Webster mice following acute or chronic administration of imipramine and fluoxetine.
Topics: Animals; Anxiety; Avoidance Learning; Behavior, Animal; Fluoxetine; Imipramine; Male; Mice; Mice, In | 1995 |
Fluoxetine in patients with major depressive disorder--a responder analysis.
Topics: Adolescent; Adult; Aged; Anxiety; Depressive Disorder; Female; Fluoxetine; Humans; Male; Middle Aged | 1995 |
Comorbid anxious signs and symptoms in major depression: impact on functional work capacity and comparative treatment outcomes.
Topics: Absenteeism; Adult; Amitriptyline; Antidepressive Agents, Tricyclic; Anxiety; Clomipramine; Comorbid | 1993 |
Anxiolytic effects of dotarizine, a possible antimigraine drug.
Topics: Animals; Anti-Anxiety Agents; Anxiety; Benzhydryl Compounds; Exploratory Behavior; Fluoxetine; Male; | 1995 |
Behavioral profiles of SSRIs in animal models of depression, anxiety and aggression. Are they all alike?
Topics: 1-Naphthylamine; Aggression; Animals; Anxiety; Binding, Competitive; Citalopram; Depression; Fluoxet | 1997 |
Antiaversive effects of 5HT2C receptor agonists and fluoxetine in a model of panic-like anxiety in rats.
Topics: Animals; Anxiety; Brain; Disease Models, Animal; Dose-Response Relationship, Drug; Escape Reaction; | 1998 |
Potential role of the gene transcription factor cyclic AMP-responsive element binding protein in ethanol withdrawal-related anxiety.
Topics: Animals; Anxiety; Central Nervous System Depressants; Cerebral Cortex; Cyclic AMP Response Element-B | 1999 |
Chronic fluoxetine in tests of anxiety in rat lines selectively bred for differential 5-HT1A receptor function.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Antidepressive Agents, Second-Generation; Anxiety; | 1999 |
Effects of acute and chronic fluoxetine treatment of CRH-induced anxiety.
Topics: Animals; Anxiety; Behavior, Animal; Corticotropin-Releasing Hormone; Drug Combinations; Fluoxetine; | 1999 |
Anxiogenic effect of central CCK administration is attenuated by chronic fluoxetine or ipsapirone treatment.
Topics: Animals; Anti-Anxiety Agents; Antidepressive Agents; Anxiety; Cerebral Ventricles; Drug Administrati | 1999 |
Effects of repeated fluoxetine on anxiety-related behaviours, central serotonergic systems, and the corticotropic axis axis in SHR and WKY rats.
Topics: Animals; Anxiety; Basal Metabolism; Behavior, Animal; Drug Administration Schedule; Fluoxetine; Hipp | 1999 |
Behavioral effects of acute and chronic fluoxetine in Wistar-Kyoto rats.
Topics: Analysis of Variance; Animals; Antidepressive Agents, Second-Generation; Anxiety; Disease Models, An | 1999 |
[The combined effect of psychotherapy and fluoxetine on obesity].
Topics: Adult; Aged; Antidepressive Agents, Second-Generation; Anxiety; Depression; Female; Fluoxetine; Huma | 1999 |
Long-term fluoxetine produces behavioral anxiolytic effects without inhibiting neuroendocrine responses to conditioned stress in rats.
Topics: Adrenocorticotropic Hormone; Animals; Anxiety; Behavior, Animal; Body Weight; Conditioning, Psycholo | 2000 |
Loss of anxiety and increased aggression in a 15-year-old boy taking fluoxetine.
Topics: Adolescent; Aggression; Antidepressive Agents, Second-Generation; Anxiety; Fluoxetine; Humans; Male; | 1999 |
Acute and chronic effects of gepirone and fluoxetine in rats tested in the elevated plus-maze: an ethological analysis.
Topics: Animals; Anxiety; Exploratory Behavior; Fluoxetine; Male; Pyrimidines; Rats; Rats, Wistar; Selective | 2000 |
The effects of sertraline and fluoxetine on anxiety in the elevated plus-maze test in mice.
Topics: Animals; Anxiety; Dose-Response Relationship, Drug; Fluoxetine; Male; Maze Learning; Mice; Selective | 2000 |
Augmented accumbal serotonin levels decrease the preference for a morphine associated environment during withdrawal.
Topics: 5-Hydroxytryptophan; Animals; Anxiety; Conditioning, Psychological; Drug Administration Schedule; En | 2001 |
Brain function in a patient with torture related post-traumatic stress disorder before and after fluoxetine treatment: a positron emission tomography provocation study.
Topics: Anxiety; Cerebrovascular Circulation; Fear; Fluoxetine; Humans; Male; Selective Serotonin Reuptake I | 2001 |
5-HT(1A) receptor mutant mice exhibit enhanced tonic, stress-induced and fluoxetine-induced serotonergic neurotransmission.
Topics: Aminopyridines; Animals; Anxiety; Exploratory Behavior; Fluoxetine; Frontal Lobe; Hippocampus; Male; | 2001 |
The alpha(2a)-adrenergic receptor plays a protective role in mouse behavioral models of depression and anxiety.
Topics: Adrenergic Uptake Inhibitors; Animals; Anxiety; Behavior, Animal; Darkness; Depression; Disease Mode | 2001 |
An investigation of the mechanisms responsible for acute fluoxetine-induced anxiogenic-like effects in mice.
Topics: Animals; Anxiety; Arousal; Buspirone; Diazepam; Exploratory Behavior; Fluoxetine; Humans; Male; Mian | 2001 |
[Prozac treatment of chronic tension headache].
Topics: Adolescent; Adult; Affective Symptoms; Antidepressive Agents, Second-Generation; Anxiety; Chronic Di | 1999 |
Balance control and posture in anxious mice improved by SSRI treatment.
Topics: Animals; Anxiety; Central Nervous System; Dose-Response Relationship, Drug; Female; Fluoxetine; Male | 2001 |
Conditional deletion of brain-derived neurotrophic factor in the postnatal brain leads to obesity and hyperactivity.
Topics: Animals; Anxiety; Body Weight; Brain; Brain-Derived Neurotrophic Factor; Fasting; Fluoxetine; Gene D | 2001 |
Anxiety-like effects induced by acute fluoxetine, sertraline or m-CPP treatment are reversed by pretreatment with the 5-HT2C receptor antagonist SB-242084 but not the 5-HT1A receptor antagonist WAY-100635.
Topics: Aminopyridines; Animals; Antidepressive Agents, Second-Generation; Anxiety; Behavior, Animal; Fluoxe | 2001 |
Anxiolytic- and antidepressant-like effects of the non-peptide vasopressin V1b receptor antagonist, SSR149415, suggest an innovative approach for the treatment of stress-related disorders.
Topics: Animals; Anti-Anxiety Agents; Antidepressive Agents; Antidepressive Agents, Second-Generation; Antid | 2002 |
Seed finding in golden hamsters: a potential animal model for screening anxiolytic drugs.
Topics: Adrenergic alpha-Agonists; Animals; Anti-Anxiety Agents; Antidepressive Agents, Second-Generation; A | 2002 |
Effects of fluoxetine on regional cerebral blood flow in obsessive-compulsive patients.
Topics: Adult; Anxiety; Cerebral Cortex; Cerebrovascular Circulation; Female; Fluoxetine; Frontal Lobe; Huma | 1991 |
Interaction of fluoxetine and pentazocine.
Topics: Adult; Anxiety; Ataxia; Drug Interactions; Fluoxetine; Humans; Hypertension; Male; Nausea; Paresthes | 1990 |
Fluoxetine may antagonize the anxiolytic action of buspirone.
Topics: Adult; Anxiety; Buspirone; Drug Interactions; Fluoxetine; Humans; Male | 1989 |
Interactions of 5HT reuptake inhibitors and ethanol in tests of exploration and anxiety.
Topics: Animals; Anxiety; Citalopram; Desipramine; Drug Interactions; Ethanol; Exploratory Behavior; Fluoxet | 1988 |
Behavioral interactions of fluoxetine and other 5-hydroxytryptamine uptake inhibitors with ethanol in tests of anxiety, locomotion and exploration.
Topics: Animals; Anxiety; Citalopram; Desipramine; Ethanol; Exploratory Behavior; Fluoxetine; Fluvoxamine; M | 1988 |